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Abstract
Introduction
Multimorbidity is common. The gaps in multimorbidity research are in the measurement of
the prevalence, the levels of multimorbidity and its associated outcomes.

Objectives
This thesis aimed to provide a uniform definition for multimorbidity, identify instruments for
measuring the level of multimorbidity, and describe patient-reported outcomes for different
levels of multimorbidity.

Methods
Three studies were conducted. The first determined the prevalence rates of multimorbidity and
explored whether there were differences among the different age, sex and ethnic groups in the
primary care population. Common dyads and triads of conditions were described. The
systematic review updated the list of instruments for measuring the level of multimorbidity for
community-dwelling adults. The third study determined the association of different levels of
multimorbidity with depression, anxiety and quality of life. The agreement between patients’
self-reported conditions and conditions recorded in their electronic medical records (EMR)
were reported.

Results
Increasing age was associated with a higher prevalence of multimorbidity. The commonest
dyad was hyperlipidaemia/hypertension, and triad was hyperlipidaemia/hypertension/diabetes.
Disease count and weighted indices were the most commonly used instruments for measuring
the level of multimorbidity.

Self-reported disease count was positively associated with

depression and anxiety, and negatively associated with quality of life. Stroke was the only
condition that showed substantial agreement between patients’ self-reported medical
conditions and the EMR.

i

Conclusion
We identified a practical definition of multimorbidity in the Singapore primary care population,
described the commonly used instruments for measuring the level of multimorbidity, and
reported the disparity of multimorbidity outcomes between patients’ self-reported chronic
conditions and EMR.

(249 words)

Keywords

Anxiety, chronic condition, concordance, depression, level of multimorbidity, measurement of
multimorbidity, patterns of multimorbidity, patient-reported outcomes, prevalence, quality of
life.
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1

Introduction

Epidemiologically, we are in the age of degenerative and human-made diseases whereby
overall mortality continues to decline1. This is mainly due to demographic changes in many
developed societies and public health improvement. During this transition, a long-term shift
occurs in mortality and disease patterns whereby degenerative diseases gradually displace
pandemic infections as the chief form of morbidity and primary death.

In 2015, the Global Burden of Disease study reported that chronic conditions like heart disease,
stroke, diabetes, chronic kidney disease and Alzheimer’s disease caused seven out of every ten
deaths in 20142. This occurred at the same time that death rates from communicable diseases
like HIV/AIDS and malaria were falling.
The report also revealed that people’s average life spans had risen by 6.1 years over the last 15
years steadily in 191 countries, resulting in a significant overall increase in life expectancy.
Not only does a longer life expectancy increase the chance of developing a chronic condition,
but the likelihood of having multiple chronic conditions (i.e., multimorbidity) also increases.
As the population ages in many societies worldwide, an increasing number of people are living
with multimorbidity.

Multimorbidity was an important but often ignored medical phenomenon until recently. Until
ten years ago, the disease-centred approach to research has led to a predominant focus on the
index disease and resulted in a dearth of information about multimorbidity and its complexity3.
In this chapter, we discussed the salient issues on what is currently known on the subject matter
and highlighted the gaps in the body of knowledge. We provided the context of multimorbidity
in Singapore next as the accompanying research activities were all conducted in the country.
Finally, we described the research studies we had undertaken to help close this gap and add to
the body of knowledge on the subject matter.

2

What is multimorbidity?

The concept of multimorbidity was first published in 1976 in Germany, and since the 1990s,
the concept has spread widely and has been researched by many worldwide4. The World Health
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Organization (WHO) defines multimorbidity as the co-occurrence of two or more chronic
medical conditions in one person5.
However, the term ‘comorbidity’ has been used interchangeably with the term ‘multimorbidity’
for a long time even up to now. Comorbidity was described in a seminal paper in 1970 by
Feinstein6 for ‘any distinct additional clinical entity that has existed, or that may occur during
the clinical course of a patient who has the index disease under study’. Since 1996, van den
Akker et al. has addressed the conceptual confusion between the two terms7,8. The consensus
is that comorbidity describes the simultaneous presence of multiple health conditions when
there is an index condition and other unrelated conditions whereas multimorbidity describes
the co-occurrence of two or more chronic medical conditions without specifying which is the
index condition. For comorbidity, health outcomes are evaluated in the context of the index
condition. For multimorbidity, health outcomes are interpreted in the context of the interaction
and burden of all the co-existing chronic conditions.

Although comorbidity is not a comprehensive way to design research interventions and care
delivery programs for the whole person, it is a concept commonly used by secondary and
tertiary care clinicians. Advocates of the concept of multimorbidity tend to focus on primary
care where the identification of an index disease is often neither obvious nor useful9.
There is an explosion of interest in multimorbidity in the last decade10,11. In 2013, the European
General Practice Research Network (EGPRN) defined multimorbidity as any combination of
chronic disease with at least one other disease (acute or chronic) or biopsychosocial factor
(associated or not) or physical risk factor. Any biopsychosocial factor, any physical risk factor,
the social network, the burden of diseases, the healthcare consumption and the patient’s coping
strategies may function as modifiers (of the effects of multimorbidity). Multimorbidity may
modify the health outcomes and lead to an increased disability or a decreased quality of life or
frailty12.

PubMed, the free search engine provided by the United States National Library of Medicine at
the National Institutes of Health, adopted multimorbidity as a medical subject heading (MeSH)
term in January 2018 and defined it as ‘the complex interactions of several co-existing
diseases’. These complex interactions have profound implications on individuals with

4
multimorbidity, their health care providers, and accounts for most of the expenditures of the
healthcare system, putting pressure on its sustainability13.

3

Epidemiology of multimorbidity

A chronic disease does not occur in isolation14. A study on multimorbidity in the primary care
setting reported that more than half of individuals with a chronic condition had at least two,
and frequently more, other conditions15. The overall estimates of the prevalence of
multimorbidity varied widely in the literature and ranged from 12.9% in participants aged 18
years and older to 95.1% in those aged 65 years and older16. Public health studies tend to use
hospital validated definition of chronic diseases to estimate population prevalence of
multimorbidity. There are very few validated conditions and in one such studies, there were
only five conditions17.
Age and lower socioeconomic status are consistently associated with multimorbidity10,16,18.
Sex and the presence of mental health problems also show associations with multimorbidity,
but the evidence is less consistent across studies16. Other risk factors for multimorbidity
include health behaviours such as smoking, obesity, and inactivity10.
Two types of patterns of multimorbidity are reported in prevalence studies14. The first pattern
is the most frequent combinations of specific conditions based on the frequency of all possible
combinations of two or three conditions (dyads and triads). Descriptive statistics showed that
the commonest dyad was the combination of hypertension and osteoarthritis followed by
different combinations of cardiovascular conditions16. The combination of hyperlipidaemia,
hypertension and diabetes was the commonest triad19,20.

The second pattern is to identify groups of conditions with the highest degree of non-random
associations using analytical statistics such as cluster or factor analysis10,16. Three distinct
patterns were commonly reported21. The first being a combination of cardiovascular and
metabolic conditions, the second pattern included mental health conditions, and the third
pattern included musculoskeletal conditions.
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Kanesarajah et al.22 suggested that from an epidemiological and health planning perspective,
using disease count to describe multimorbidity is useful to establish the prevalence of
multimorbidity. However, for clinical practice and health policy, patterns of conditions that
tend to co-occur are more useful. Public health studies tend to use hospital validated definition
of chronic diseases to estimate population prevalence of multimorbidity. There are very few
validated conditions and in one such studies, there were only five conditions.

4

Problems of multimorbidity
4.1

From the patients’ perspective

Multimorbidity affects individuals to varying degrees. Living with multimorbidity is a state of
complexity that goes beyond counts of conditions and symptom burden23.

Patient’s

perspectives of living with multimorbidity speak more to psychological and functional
challenges leading to poorer quality of life than to disease-specific issues24.

The risk of psychological distress increased five times for individuals with a high level of
multimorbidity compared to those with no multimorbidity, after controlling for age, sex, social
support and economic status25. Clinical depression was two to three times more likely in people
with multimorbidity compared to people without multimorbidity or those who had no chronic
physical condition26. However, clinically depressed patients with chronic physical conditions
were inconsistently picked up in primary care27.

The functional challenges of individuals with multimorbidity included coping with managing
the complexity of multiple chronic conditions, physical limitations experienced such as pain or
fatigue, financial constraints, complexity of communication with healthcare providers,
inadequate or inappropriate family and social support, logistical challenges in managing the
scheduling of different appointments or coordination of medications, lifestyle changes, and the
burden of treatment imposed28,29.

4.2

From the care providers’ perspective

Generally, medical and public health programs targeting commonly defined chronic conditions
have been fixated on individual chronic conditions without considering the broader context of
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co-occurring chronic conditions.

Clinical practice guidelines are written by committees

dominated by specialists, mainly drawing on research in selected individuals without other cooccurring medical conditions30. The applicability of existing disease management guidelines
to individuals with multimorbidity is limited, particularly for those with discordant *
combinations31,32.

Medical interventions may be less effective in individuals with

multimorbidity than in individuals with no other comorbidities included in clinical trials. Even
if treatments were effective, older individuals with multimorbidity might have less to gain
because of their reduced life expectancy33.

Basing standards for quality of care and pay for performance on existing practice guidelines
could lead to inappropriate management and create perverse incentives that emphasise the
wrong aspects of care for individuals with multimorbidity and diminish the quality of their
care33. The struggle most family physicians experience is in finding the balance of promoting
autonomy for individuals with multimorbidity in self-management and for professional
autonomy in straying away safely from clinical guidelines to provide individualised care34. In
an attempt to achieve this patient-centred care, this can lead to potential conflicts with specialist
services and confuse patients.

4.3

From the health system’s perspective

There is a global consensus that multimorbidity is a growing concern for healthcare
policymakers trying to provide optimal healthcare services within resource-constrained
environments11. Multimorbidity is associated with higher levels of utilisation across almost all
resource types including medications, primary care, specialist outpatient consultations,
emergency department presentations and hospitalizations11,35.

Moreover, it appears that

spending more money is not always better for health in healthcare36. This puts into doubt the
sustainability of healthcare services for managing the complexity of multimorbidity using the
current model of care. A revamped and better model of care will need to be developed and
implemented for managing the inevitable increase in the number of patients with
multimorbidity. More thoughtful care for individuals with multimorbidity and shifting the

*

Conditions that are not directly related in either their pathogenesis or management and do not share an underlying
predisposing factor (31. Lugtenberg M, Burgers JS, Clancy C, et al. Current guidelines have limited applicability to patients
with comorbid conditions: a systematic analysis of evidence-based guidelines. PLoS ONE 2011;6(10):e25987. doi:
10.1371/journal.pone.0025987)
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goals towards medical care that is less disruptive to their lives may be the solution to the everincreasing health care spending and achieve better patient/provider satisfaction37.

5

Multimorbidity interventions and their outcomes

Most of the interventional studies for multimorbidity are relatively recent, reflecting the fact
that research to date has focused on description and impact rather than the evaluation of the
effectiveness of the intervention. Many of these studies were not robust methodologically and
most had no control groups for comparison38-40. In general, none of the intervention studies
fully supported the implementation of the following modes of interventions – chronic care
model41, promotion of self-management39, comprehensive care management38, nurse-led case
management40, and general case-management42.

Interventions that targeted well-defined conditions like depression and diabetes or focused on
specific problems experienced by individuals such as functional status were more effective
than interventions with a broader focus43. Therefore, attention to particular issues, risk factors
or practical difficulties using a nuanced management approach rather than a one-size-fits-all
general approach may be superior39.

6

Gaps in knowledge – prevalence, levels, and outcomes of

multimorbidity
Measurements are the foundation of medical research and clinical practice44,45. The major gaps
in multimorbidity research are in the measurement of the prevalence of multimorbidity, the
measurement of the different levels of multimorbidity, and the measurement of outcomes
associated with multimorbidity.

And the fundamental reason for these gaps is in the

contentious issues related to the definition of multimorbidity. Even though the World Health
Organization (WHO) defines multimorbidity as the co-occurrence of two or more chronic
medical conditions in one person5, many other different definitions of multimorbidity exist as
described in Section 2 (p2-4).

8

6.1

Prevalence and definition of multimorbidity

Disease count is the most typical approach to measure the prevalence of multimorbidity46.
However, even using the simple count of chronic conditions resulted in a wide range of
prevalence estimates being reported in epidemiological studies. Estimates of multimorbidity
prevalence vary widely from 12.9% to 95.1% internationally16.

Using disease count to determine prevalence estimates is greatly influenced by five
components in the definition of multimorbidity : a) the types of conditions selected to form the
multimorbidity list; b) the total number of conditions considered in the multimorbidity list; c)
the data sources of the conditions; d) the cut-points used to define multimorbidity; and e) the
reference population being measured47-49.

6.1.1

The type of conditions selected to form the multimorbidity list of conditions

There is a lot of controversy in the types of conditions that are selected to form the list of
conditions used in multimorbidity research. Primarily, the conditions included in the list of
conditions are chronic diseases or noncommunicable diseases as defined by the World Health
Organisation, i.e., they are not passed from person to person, of long duration and generally
slow in progression50. However, it is not so apparent what a ‘chronic disease’ is.
Bernell and Howard51 described many variations in the diseases that are included under the
umbrella term ‘chronic disease’ and also the variation in the time a disease must be present for
it to be referred to as chronic from different professional and academic bodies. To add to the
confusion, the European professional body included both acute and chronic medical conditions
and also social conditions like poverty12, the National Institute for Health and Care Excellence
(NICE) guideline on multimorbidity included symptoms experienced by individuals like
frailty52, and a multimorbidity study in Ghana excluded mental health conditions53.

While it is idealistic to bring into focus all the possible needs of individuals with
multimorbidity, there are concerns of including acute conditions in the primary care context
and operationalisation of social factors10,54.

Concerning the inclusion of mental health

conditions, Fortin et al.55 emphasised that excluding psychiatric diagnoses in primary care for
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counting towards multimorbidity is unacceptable. Two recommendations were suggested for
the progress of research in multimorbidity - either unrestricted eligibility of health conditions
or an agreement on a defined list of key conditions43.

6.1.2

The total number of conditions considered in the multimorbidity list

The number of conditions used in multimorbidity prevalence studies ranged from 4 to 14754.
It has been reported that studies that included a higher number of conditions would report a
higher prevalence rate of multimorbidity compared to studies using a lower number of
conditions47,48.

6.1.3

The data sources of chronic conditions

Data sources could be from chart reviews, administrative data, or self-reports from patients49.
Fortin et al.56 reported that health administrative data based on the billing system
underestimated the prevalence of multimorbidity when compared to self-reported chronic
conditions. However, other studies have raised concerns about the reliability of self-reporting
of medical conditions due to biases, including respondent recall and poor respondent
understanding57,58.

6.1.4

The cut-points used to define multimorbidity

Holzer et al.59 reported that the cut-points of two or three chronic conditions provide essentially
the same information on prevalence. However, Fortin et al.47 reported that ‘three or more’
conditions better identify patients with higher needs that is more meaningful for primary care
physicians.

6.1.5

The reference population

Generally, prevalence estimates of multimorbidity for the family practice-based population
were higher than those for the general population48.

The prevalence estimates of

multimorbidity also increase with age with the prevalence in older persons almost reaching
100%10.
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Although the prevalence of multimorbidity increases with age, the absolute number of
individuals with multimorbidity is higher in those aged less than 65 years old15,60.
Multimorbidity is not uniquely an ageing-related phenomenon as one would expect. Research
emphasis should also be on understanding the optimal health systems for younger people with
multimorbidity49.

In summary, there is no common lexicon amongst stakeholders in the definition, and therefore
the measurement of the prevalence of multimorbidity. The definition of multimorbidity needs
further clarification and consensus.

Most researchers agree that a precise definition of

multimorbidity to allow for generalisability or applicability of studies is lacking. While waiting
for the broad consensus of the definition and measurement of multimorbidity to materialise,
Fortin et al.47 suggested that future studies should include two operational definitions of
multimorbidity, i.e., for two or more and three or more chronic conditions. The authors also
urged researchers to carefully consider the specific diagnoses included in the list of chronic
conditions and to state the recruitment and data collection methods clearly.

Comparing different definitions of multimorbidity and determining the prevalence of
multimorbidity are key goals of the thesis described later in this chapter.

6.2

Measurement of the different levels of multimorbidity

For measurement of the level of multimorbidity, Lefevre et al.14 listed four common methods.
They are: by simple counts of chronic diseases from a list of individual conditions (i.e., disease
count), by grouping chronic diseases into dyads or triads (i.e., dyad and triad patterns), by
identifying groups of people with common disease and characteristics that occur more often
than by chance, and by using an index of variable complexity (i.e., weighted indices). However,
this does not clearly explain the different purposes of measuring multimorbidity45. According
to de Vet et al.61, the three main purposes of measurement in medicine are for diagnosis,
evaluation of intervention, and prediction of outcome. The instrument for each of the above
purpose is called a discriminant measurement, an evaluation measurement, aobjectivesnd a
prediction measurement respectively. Each of these four measurement methods described by
Lefevre et al.14 can be used for any of the three different purposes described by de Vet et al.61
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The first three methods described by Lefevre et al.14 are usually used for measuring the
prevalence or patterns of multimorbidity (consistent with the purpose of diagnosis described
above). All three methods have already been described in Section 3 (p4). The three methods
of measurements help to differentiate between those who have multimorbidity and those
without multimorbidity, or those with a certain pattern of multimorbidity from those without.
One major criticism of these three methods is that the severity of individual conditions is not
usually specified47. Only 23% of multimorbidity studies reported the severity of individual
conditions and they were reported in many different ways54. A concern on the lack of reporting
on severity is that common conditions in the population like hypertension and hyperlipidaemia
are not necessarily those with the most significant impact on individuals’ functional status or
quality of life54. Relying too much on these conditions without indicating their severity when
describing the prevalence of multimorbidity will shift the focus to awareness of future illness
rather than the actual disease burden and functional status of individuals with multimorbidity.
The fourth method described by Lefevre et al.14 of using indices of variable complexity (i.e.,
weighted indices) is usually used for measuring the different levels of multimorbidity in
association with specific outcomes either for evaluation of intervention or for prediction of an
outcome. Disease count†, which is the first method described by Lefevre et al.14, is also
commonly used for the same purpose. When a group of individuals with multimorbidity has
already been identified, these two methods help to categorise these individuals into different
levels of the overall multimorbidity. The systematic review by Huntley et al.46 described theses
two methods as indices for the measurement of the morbidity burden of multimorbidity.

In this same systematic review, seventeen different indices used for measuring the morbidity
burden for multimorbidity in the primary care and the general population were found. The
most common index was ‘disease count’. Other common indices for measuring multimorbidity
in relation to a particular outcome include the Charlson Index, Adjusted Clinical Groups
System, and Cumulative Illness Rating Scale46. In general, these indices weighted individual
conditions differently and then added the scores up to provide a total score. Even though most
of these indices were initially developed and validated in the hospital setting, many of them
have been adapted for use in the primary care and the community populations.
†

‘Disease count’ as a measuring instrument has two purposes here. One is for measuring the prevalence of multimorbidity,
and the other is for measuring the different levels of multimorbidity.
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The systematic review by Huntley et al.46 included original articles only till the end of 2009,
and there has not been any update on the use of the existing measurement indices or new
measurement indices created since then. Getting a summary update of the measurement
instruments used for measuring the different levels of multimorbidity for specific outcomes for
community-dwelling individuals is the next key goal of the thesis described later in this chapter.

6.3

Measurement of the outcomes associated with multimorbidity

The use of clinical outcomes has always been the norm in medical research. However, there
is increasing recognition of involving patients in clinical research, evaluation of health care
service delivery, and quality improvement62. Good clinical care requires patients to provide
information regarding how they are feeling, their symptoms, and any effects of treatment.

A patient-reported outcome is directly reported by the patient without interpretation of the
patient’s response by a clinician or anyone else and pertains to the patient’s health, quality of
life, or functional status associated with health care or treatment62. However, heterogeneity in
the choice of outcome measures in multimorbidity research has led to a lack of consistent
evidence for multimorbidity intervention research63.
Sasseville et al.64 compiled a list of patient-reported outcomes used in multimorbidity
intervention research into six domains including general health, psycho-social health, disease
management, health-associated behaviours, functional, and health services. The most universal
three outcomes reported in their scoping review were depression under psychosocial health,
quality of life under general health, and self-efficacy under disease management. However,
these outcomes were rarely reported together. Care satisfaction, goal assessment, social health
and communication with the providers were the least frequently reported patient-reported
outcomes.

Core outcome sets (COS) represent the minimum that should be measured and reported in all
clinical trials of a specific condition or conditions65. This is in relation to the recognition that
outcomes measured in clinical trials were not always relevant to health service users and
policymakers66. The widespread adoption of COS can help improve the uniformity in outcome
measurement and reduce outcome reporting bias67. In accordance with the above, the long-
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awaited set of core outcomes of multimorbidity (COSmm) was recently published in 2017 by
Smith et al.68 after consulting a Delphi panel of experts. Seventeen core outcomes were
identified, and the three essential core outcomes were quality of life, mental health outcomes,
and mortality.

Obtaining patient-reported outcomes and relating them to the different levels of multimorbidity
is another key goal of the thesis described later in this chapter.

7

Conceptual frameworks

Theories are integral to healthcare practice and research69. Making explicit the theoretical
assumptions is vital as they can offer a generalisable framework for engaging with the concept
of multimorbidity, a concept that is still unclear and inconsistent as shown in the previous
sections. More theory-driven research should help us decide on the best approaches to provide
solutions to the challenges generated by multimobidity70.

Realistically, it is impossible to pile on the recommendations from the Clinical Practice
Guidelines of each of the single chronic diseases for patients with multimorbidity as doing so
would overburden them and render the health system unsustainable. As such, we adopted two
conceptual frameworks for the research work done for this thesis. One is the Patient Centred
Clinical Method71 (PCCM) that focuses on building a positive interaction between clinicians
and their patients at both the personal and practice level.
“Patient-centred care is the willingness to become involved in the full range of difficulties
individuals bring to their doctors, and not just their biomedical problems.”72

The PCCM framework outlines four components for the clinician to combine medical science
with knowledge of patients as people, their experiences, their values and their beliefs within
their context, with an ongoing and affirmative relationship.

The other framework is applicable at the personal, practice and policy levels. Minimally
disruptive medicine (MDM) draws attention to the impact of treatment burden, imposed by the
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clinician and the health care system, on patients’ capacity to cope with their medical conditions
on top of their other life demands73.
“Minimally disruptive medicine is a patient-centred approach to care that focuses on achieving
patient goals for life and health while imposing the smallest possible treatment burden on
patients’ lives. It is particularly appropriate for patients who are at risk of being (or who
already are) overwhelmed by the demands of life, illness, and health care. Such patients include
the expanding group of vulnerable individuals with multiple chronic conditions.”74

The MDM framework is a theory-based, patient-centred, and context-sensitive approach to
care that focuses on achieving patients’ goals while imposing the smallest possible burden on
their lives74. The four principles for MDM are to establish the weight of the burden, encourage
coordination in clinical practice, acknowledge multimorbidity in clinical evidence, and
prioritise treatment from the patient perspective73.

The two theories work in tandem at the personal, practice and policy levels. PCCM will
promote the holistic patient-centred care tailored to the overall needs of individuals with
multimorbidity in an ongoing, positive relationship over the long term. MDM is designed to
provide comprehensive, evidence-based, supportive care that fits into the patient’s life. Both
PCCM and MDM are approaches used in the intervention and management of multimorbidity
and will be used in interpreting the results of the proposed studies which are non-interventional.

8

Family medicine and multimorbidity

There is debate in the medical community as to who should coordinate all the medical
conditions an individual with multimorbidity faces. Articles and editorials in the specialty
literature advocate shifting the care of chronically ill persons from primary to specialty care75.
The argument for such a shift can be found in the growing body of evidence demonstrating that
specialists are more knowledgeable on the specific condition and are more likely to follow
disease-specific guidelines76. Arguments opposing the shift of chronic illness care from
generalists to specialists include concerns about the receipt of preventive care, the care of
comorbid conditions outside of the specialty focus, and cost75.
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In 2009, Stange and Ferrer77 described the paradox of primary care. They observed that
primary care is associated with low levels of evidence-based care for individual diseases.
However, healthcare systems based on primary care have healthier populations, use fewer
resources, and have less health inequality. Homa et al.78 explored the above observation further
by developing an agent-based computer simulation model with a participatory group modelbuilding process. Primary care in the model is less effective than specialty care in treating
single diseases, but it has the ability to manage multiple diseases at once78. Primary care also
can provide disease prevention, help improve individuals’ health behaviours and lower their
threshold for seeking care. In a model simulation with primary care features turned off,
individuals have poorer health. In a model simulation with all primary care features turned on,
better population health was observed, with significant improvements in individuals who are
disadvantaged or those with multimorbidity.

However, Rothman and Wagner reasoned that most studies of the quality of chronic disease
care had not differentiated the sources of care or the specialty of the primary clinician75. The
few available comparative studies of primary and specialty care made it clear that the quality
gap pertains to both. They suggested that the practice environment and system determine the
quality of chronic disease care far more prominently than whether the care provider is a
specialist or a generalist.

Primary care practices offer an ideal setting to study individuals with diverse patterns of
multimorbidity79. It is the best setting for studying the causality of seemingly unrelated chronic
diseases and including individuals with multimorbidity into clinical trials. Family medicine is
more patient-centred and less disease-focused. The rationale for the discipline is based on the
health of people and populations, not the one-by-one counting of diseases, their diagnoses, and
their management80. In concordance with the way multimorbidity is described in PubMed as
‘the complex interactions of several co-existing diseases’, the goal is not to manage each
disease separately but to provide holistic care and to improve both clinical and patient-reported
outcomes instead. Family physicians who adopt the patient centred clinical method (PCCM)
will be the most likely professionals to lead collaborative work with other professionals in
primary, secondary and tertiary healthcare; together with policymakers, the patients themselves
and their caregivers to achieve the above aims. Afterall, the patients they serve traverse through
the whole health care system, and it is myopic to make the artificial divide between primary
and specialty care for individuals with multimorbidity. The crux is in the formation of a
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practice environment and system that allows coordination and continuity of healthcare to
happen with minimal disruption to the patients.

9

Multimorbidity in Singapore

Singapore is a city-state country in southeast Asia with a population of 5.6 million, of which
close to 4.0 million are Singapore residents81. The rest comprises permanent residents and nonresidents, including foreign workers, their dependants and international students. Singapore is
a multi-ethnic society where the Chinese formed 74% of the resident population, the Malay at
13% and the Indian at 9.2% according to the 2010 Census82. According to the Bloomberg
Healthiest Country Index which ranks 169 economies according to factors that contribute to
overall health, Singapore was ranked fourth position in 2017 and eighth position in 2019.

One in four Singaporeans aged 40 years and older have at least one chronic condition and the
risk increases with age. By 2030, one in four adults will be 65 and above, up from one in eight
today and many of them will have multimorbidity83. Total life expectancy at birth rose from
65.8 years in 1970 to 82.5 years in 2013. Life expectancy at age 65 rose from 8.4 years to 20.6
years over the same period. Therefore, not only has the elderly population grown but the
elderly, as a group, are themselves getting older with longer life expectancy, many of them
with multimorbidity84. Longevity is not equivalent to good health. A local study projected
that the number of seniors who require assistance with daily activities would increase from
31,738 in 2010 to 82,968 in 2030, and more women than men will require assistance85.

Unfortunately, only four studies could be found in Singapore looking at multimorbidity
specifically86-89. Subramaniam et al.86 reported that 16.3% of the Singapore general population
has two or more chronic conditions.

Those who were older, economically inactive,

unemployed, overweight or obese had higher odds of having multimorbidity. Individuals from
the Malay ethnic group had significantly lower odds of multimorbidity as compared to the
Chinese ethnic group. Picco et al.87 reported that the prevalence of multimorbidity was 51.5%
for those aged 60 years and above in the general population of Singapore. The authors also
found that the total societal cost of multimorbidity equated to SGD‡15,148 per person annually
for those with multimorbidity while those with one or no chronic conditions, the total annual
‡

SGD – Singapore Dollar (1.00 SGD is equivalent to 0.99 Canadian dollar)
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societal costs per person were SGD5,610 and SGD2,806 respectively. Quah et al.88 conducted
a study on older adults in the primary care setting and found that the prevalence of
multimorbidity was 89.4% for those above 65 years old and was associated with poorer quality
of life. Ge et al.89 interviewed community-dwelling adults aged 21 years and above and
reported that the prevalence of multimorbidity was 35.0%. They also reported that there was
no difference in the prevalence rates between the two sexes.

Among the four multimorbidity studies conducted in Singapore, different lists of chronic
medical conditions were used. Subramaniam et al.86 used eight conditions, Picco et al.87 used
ten, Quah et al.88 used fourteen, and Ge et al.89 used seventeen. None of the studies described
clearly how and why they chose the list of chronic conditions in their study. All four studies
used data sources from patients’ self-report. All the studies used two or more chronic conditions
as the cut-point to define multimorbidity. Three of the reference populations were from the
general population, and one was from a practice-based population. Two of the studies were
for all adults while the other two were for older adults. Only one out of the four studies
measured the levels of multimorbidity using disease count and drug count. The different
characteristics of the four studies are summarised in Table 1-1.
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Table 1-1. A summary of the different characteristics of measuring prevalence, levels, and
outcomes of multimorbidity of studies conducted in Singapore

Definition of
chronic disease
(Section 6.1.1)
No. of
conditions
(Section 6.1.2)

Subramaniam et al.86
(Published in 2014)
No

Picco et al.87
(Published in 2016)
No

Quah et al.88
(Published in 2016)
No

Ge et al.89
(Published in 2018)
Diseases that are
irreversible and
persistent throughout
adulthood

8

10

14

17

Source of list of
chronic
conditions
(Section 6.1.2)
Sources of data
(Section 6.1.3)

Modified Composite
International
Diagnostic Interview
(CIDI)
Self-reported

Not mentioned

Conditions from the
Singapore Mental
Health Study 2011

Not mentioned

Self-reported

Self-reported

Cut-point
(Section 6.1.4)
Reference
population
(Section 6.1.5)
Age group
(Section 6.1.5)
Measured
levels of
multimorbidity
(Section 6.2)

2 conditions

2 conditions

2 conditions

General population

General population

Practice-based
population

≥ 18 years old

≥ 60 years old

≥ 65 years old

No

No

Patientreported
Outcomes
(Section 6.3)

Yes
1.
2.

Yes

No

Health-related quality
of life

Health care utilisation
and costs

2.
3.

General population
≥ 21 years old
No

Disease Count
Drug Count
Yes

1.

At least one of the
sources from selfreported or from
chronic disease
management system
database
2 conditions

Health-related
quality of life
Functional
disability
Chronic
musculoskeletal
pain

Yes
Physical function

10 Proposed studies
In 2015, Le Reste et al.4 established a research agenda for multimorbidity and suggested that
the highest priorities should be given to the measurement of multimorbidity and the impact of
multimorbidity on the different stakeholders.

This agenda has been supported by many
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investigators. However, the unintended consequence was a marked variation among studies of
the prevalence of multimorbidity concerning both methodologies and findings90. Furthermore,
observational studies of multimorbidity were generally not done well with questionable
generalisability relating to issues of sampling, attrition and non-response91.

The key message for this chapter is the immaturity of the different measurements of
multimorbidity: prevalence, levels of morbidity burden, and outcomes. This thesis aimed to
provide a uniform definition for multimorbidity, identify a list of instruments to measure the
levels of multimorbidity and explore some patient-reported outcomes for different levels of
multimorbidity.

As primary care practices offer an ideal setting to study individuals with diverse patterns of
multimorbidity79, the following three studies for this thesis were all conducted in the primary
care setting. The research activities were focused on clarifying the definitions, measurements
and the impact of multimorbidity. No attempt was made to conduct intervention trials for the
current management of multimorbidity in this thesis.

As with most research in multimorbidity, acute, social and non-medical conditions were not
included in the list of conditions for multimorbidity in this thesis. Only chronic conditions
were used. Frailty is interrelated with multimorbidity as they are both age-related and highly
correlated but they are two different concepts or clinical conditions92. Frailty will not be
considered and discussed further in this thesis. However, as described in Section 6.1.1 (p8),
defining what constitutes a chronic condition is not simple51. N’Goran et al.93 described a fourstep study in family medicine in Switzerland to define the list of conditions family doctors
coded in their medical records which were deemed to be considered ‘chronic’. A similar
approach, on a smaller scale, was conducted to emulate their study to create a master list of
chronic conditions in Singapore.

The three studies are briefly described below.

20

10.1 The prevalence and the common patterns of multimorbidity in
Singapore: An epidemiology study based on administrative data

This was a cross-sectional epidemiology study looking at the prevalence of multimorbidity in
the primary care setting by using administrative data. We used two multimorbidity lists (one
local source and the other from an international source) and compared two different cut-offs of
‘two or more’ or ‘three or more’ chronic conditions to define multimorbidity. We used the full
age range for the study to look at the changes from early adulthood to the older age group. We
hypothesised that the standardised prevalence rate of multimorbidity might differ between the
different sex and among different age and ethnic groups.
Violan et al.16 encouraged studying the patterns of the clustering of chronic diseases because it
helps to identify what makes certain conditions co-occur from the aetiological perspective;
tailors special care to a stratified stratum of people who are at high risks with a familiar pattern
from the clinical perspective; and prevent multimorbidity and its associated risks from the
policy perspective.

As such, we also described the most common dyads and triads of

multimorbidity for those ages 45 years old and above and reported the crude prevalence rates
of the dyads and triads for the different ethnic groups and sex.

The study aimed to describe the epidemiology of chronic conditions in primary care, establish
the standardised prevalence rates of multimorbidity in the primary care population, compare
the standardised prevalence rates among different age, sex and ethnic groups, and describe the
most common dyads and triads for those 45 years and older by each sex/ethnic groups. We
explicitly reported all the definitions of the variables so that the study could be easily replicated.

10.2 A systematic review of the instruments used for measuring the
level of multimorbidity

This was a systematic review that used three electronic databases to provide an update from
Huntley et al.’s

46

review on the current instruments used for measuring the level of

multimorbidity in the primary care or general population setting. The other objectives were to
report the advantages and disadvantages of using selected instruments, provide the details of
the data sources and resources required to use the instruments, and compile a list of
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corresponding instruments for measuring the level of multimorbidity for the three essential
core outcomes identified for multimorbidity (COSmm)68.
The study aimed to provide a useful and handy resource for researchers and clinicians who can
easily choose an instrument for measuring the level of multimorbidity for a specific outcome.

10.3 A cross-sectional study on the level of multimorbidity and its
association with depression, anxiety and quality of life

Based on the common triads of multimorbidity noted in the polyclinics, we targeted the group
of patients with the most common triad of chronic conditions in Singapore and looked at how
the levels of multimorbidity were associated with depressive symptoms, anxiety symptoms,
and quality of life. We also looked at what other sociodemographic factors were associated
with the same outcomes. The outcomes were chosen as they were part of the patient-centred
COSmm outcomes.

This was a cross-sectional study using interviewer-administered

questionnaires where we took into account the rigour for research design, population and
sampling, data definition, and outcome measures used in cross-sectional studies as suggested
by Stewart et al.90 A concordance study on patient self-report of the presence or absence of
chronic condition with those recorded in the clinical notes was also conducted.

The main study aim was to describe the baseline patient-reported outcomes of patients with the
most common triad of chronic conditions seen in primary care for different levels of
multimorbidity.
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1 Introduction
Chapter One has clearly demonstrated that individuals with multimorbidity are the rule in
primary care1. The overall estimates of the prevalence of multimorbidity varied widely in the
literature and ranged from 12.9% in participants aged 18 years and older to 95.1% in those
aged 65 years and older2.
Even though multimorbidity is a common phenomenon, there were only four studies3-6 done
in Singapore that looked at it so far. The prevalence rates of multimorbidity in these four
studies ranged from 16.3% to 89.4%, which was not too different from the range reported in
the literature. The reason for the wide range is due to varying standards of measuring
multimorbidity7.

Issues with multimorbidity studies in Singapore included the the lack of proper definition of
chronic disease, the total number of conditions considered in the multimorbidity list, the data
source, and the reference population (Chapter One Table 1-1 p18). Subramaniam et al.3 used
a list of eight chronic conditions, Picco et al.4 used ten, Quah et al.5 used fourteen, and Ge et
al.6 used seventeen conditions. Out of the four studies, only Ge et al.6 gave a brief description
of what chronic disease was while the other three did not provide any definition. The data
source for the chronic conditions was self-reported in three of the studies while the data source
for the fourth study was from a combination of self-report and administrative data. The
reference population for three of the studies was from the general population3,4,6 whereas the
reference population for Quah et al.5 was from the primary care population. Two of the studies
included younger adults (≥18 years old3 and ≥21 years old6) whereas the other two studies only
targeted older adults (≥60 years old4 and ≥65 years old5).
Subramaniam et al.3 reported that the prevalence of multimorbidity was 16.3% in the Singapore
general population. Her team also reported that individuals from the Malay ethnic group had
significantly lower odds of multimorbidity as compared to the Chinese ethnic group. Picco et
al.4 reported that the prevalence of multimorbidity was 51.5% in those aged 60 years and above
in the general population of Singapore. Quah et al.5 conducted a study on older adults aged 65
years and above in the primary care setting and reported that 89.4% of them had two or more
chronic conditions. Ge et al.6 interviewed community-dwelling adults aged 21 years and above
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and reported that the prevalence of multimorbidity was 35.0%. They also reported that there
was no difference in the prevalence rates between the two sexes. The only similarity in these
four studies was that multimorbidity was defined by the unweighted count of two or more
chronic conditions.

Primary care practices offer an ideal setting to study individuals with diverse patterns of
multimorbidity8. Studies using primary care as their source population can provide insights on
the optimal intervention of care for individuals with multimorbidity as compared to using
information from the general population which are more desirable for surveillance and public
health analysis9.

An increased understanding of the epidemiology of multimorbidity is needed to inform how
health care in Singapore should be organised and delivered to patients with multimorbidity.
However, efforts to manage and study multimorbidity in Singapore are hampered by a lack of
basic, up-to-date, and consistent epidemiologic data. The lack of consensus on the definition
of multimorbidity makes it difficult to compare the magnitude of the problem internationally
and among different health care settings in Singapore.

We proposed to measure the prevalence of multimorbidity in the primary care setting by using
a local list of chronic conditions for defining multimorbidity and an internationallyrecommended list from the literature. We also adopted Fortin et al.’s10 suggestion to include
two operational definitions of multimorbidity, that is, multimorbidity defined as a cut-off of
‘two or more’ and ‘three or more’ chronic conditions. As the prevalence of multimorbidity is
dependent on the prevalence of each of the individual chronic conditions that made up the list,
the epidemiology of the chronic conditions belonging to each list were also described.

Most studies found that the proportion of individuals with multimorbidity tended to increase
rapidly in the fourth decade of life10. As such, we described the most common patterns of
multimorbidity (i.e., dyads and triads) stratiﬁed by sex and ethnicity for patients who were 45
years and older that visited primary care. This would provide evidence for primary care
physicians to create meaningful multimorbidity guidelines for the common patterns of
multimorbidity seen in primary care that occur at high frequency.
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The objectives of the study were to: (1) describe the epidemiology of chronic conditions
depicted in the two lists for the sample population; (2) determine the overall prevalence rates
of multimorbidity (crude and standardised) in the National Healthcare Group polyclinics based
on two different lists of chronic conditions and two different deﬁnitions of multimorbidity in
terms of cut-points; (3) determine whether there were differences in standardised prevalence
rates among the different age, sex and ethnic groups; and (4) describe the common dyads and
triads of chronic conditions, stratified by ethnicity and sex in primary care patients who were
45 years and above with multimorbidity. We hypothesised that there were differences in sex2,
ethnicity3 and age11 based on existing literature.

2 Methods
This was a cross-sectional study determining the prevalence and common patterns of
multimorbidity amongst all patients who consulted a doctor in the National Healthcare Group
Polyclinics (NHGP) between 1st Jul 2015 and 30th Jun 2016. We received approval from the
ethics review board (National Healthcare Group Domain Specific Review Board Reference
number 2018/00466) on 18 June 2018. We followed the reporting of studies conducted using
observational routinely-collected health data (RECORD) statement as a guideline in preparing
the report12. There was no funding for this project.

2.1

Setting and study population

There are eighteen polyclinics spread over the island of Singapore. Each polyclinic serves as
a primary care safety net providing government-funded subsidised primary care.

Each

polyclinic offers a one-stop health centre for chronic disease management, National Childhood
Immunisation program, children development assessment, women’s cancer screening,
antenatal care, health promotion, education and disease prevention, medical education and
training, and National emergency planning and mobilisation.
The primary health care services in Singapore underwent a major restructuring on 1st October
2000 and was reorganised into two clusters – National Healthcare Group Polyclinics (NHGP)
and SingHealth Polyclinics (SHP)13. This clustering and reorganisation provided a platform
for consolidation and integration in order to bring about better health outcomes and greater
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efficiency while maintaining some competition. NHGP consisted of nine polyclinics and they
were located geographically in the central, western and northern parts of Singapore. SHP also
consisted of nine polyclinics and they were located geographically in the central and eastern
parts of Singapore.

About 300 primary care doctors work in the eighteen polyclinics (public primary care)
compared to another 2,700 primary care doctors who work in 1,700 private general practitioner
clinics14,15. Although the private clinics provided about 80% of the total primary care clinical
load, they only provided about 55% of the demand for primary care chronic disease
management. As such, the 10% of primary care doctors in the eighteen polyclinics managed
45% of all the patients with chronic diseases in primary care.

This study included all the patients who visited the nine polyclinics of NHGP.

2.2

Data Source

The source population of this study were all patients who visited National Healthcare Group
Polyclinics (NHGP). Data were collected from the National Healthcare Group Polyclinics
(NHGP) Business Informatics (BI) system that is an administrative database that captures all
the consultation episodes, clinical parameters from structured data fields within the electronic
medical records (EMR) e.g., blood pressure readings, body mass index, diagnoses codes,
pharmacy data, laboratory data, and billing16. All the data collected were linked using patients’
National Registration Identity Card (NRIC) number. We de-identified all patient information
according to the personal data protection act (PDPA). A separate ‘patient key’ was created for
each patient for de-identification by the Office of Clinical Informatics (OCI). Subsequently,
NRICs were removed from the dataset prior to being made available to the research team. OCI
cut the data for this research study on 14th September 2018. Data cleaning was then conducted
by the research team based on the de-identified list before the analysis was performed.

The National Healthcare Group Polyclinics (NHGP) BI system is used for generating reports
to the Singapore Ministry of Health regularly. System integration and user acceptance tests
were implemented before any new information request from the NHGP BI system to ensure
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completeness and accuracy of data. Regular surveillance is also scheduled by the OCI to rectify
any anomalies detected.

For this study, the study population was the total unique number of patients of age ranging
from 0 to 99 years old who had consulted a family physician at least once in NHGP between
1st Jul 2015 and 30th Jun 2016 for any reason documented with an ICD-10 diagnosis code. We
excluded all patient encounters in the polyclinic that did not include an ICD-10 diagnosis code
by a physician, for example, well-child visit and vaccination.

2.3
rate

Determining the denominator and numerator for the prevalence

2.3.1

Denominator

Epidemiology is the study of disease about populations17. The ‘population at risk’ (PAR) is a
basic concept of epidemiology and denotes the ‘denominator’ used for calculating the
prevalence of a condition where the cases with the condition observed are used as the
numerator.

In the 1970-80s, there was a lot of discussion in the family medicine literature on the
ascertainment of the PAR, i.e., the denominator problem. Six methods have been proposed,
each with its limitations18. These include the: (1) Census method where a single medically
isolated practice serving a well-defined community could estimate its denominator by
obtaining the community census; (2) Registration by intent method where every patient informs
the practice about which members of their family considers the practice to be their regular
source of care; (3) De facto registration method where the denominator is determined by the
number of individuals who have visited a practice one or more times during a specified time
period; (4) Indicator disease method where a disease of relatively constant frequency across
all patient populations is identified, and the number of patients seen with that disease annually
is then used to extrapolate the total population (i.e., the denominator); (5) Episodes of illness
method where the frequency of episodes of illness was assumed to follow a negative binomial
distribution. Hence, if the practice was able to determine the annual number of episodes of
illness for each of their patients, the practice denominator could be derived from that number;
and (6) Utilisation correction factor method where the denominator is estimated by assuming
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that relatively constant proportions of the populations served will visit the practice during a
particular time period.

Only the ‘de facto registration’ and ‘Utilisation correction factor’

methods are the widely acceptable ascertainment methods18.
Bass19 argued that, although the ‘de facto registration’ method was useful in describing the
workload of the practice, the method resulted in too many sources of variability to allow
adequate comparisons of incidence and prevalence rates across practices. He suggested that
the most acceptable denominator for office morbidity studies was best done by the ‘utilisation
correction factor’ which could be determined by a separate study or through analysis of health
insurance statistics19.
However, not many investigators have used the ‘utilisation correction factor’ as a denominator.
Recent examples included a Belgium primary care database that consisted of 43 practices20 and
a research team in Australia that has consistently used this method to adjust for the PAR from
publications dating from 2008 to 2017 on the prevalence of chronic disease or multimorbidity2124

.

For those using a capitation model, investigators used the register list25,26 for their primary care
service.

For those in a fee-for-service model, many investigators used the ‘de facto

registration’ method by using the number of patients seen over a pre-defined time-frame in a
health-care setting and excluded disease-free persons who were not seeking health care9. , .
The pre-defined time-frame ranged from at least once a year for three consecutive years27, one
visit within a time-frame of six months28, to as short as one visit in three weeks29. Most studies
used unique patients seen in one year as their denominators21,23,24,30,31.
Perusing the Singapore National Health Survey 201032, the percentage of the general
population who visited the polyclinic was not captured and therefore the ‘utilisation correction
factor’ is unknown. A separate study needs to be conducted in the general population to derive
the PAR by including both groups of persons who visited and did not visit the polyclinics. This
is not permissible in the timeline for the PhD study and is not within the scope of work of the
thesis.

This study was conducted in a fee-for-service primary care environment in the polyclinic
setting. As such, no listing or practice register can be used. Therefore, the study team decided
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to use the ‘de facto registration’ method by including all patients who had consulted a doctor
in National Healthcare Group Polyclinics (NHGP) at least once between 1st Jul 2015 and 30th
Jun 2016 as the denominator.

2.3.2

Numerator

Four senior family physicians in the National Healthcare Group Polyclinics (NHGP) worked
together to provide a full list of chronic conditions based on our local clinical practice and
doctors’ coding practices that fulfilled the criteria of the definition of chronicity.

We

simplified and adopted the steps used by N’Goran et al.33 to create a master list of chronic
conditions used in the local context that were deemed suitable for a study of multimorbidity in
Singapore. We used O’Halloran and colleagues’ definition of chronicity of a disease as lasting
at least six months, having a documented pattern of recurrence or deterioration, and having an
impact on an individual’s quality of life34.

As there was no consensus among the four senior family physicians on which multimorbidity
list of chronic conditions to use, the study team adopted two lists where one was readily
available locally, and another was from an international source. The local list, which consisted
of 20 conditions, was the Chronic Disease Management Programme (CDMP) list35 from the
Ministry of Health whereby the government subsidised medical costs for Singaporeans with
these conditions.

The international list, which also consisted of 20 conditions, was

recommended by Fortin et al.36 These two lists will hereafter be referred to as the CDMP list
and the Fortin list respectively. Using the International Statistical Classification of Diseases
and Related Health Problems revision 10 (ICD-10), we subsequently matched all NHGP
chronic conditions diagnosis codes with the CDMP list (Appendix 2-1) and Fortin list
(Appendix 2-2) to determine the number of patients with any of those conditions in the NHGP
database.

The study team was also unable to come to a consensus on which cut-point to select for the
definition of multimorbidity. We followed the recommendation of Fortin et al.10 of using two
operational definitions of multimorbidity. Therefore, we included both cut-offs of ‘two or
more’ chronic conditions (hereafter referred to as MM2+) and ‘three or more’ chronic
conditions (hereafter referred to as MM3+).
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The numerator was therefore, the number of patients who consulted a family physician in the
specified period who had ‘two or more’ or ‘three or more’ chronic conditions based on the
CDMP and Fortin lists.

This resulted in four numerators used with the same denominator:
a. The number of patients who visited the polyclinic with at least one doctor visit and at
least two chronic conditions based on the CDMP list
b. The number of patients who visited the polyclinic with at least one doctor visit and at
least two chronic conditions based on the Fortin list
c. The number of patients who visited the polyclinic with at least one doctor visit and at
least three chronic conditions based on the CDMP list
d. The number of patients who visited the polyclinic with at least one doctor visit and at
least three chronic conditions based on the Fortin list

2.4

Outcome variables

For objective 1 (p31), the outcomes for the epidemiology of chronic conditions were the crude
prevalence rates of single chronic conditions or single categories as described by the CDMP
and Fortin lists. The outcomes for objective 2 were the crude prevalence rates and standardised
prevalence rates of multimorbidity. For objective 3, the standardised prevalence rates of
different age, sex and ethnic groups were compared. Finally, objective 4 described the most
common dyads and triads for patients age 45 years and older. The most common dyads and
triads of each sex and ethnic groups were determined by the crude prevalence rates.

2.4.1

Crude prevalence rate

The crude prevalence rate was expressed as a numeral with the numerator as the number of
patients with multimorbidity and the denominator as the total number of unique patients who
had consulted a doctor in National Healthcare Group Polyclinics (NHGP) at least once between
1st Jul 2015 and 30th Jun 2016. There were four crude prevalence rates due to four numerators
as described in Section 2.3.2 above.
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2.4.2

Standardised prevalence rate

As it was likely that different prevalence rates may occur in different sub-populations, a
comparison of crude prevalence rates would be misleading since it would not be reflective of
the population. Therefore, we used the standardised prevalence rate as a summary measure.
We used the direct standardisation method as detailed by Bains38. Confidence intervals of 95%
were calculated using the Poisson approximation around the standardised rates39. To determine
whether prevalence rates of multimorbidity differ among age, sex and ethnic groups, the
standardised prevalence rates were altered to 1) age-stratified, sex-and-ethnicity standardised
prevalence rate; 2) sex-stratified, age-and-ethnicity standardised prevalence rate; and 3)
ethnicity-stratified, age-and-sex standardised prevalence rate respectively.
We used superscripts ‘a’ for age-stratified, sex-and-ethnicity standardised prevalence rate, ‘g’
for sex-stratified, age-and-ethnicity standardised prevalence rate, and ‘e’ for ethnicitystratified, age-and-sex standardised prevalence rate attached to the phrase ‘standardised
prevalence rate’ in the results section to clearly describe the different rates used.

The

standardised prevalence rate with a superscript ‘t’ attached provides the weighted average of
the prevalence rate where the weights were the proportions of persons in the corresponding
age/sex/ethnic groups according to the 2016 Singapore population37 (Appendix 2-3). It will be
termed age-sex-ethnicity standardised prevalence rate for short.

2.4.3

Dyads and Triads

Dyads were created by summing every combination of two chronic conditions separately from
the CDMP and Fortin lists respectively. Triads were created by summing every combination
of three chronic conditions.

For the most common dyads and triads of the total population, the number of unique patients
age 45 years and above with the specified dyad (or triad) of each list was denoted the numerator.
The denominator was all patients age 45 years and above who had consulted a doctor in
National Healthcare Group Polyclinics (NHGP) at least once between 1st Jul 2015 and 30th Jun
2016. We chose ‘45 years old and above’ as the 45-49 years old age group was found to be
the age group with the steepest rise of multimorbidity shown in Fig 2-2 (p44).
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For the most common dyads and triads of a specific sub-population, the numerator and
denominator would be altered accordingly. For example, for the most common dyads of the
Chinese male population within the study population, the numerator would be the number of
unique Chinese male patients age 45 years and above with the specified dyads of each list; and
the denominator would be all Chinese male patients age 45 years and above who had consulted
a doctor in NHGP at least once between 1st Jul 2015 and 30th Jun 2016. For all cases, the most
common dyads and triads were defined as a crude prevalence of 1.0% or more.

2.5

Independent variables

The independent variables (with no implication of causation) were age, sex and ethnicity. Age
was divided into four categories – ‘0-24’,‘25-44’, ‘45-64’, ’65-99’ following similar age groups
used by Ashman et al.40 and Fortin et al.26. Sex was classified into male and female. Ethnicity
was categorised into Chinese, Malay, Indians, and Others.

2.6

Analysis

The sample size was determined by the number of patients aged 0 to 99 who visited the
National Healthcare Group Polyclinics (NHGP) for at least one doctor consultation between
1st Jul 2015 and 30th Jun 2016. We used listwise deletion method for missing data41.

For descriptive statistics, we described the mean for continuous variables and their respective
standard deviation. For categorical variables, we described proportions and their respective
confidence intervals where appropriate.

In objective 1 (p31) for describing the epidemiology of chronic conditions, the age group of
patients (x-axis) was plotted against the proportion of patients with different number of chronic
conditions (y-axis) in a line graph. We calculated the gradient between consecutive age groups
using the formula as follows:
Gradienti = (yi+1 - yi) / (xi+1 - xi)§

§

Gradienti = gradient of age group i,
yi = prevalence of age grp i
xi = lower limit of age grp i
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The highest gradient value indicated the sharpest rise in the percentage of patients with a
specific number of chronic conditions within that specified age group.

For the third objective (p31), we considered no overlap of the 95% confidence intervals for the
standardised prevalence rates among the different age, sex and ethnic groups as statistically
significant. For multiple comparisons, we adjusted with Bonferroni adjustment by taking the
statistically significant p value as less than 0.05 divided by the number of comparisons.
However, we considered only an absolute difference between the different groups of 5.0% for
clinical significance.

For the fourth objective (p31), we used the crude prevalence rate to rank the most common
dyads and triads of co-occurring chronic conditions for primary care patients who were 45
years and above for the same population. We listed only the common dyads and triads with an
overall crude prevalence rate of at least 1.0% and above. We next compared the dyads and
triads among different sex and ethnic groups. For multiple comparisons, we adjusted with
Bonferroni adjustment by taking the statistically significant p value as less than 0.05 divided
by the number of comparisons. We considered an absolute difference between the subgroups
of 10.0% or a relative difference of 300% for clinical significance.

IBM SPSS version 21 and Microsoft Office Excel 2016 were used for all statistical calculations
and analyses.

2.7

Sub-group analysis

As the crude prevalence rates of the common dyads and triads would likely be determined in a
large part by the majority Chinese ethnic group for the overall population, a sub-group analysis
was made by determining the common dyads and triads for each of the three major ethnic
groups stratified by sex. This sub-group analysis was performed using the multimorbidity list
that gave a higher standardised prevalence rate between the two lists. We listed only the
common dyads and triads with crude prevalence rates of at least 1.0% and above.
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3 Results
3.1

Demographics of the study population

This study included 787,447 unique patients who consulted a doctor in the National Healthcare
Group Polyclinics (NHGP) at least once between 1st Jul 2015 and 30th Jun 2016. We excluded
one individual whose sex was not recorded. The final sample size was 787,446.

Within this study population, there were more adults aged between 65-99 years and fewer
adults aged 0-44 years who visited a family physician over the one-year period when compared
to the national population (Table 2-1). Using the CDMP list of conditions, the average number
of chronic conditions increased from 0.1 for the ‘0-24’ year age group to 0.2 for the ‘25-44’
year age group to 1.3 for the ‘45-64’ year age group and to 2.4 for the ‘65-99’ year age group.
Using the Fortin list, the average number of chronic conditions increased from 0.1 for the ‘024’ year age group to 0.4 for the ‘25-44’ year age group to 1.7 for the ‘45-64’ year age group
to 3.0 for the ‘65-99’ year age group.

Patients under 25 years old had very low rates of chronic conditions for both the CDMP and
Fortin lists. The increase from the ‘25-44’ year age group to the ‘45-64’ year age group was
6.5 times for CDMP list and 4.3 times for the Fortin list. The average number of chronic
conditions almost doubled from the ‘45-64’ year age group to the ‘65-99’ year age group for
both lists.

In terms of ethnicity, there were fewer Chinese, more Malays, Indians, and patients of other
ethnicity** in this study population who visited a family physician over the one-year period
compared to the national population. The mean age of the different ethnic groups was very
different compared to each other. The Chinese were the oldest at 47.1 years old, followed by
the Indians at 39.7 years old, the Others at 37.1 years old, and finally the Malays at 35.1 years
old.

**

Others included mainly Eurasians, Caucasians, Javanese.
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For the CDMP list of conditions, the Chinese had an average of 1.1 chronic conditions,
followed by the Indians with 0.9, the Malays at 0.7, and the Others at 0.6. For the Fortin list
of conditions, the Indians had the highest average of 1.2 chronic conditions, followed by the
Chinese at 1.1, the Malays at 1.0, and the Others at 0.8.

Compared to the national population, there were slightly fewer female (50.9% vs 51.2%) and
more male (49.1% vs 48.8%) patients in the study population. The mean age of the female
patients was 2.9 years older than the male patients (45.3 vs 42.4). The mean number of chronic
conditions was the same for both sexes, 1.0 for CDMP conditions and 1.3 for Fortin conditions.

Table 2-1. Demographics of the study population of patients (N=787,446)
Number of
patients
(N)
Age Group
0-24
201,839
25-44
165,212
45-64
252,206
65-99
168,189
Ethnic Group
Chinese
537,234
Malay
127,501
Indian
78,452
Others
44,529
Sex
Female
400,965
Male
386,481

3.2

Age (years)
Mean (SD)

Number of
CDMP
Conditions,
Mean (SD)

Number of
Fortin
Conditions,
Mean (SD)

26.9
30.5
29.3
13.3

12.9 (0.18)
34.0 (0.02)
55.4 (0.01)
73.5 (0.02)

0.1 (0.000)
0.2 (0.001)
1.3 (0.003)
2.4 (0.004)

0.1 (0.001)
0.4 (0.002)
1.7 (0.003)
3.0 (0.004)

68.2
16.2
10.0
5.6

74.3
13.4
9.1
3.2

47.1 (0.03)
35.1 (0.06)
39.7 (0.08)
37.1 (0.09)

1.1 (0.002)
0.7 (0.004)
0.9 (0.005)
0.6 (0.005)

1.1 (0.002)
1.0 (0.005)
1.2 (0.006)
0.8 (0.007)

50.9
49.1

51.2
48.8

45.3 (0.04)
42.4 (0.04)

1.0 (0.002)
1.0 (0.002)

1.3 (0.003)
1.3 (0.003)

Percentage
(%)

National
Proportion
2016 (%)

25.6
21.0
32.0
21.4

The CDMP and Fortin lists of chronic conditions

Sections 3.2 and 3.3 address objective 1, the epidemiology of chronic conditions depicted in
the two lists for the sample population. Table 2-2 lists the patient counts and crude prevalence
rates of all the single chronic conditions of both the CDMP and Fortin lists.

Four NHGP senior family physicians in the study team unanimously agreed that the ICD code
for ‘back pain’ was not considered to be a chronic condition that was reliably coded in the
context at our primary care setting for ‘chronic musculoskeletal conditions causing pain or
limitation’ in the Fortin’s list. As such, we only used 19 out of the 20 conditions in the Fortin
list.
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Table 2-2. Crude prevalence rates of chronic conditions - CDMP and Fortin lists
(N=787,446)
Rank
1
2
3
4
5
6

CDMP Conditions

Patient
Count

%

Hyperlipidaemia
Hypertension
Diabetes
Ischaemic Heart Disease
Asthma

257,114
221,760
125,058
36,401
28,778

32.7
28.2
15.9
4.6
3.7

21,638

2.7

Chronic Kidney Disease

7

Osteoarthritis

18,378

2.3

8

Benign Prostate
Hypertrophy

13,031

1.7

9

Osteoporosis

7,283

0.9

7,241

0.9

6,085

0.8

5,080

0.6

3,571

0.5

2,889
2,734
2,010
1,900
1,700
51
0

0.4
0.3
0.3
0.2
0.2
0.0††
0

10
11
12

13
14
15
16
17
18
19
20

Stroke
Anxiety
Chronic Obstructive
Pulmonary Disease
(COPD)
Dementia
Schizophrenia
Epilepsy
Rheumatoid Arthritis
Parkinson's
Major Depression
Bipolar Disorder
Psoriasis

Fortin Conditions
Hyperlipidaemia
Hypertension
Diabetes
Arthritis &/or Rheumatoid arthritis
Obesity
Cardiovascular disease (Angina,
Myocardial infarction, Atrial
fibrillation, poor circulation of lower
limbs)
Asthma, COPD, or Chronic
bronchitis
Chronic hepatitis
Stroke and Transient Ischaemic
Attack
Stomach problem
(reflux, heartburn, or gastric ulcer)
Kidney disease or failure
Thyroid disorder
Heart failure
(including valve problem or
replacement)
Depression or anxiety
Chronic urinary problem
Any Cancer in the last 5 years
Osteoporosis
Dementia or Alzheimer's disease
Colon problem (irritable bowel)

Patient
Count

%

257,114
221,760
124,954
100,838
48,893

32.7
28.2
15.9
12.8
6.2

43,559

5.5

32,611

4.1

25,918

3.3

23,628

3.0

22,233

2.8

22,221

2.8

20,781

2.6

20,538

2.6

14,910
13,031
7,940
7,283
3,571
1,571

1.9
1.7
1.0
0.9
0.5
0.2

The commonest three conditions for both lists were ‘hyperlipidaemia’, ‘hypertension’ and
‘diabetes’ in descending order (Table 2-2). There were three conditions in the CDMP list that
were above 10.0% prevalence rate compared to four conditions in the Fortin list. There were
eight conditions altogether with a prevalence rate of above 1.0% in the CDMP list compared
to 16 conditions in the Fortin list. There was zero patient count for ‘psoriasis’ in the CDMP
list.

Five of the conditions in the CDMP list were not found in the Fortin list. They were a
dermatological condition – ‘psoriasis’; two neurological conditions – ‘epilepsy’ and
‘Parkinson’s disease’; and two psychiatric conditions – ‘bipolar disorder’ and ‘schizophrenia’.

††

Actual value is 0.006%
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There was a total of four psychiatric conditions in the CDMP list (anxiety, schizophrenia, major
depression, and bipolar disorder), and all of them recorded a prevalence rate of less than 1.0%
each.

Seven of the Fortin list conditions were not found in the CDMP list. They were three
gastrointestinal conditions – ‘chronic hepatitis’, ‘stomach problem’, and ‘colon problem’; two
endocrine conditions – ‘thyroid disorder’ and ‘obesity’; one cardiovascular condition – ‘heart
failure’; and ‘any cancer in the last five years’. There was only one psychiatric condition
(‘depression or anxiety’) in the Fortin list with a prevalence rate of more than 1.0%.

3.3

Prevalence of chronic conditions

Figures 2-1 and 2-2 report the percentage of patients with chronic conditions based on the
standardised prevalence ratea for sex and ethnicity stratified by age. The proportion of patients
with chronic conditions increased with the advancement of age.

For the CDMP list (Figure 2-1), the steepest gradient occurred at age 50-54 for those with two
conditions; and for those with three conditions, the steepest gradient occurred at age 65-69
(Appendix 2-4). According to the CDMP list, 50% of the population in primary care would
have one chronic condition in their 50s, two conditions in their 60s and three conditions in their
70s.

For the Fortin list (Figure 2-2), the steepest gradient occurred at age 45-49 for those with two
conditions; and for those with three conditions, the steepest gradient occurred at age 50-54
(Appendix 2-4). According to the Fortin list, 50% of the population in primary care would have
one chronic condition in their 40s, two conditions in their 50s, three conditions in their 60s,
and four conditions in their 80s.
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Figure 2-1. Number of chronic conditions by age-group (CDMP list)

Figure 2-2. Number of chronic conditions by age-group (Fortin list)
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3.4

Prevalence rates of multimorbidity

Section 3.4 addresses objective 2, the prevalence of multimorbidity using two different lists
and two different cut-points. The standardised prevalence ratest of multimorbidity using the
CDMP list were lower than that of the Fortin list (Table 2-3). The standardised prevalence
ratest were also lower than that of the crude prevalence rate. The standardised prevalence ratet
of multimorbidity was lower when MM3+ was used to define multimorbidity as compared to
MM2+.

Table 2-3. Prevalence rates of multimorbidity

Prevalence (Crude)
Age-sex-ethnicity
standardised
prevalence rate
t

CDMP MM2+
% (CI)

Fortin MM2+
% (CI)

CDMP MM3+
% (CI)

Fortin MM3+
% (CI)

29.6

33.9

17.3

23.7

21.9
(21.8, 22.0)

25.9
(25.8, 26.0)

12.0
(12.0, 12.1)

17.2
(17.2, 17.3)

Age-sex-ethnicity standardised prevalence rate

3.5 Comparing the standardised prevalence rates of multimorbidity
among age, sex and ethnic groups
Section 3.5 addresses objective 3, to determine whether there were differences in the standard
prevalence rates among different age, sex, and ethnic groups.

3.5.1

Age

The prevalence rate of multimorbidity increased with age as shown in Table 2-4. The
standardised prevalence ratesa were generally lower than the crude prevalence rate for those in
the ‘0-24’ year age group. The standardised prevalence ratesa were generally higher than the
crude prevalence rate for those in the ‘25-44’ year age group, lower for those in the ‘45-64’
year age group, and about the same for those in the ‘65-99’ year age group.
Patients under 25 years old had very low standardised prevalence ratesa (range from 0.01% to
0.61%) of multimorbidity for both the CDMP and Fortin lists. Using the CDMP list and MM2+

a

Age-stratified, sex-and-ethnicity standardised prevalence rate
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definition, the standardised prevalence ratea of multimorbidity increased by more than six times
from the ‘25-44’ year age group (5.7%) to the ‘45-64’ year age group (37.6%) and more than
12 times from the ‘25-44’ year age group to the ‘65-99’ year age group (72.3%).
Using the CDMP list and MM3+ definition, the standardised prevalence ratea of multimorbidity
increased by more than 10 times from the ‘25-44’ year age group (1.8%) to the ‘45-64’ year
age group (18.4%) and more than 26 times from the ‘25-44’ year age group to the ‘65-99’ year
age group (48.5%).
Using the Fortin list and MM2+ definition, the standardised prevalence ratea of multimorbidity
increased by more than five times from the ‘25-44’ year age group (8.9%) to the ‘45-64’ year
age group (45.3%) and more than eight times from the ‘25-44’ year age group to the ‘65-99’
year age group (77.3%).
Using the Fortin list and MM3+ definition, the standardised prevalence ratea of multimorbidity
increased by more than seven times from the ‘25-44’ year age group (4.0%) to the ‘45-64’ year
age group (28.5%) and more than 15 times from the ‘25-44’ year age group to the ‘65-99’ year
age group (60.9%).

There were clinically and statistically significant differences (after Bonferroni adjustment)
among the standardised prevalence ratesa of multimorbidity among all the four different age
groups as there were no overlap of the confidence intervals and the absolute difference between
them were at least 5.0% or more.
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Table 2-4. Prevalence rates of multimorbidity stratified by age-groups
0-24
Crude
Prevalence
%

Agestratified,
sex-andethnicitystandardised
prevalence
% (CI)

25-44
Crude
Prevalence
%

Agestratified,
sex-andethnicitystandardised
prevalence
% (CI)

45-64
Crude
Prevalence
%

65-99

Agestratified,
sex-andethnicitystandardised
prevalence
% (CI)

Crude
Prevalence
%

Agestratified,
sex-andethnicitystandardised
prevalence
% (CI)

CDMP
MM2+

0.16

0.13
(0.12, 0.15)

5.2

5.7
(5.6,5.8)

40.4

37.6
(37.4, 37.9)

72.5

72.3
(71.9, 72.7)

CDMP
MM3+

0.02

0.01
(0.01, 0.02)

1.7

1.8
(1.8, 1.9)

20.3

18.4
(18.3, 18.6)

48.8

48.5
(48.2, 48.9)

Fortin
MM2+

0.73

0.61
(0.58, 0.65)

8.1

8.9
(8.7, 9.0)

48.2

45.3
(45.1, 45.6)

77.5

77.3
(76.9, 77.7)

Fortin
MM3+

0.11

0.08
(0.07, 0.10)

3.7

4.0
(3.9, 4.1)

30.9

28.5
(28.3, 28.7)

61.1

60.9
(60.5, 61.2)

a

Age-stratified, sex-and-ethnicity standardised prevalence rate

3.5.2

Sex

The standardised prevalence ratesg of multimorbidity were higher for male patients when
compared to female patients for both the CDMP and Fortin lists and both multimorbidity
definitions (MM2+ and MM3+ cut-offs) as shown in Table 2-5. Although there were no
overlaps between the confidence intervals indicating that the difference between the sexes were
statistically significant (after Bonferroni adjustment), the difference in standardised prevalence
rates between the two sexes were less than 5.0% and was therefore deemed not to be clinically
significant.
Table 2-5. Prevalence rates of multimorbidity stratified by sex
Crude
Prevalence %

g

Female
Sex-stratified, age-andethnicity-standardised
prevalence
% (CI)

Crude
Prevalence %

Male
Sex-stratified, age-andethnicity-standardised
prevalence
% (CI)

CDMP
MM2+

29.4

20.4
(20.3, 20.5)

29.7

23.4
(23.3, 23.6)

CDMP
MM3+

16.5

10.9
(10.8, 11.0)

18.1

13.2
(13.1, 13.3)

Fortin
MM2+

34.6

25.0
(24.8, 25.1)

33.2

26.8
(26.7, 27.0)

Fortin
MM3+

24.0

16.5
(16.4, 16.6)

23.4

18.0
(17.9, 18.1)

Sex-stratified, age-and-ethnicity standardised prevalence rate

48
3.5.3

Ethnicity

We next compared the standardised prevalence ratese of multimorbidity among the different
ethnic groups (Table 2-6). Using the CDMP list and MM2+ definition, the standardised
prevalence ratee of multimorbidity in decreasing order for each ethnic group was Chinese
(22.6%), Indian (21.1%), Malay (20.2%), followed by Others (14.3%). The order changed
when the MM3+ definition was used. In decreasing order, the Indian ethnic group had the
highest standardised prevalence ratee of multimorbidity at 12.9%, followed by Malay at 12.4%,
then Chinese at 12.1%, and finally Others at 7.5%.
For CDMP MM2+, the differences in standardised prevalence ratese of multimorbidity were
statistically different (after Bonferroni adjustment) among all ethnic groups but only the
differences between the Others ethnic group and each of the three major ethnic groups were
clinically significant.

For CDMP MM3+, clinically significant difference (an absolute

difference of 5% between standardised prevalence rates) was noted between the Others ethnic
group and the Indian ethnic group only.
The ranking order of the ethnic groups based on the standardised prevalence ratee of the Fortin
list was consistent for both MM2+ and MM3+ definitions. They were Chinese (MM2+ 26.8%,
MM3+ 17.5%‡‡), followed by Indian (MM2+ 24.9%, MM3+ 17.5%§§), then Malay (MM2+
23.5%, MM3+ 16.8%), and finally Others (MM2+ 17.3%, MM3+ 11.1%).

There were statistically significant differences (after Bonferroni adjustment) in the
standardised prevalence ratese of the Fortin list among all the four ethnic groups except between
the Chinese and Indian ethnic groups (Chinese – 17.5%, CI 17.4% - 17.6%; Indians – 17.5%,
CI 17.3% - 17.8%) where the confidence intervals overlapped. Similar to the CDMP MM2+
list, only the differences between the Others ethnic group and each of the three major ethnic
groups were clinically significant for both Fortin MM2+ and MM3+ cut-offs.

‡‡
§§

Actual standardised prevalence ratee was 17.548%
Actual standardised prevalence ratee was 17.545%.
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Table 2-6. Prevalence rates of multimorbidity stratified by ethnicity
Chinese
Crude
Prevalence
%

Ethnicitystratified,
age-and-sex
standardised
prevalence

Malay
Crude
Prevalence
%

% (CI)

e

Indian

Ethnicitystratified,
age-and-sex
standardised
prevalence

Crude
Prevalence
%

% (CI)

Ethnicitystratified,
age-and-sex
standardised
prevalence

Others
Crude
Prevalence
%

% (CI)

Ethnicitystratified,
age-and-sex
standardised
prevalence %
(CI)

CDMP
MM2+

32.8

22.6
(22.5, 22.7)

21.7

20.2
(20.0, 20.5)

27.1

21.1
(20.8, 21.4)

16.7

14.3
(14.0, 14.7)

CDMP
MM3+

18.7

12.1
(12.0, 12.2)

13.7

12.4
(12.2, 12.5)

17.4

12.9
(12.7, 13.1)

9.4

7.5
(7.3, 7.7)

Fortin
MM2+

37.6

26.8
(26.7, 26.9)

24.9

23.5
(23.2, 23.8)

31.1

24.9
(24.6, 25.2)

19.7

17.3
(16.9, 17.7)

Fortin
MM3+

26.0

17.5
(17.4, 17.6)

18.2

16.8
(16.6, 17.0)

23.0

17.5
(17.3, 17.8)

13.3

11.1
(10.8, 11.4)

Ethnicity-stratified, age-and-sex standardised prevalence rate

3.6

The most common dyads and triads

Sections 3.6 and 3.7 address objective 4 regarding the dyads and triads of chronic conditions.
Table 2-7 to 2-10 show a list of common dyads and triads for patients age 45 years and above
for the overall population (n=420,395) for each of the multimorbidity lists and cut-points. The
most common dyads and triads were defined by a crude prevalence of 1.0% or more. The list
of common dyads and triads obtained was further stratified into different groups based on their
ethnicity and sex.

The Others ethnic group did not have any dyads or triads with a crude

prevalence rate that exceeded any of the three major ethnic groups. As such, for the rest of this
section, we described the patterns of multimorbidity among the three major ethnic groups only.

The dyad or triad with the highest crude prevalence rate among the different ethnic/sex groups
would have a superscript ‘#’ symbol tagged next to it. We considered an absolute difference in
crude prevalence rates among the different subgroups of 10.0% or a relative difference of 300%
for clinical significance. An asterisk was put next to a crude prevalence rate if it was lower
than the highest crude prevalence rate for the specific dyad or triad based on the above two
criteria.
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3.6.1

CDMP Dyads

Table 2-7. The most common dyads using the CDMP list – Crude prevalence rates
Rank

CDMP Dyads

Overall
(n = 420,395)

Chinese
(n=323,941)
Female
Male
(n = 174,750)

(n=149,191)

Malay
(n=47,541)
Female
Male
(n=25,338)

Indian
(n=33,870)
Female
Male

(n=22,203)

(n=17,633)

(n=16.237)



43.1%

44.3%

43.9%

4

Hyperlipidaemia/
Hypertension
Hypertension/
Diabetes
Hyperlipidaemia/
Diabetes
Diabetes/IHD

5

Hypertension/IHD

3.4%

1.9%

5.3%

1.5%*

4.5%

1.7%*

4.5%

6

Diabetes/CKD

2.3%

1.8%

2.5%

4.1%

3.5%

2.0%

1.9%

7

Hypertension/CKD

1.4%

1.1%

2.0%

1.1%

1.8%

0.5%*

0.7%

8

IHD/CKD
Hypertension/
Osteoarthritis

1.3%

0.8%*

1.7%

1.3%

2.4%

1.0%

1.7%

1.1%

1.5%

0.8%

1.2%

0.7%

1.1%

0.5%

10

Hypertension/Asthma

1.1%

0.9%

0.8%

2.2%

1.4%

2.1%

1.0%

11

Diabetes/Asthma

1.0%

0.7%*

0.5%*

2.8%

1.2%*

4.3%

2.1%

1
2
3

9

44.1%

41.4%

47.4%

47.9%

23.3%

20.0%*

23.7%

31.4%

26.5%

32.1%

31.8%

5.1%

3.6%*

4.8%

6.0%

7.0%

10.7%

12.7%

4.6%

2.6%*

5.8%

3.7%*

7.5%

5.9%

11.6%





15,043 participants were excluded from the Others Ethnic Group. Highest crude prevalence rate in that row; Clinically
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row;  Ischaemic Heart
Disease;  Chronic Kidney Disease

There were eleven CDMP dyads with a crude prevalence rate of 1.0% and above for the overall
population (n=420,395) (Table 2-7). The CDMP dyads consisted of different combinations of
the seven most prevalent CDMP chronic conditions (hyperlipidaemia, hypertension, diabetes,
IHD, asthma, CKD and osteoarthritis) listed in Table 2-2.

The top two dyads were hyperlipidaemia/hypertension (44.1%) and hypertension/diabetes
(23.3%) with a crude prevalence rate of more than 10.0%. These two dyads were also the top
two dyads for all the subgroups stratified by sex and ethnicity with a crude prevalence rate of
more than 10.0%. In addition to these two dyads, the Indian females had one more dyad
(hyperlipidaemia/diabetes),

and

the

Indian

males

had

two

more

dyads

(hyperlipidaemia/diabetes and diabetes/IHD) with a crude prevalence rate of more than 10.0%.

The Chinese had three dyads with crude prevalence rates that surpassed the other ethnic groups,
and the Malays and Indians had four dyads each.
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The Chinese females had five dyads with crude prevalence rates that were clinically
significantly lower than other ethnic/sex groups. The Indian males had no dyads with crude
prevalence rates that were clinically significantly lower than the other ethnic/sex groups.

3.6.2

CDMP Triads

Table 2-8. The most common triads using the CDMP list – Crude prevalence rates
Rank

CDMP Triads

Overall
(n = 420,395)

Chinese
(n=323,941)

Malay
(n=47,541)

Indian
(n=33,870)

Female

Male

Female

Male

Female

Male

(n = 174,750)

(n=149,191)

(n=25,338)

(n=22,203)

(n=17,633)

(n=16.237)

Hyperlipidaemia/
21.9%
19.0%*
22.1%
29.7%
24.8%
29.8%
30.2%
Hypertension/
Diabetes
2
Hypertension/
4.2%
2.5%*
5.2%
3.5%
6.7%
5.4%
9.8%
Diabetes/
IHD
3
Hyperlipidaemia/
3.1%
1.8%
1.4%*
4.3%
1.5%*
4.3%
5.0%

Hypertension/IHD
4
Hypertension/
2.2%
1.8%
2.4%
3.3%
1.9%
1.8%
4.0%
Diabetes/CKD
5
Hyperlipidaemia/
1.2%
0.9%
0.9%
1.4%
0.4%*
0.6%
1.6%
Hypertension/CKD
15,043 participants were excluded from the Others Ethnic Group.  Highest crude prevalence rate in that row;  Clinically
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row;  Ischaemic Heart
Disease;  Chronic Kidney Disease
1

There were five CDMP triads with a crude prevalence rate of 1.0% and above for the overall
population (n=420,395) (Table 2-8). The CDMP triads consisted of different combinations of
the four most prevalent and the sixth most prevalent CDMP chronic conditions
(hyperlipidaemia, hypertension, diabetes, IHD, CKD) listed in Table 2-2. ‘Asthma’ (fifth most
prevalent CDMP chronic condition) was not included in the top five CDMP triads.

Hyperlipidaemia/hypertension/diabetes was the top triad for all the ethnic groups for both
sexes. Hypertension/diabetes/IHD was the second most common triad for all the ethnic groups
for both sexes except the Malay females, where hypertension/diabetes/CKD (4.0%) was more
common than hypertension/diabetes/IHD (3.5%). When comparing the crude prevalence rates,
both the Chinese and Indians had two triads each that surpassed the other ethnic groups and the
Malays had one. The males of all the three ethnic groups had no triads with crude prevalence
rates that were clinically significantly lower than the other ethnic/sex groups.
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3.6.3

Fortin Dyads

There were 19 dyads with a crude prevalence of rate of 1.0% and above for the overall
population (n=420,395) (Table 2-9). The Fortin dyads consisted of different combinations
from the most prevalent Fortin chronic conditions as listed in Table 2-2. They included all the
top eleven single chronic conditions (hyperlipidaemia, hypertension, diabetes, arthritis &/or
rheumatoid arthritis, obesity, cardiovascular disease, chronic hepatitis, stroke/transient
ischaemic attack, and kidney disease or failure) except ‘asthma/COPD or chronic bronchitis’
and ‘stomach problems’ (i.e., nine single conditions in total).

The top two dyads were hyperlipidaemia/hypertension (42.9%) and hypertension/diabetes
(22.8%) with a crude prevalence rate of more than 10.0%. These two dyads were also the top
two dyads for all the subgroups stratified by sex and ethnicity with a crude prevalence rate of
more than 10.0%. In addition to these two dyads, Malay females had one more dyad
(diabetes/obesity), Indian females had one more dyad (diabetes/arthritis), and Indian males had
one more dyad (hyperlipidaemia/diabetes) with a crude prevalence rate of more than 10.0%.
The Indians had nine dyads with crude prevalence rates that surpassed the other ethnic groups,
and both the Chinese and Malays had five dyads each.

The Malay females had four dyads with crude prevalence rates that were clinically significantly
lower than other ethnic/sex groups. The Malay males had no dyads with crude prevalence rates
that were clinically significantly lower than the other ethnic/sex groups.
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Table 2-9. The most common dyads using the Fortin list – Crude prevalence rates
Chinese
(n=323,941)
Female
Male

Malay
(n=47,541)
Female
Male

Indian
(n=33,870)
Female
Male

Rank

Fortin Dyads

Overall
(n = 420,395)

(n = 174,750)

(n=149,191)

(n=25,338)

(n=22,203)

(n=17,633)

(n=16.237)

1

Hyperlipidaemia/
Hypertension
Hypertension/
Diabetes
Hypertension/Arthritis

42.9

43.2%

45.9%

46.6%

41.0%

43.3%

41.7%

22.8

21.3%*

23.1%

30.6%

25.4%

31.3%

30.3%

6.8

7.1%

5.8%

6.5%

4.8%

6.8%

4.1%

6.3

5.5%

4.7%*

8.5%

6.1%

14.7%

9.6%

4.6

3.8%

4.4%

5.2%

6.0%

9.3%

10.4%

4.1

3.0%*

3.1%*

11.9%

6.6%

8.3%

6.0%

3.5

3.3%

4.9%

2.3%*

5.3%

3.1%

7.9%

3.1

2.2%*

1.5%*

8.2%

3.6%

9.6%

3.4%

2.8

3.0%

4.6%

1.1%*

3.5%

0.9%*

3.1%

2.5

2.6%

1.7%

2.4%

1.5%

3.4%

2.0%

2.1

1.8%

1.9%

5.0%

2.8%

2.8%

1.5%*

1.9

1.8%

2.2%

1.0%*

2.1%

2.2%

3.7%

1.3

1.0%

1.3%

2.3%

2.9%

2.6%

2.9%

14

Diabetes/Arthritis
Hyperlipidaemia/
Diabetes
Diabetes/Obesity
Diabetes/
Cardiovascular
Arthritis/ Obesity
Hypertension/
Cardiovascular
Hyperlipidaemia/
Arthritis
Hypertension/Obesity
Arthritis/
Cardiovascular
Obesity/
Cardiovascular
Hypertension/Stroke

1.3

1.5%

2.0%

0.6%*

1.0%

0.4%*

0.8%

15

Cardiovascular/Stroke

1.3

1.3%

1.7%

1.0%

1.7%

0.9%

1.9%

2
3
4
5
6
7
8
9
10
11
12
13

1.2
1.3%
1.1%
1.3%
0.8%
1.4%
1.5%
Diabetes/Stroke
Cardiovascular/
17
1.2
1.1%
1.4%
1.4%
1.0%
1.6%
2.3%
Kidney
18
1.1
1.1%
1.3%
1.5%
0.8%
0.9%
1.6%
Diabetes/Kidney
Diabetes/
19
1.1
1.2%
0.5%
0.7%
0.8%
1.1%
1.4%
Chronic Hepatitis
15,043 participants were excluded from the Others Ethnic Group.  Highest crude prevalence rate in that row;  Clinically
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row
16

3.6.4

Fortin Triads

There were 12 triads with a crude prevalence rate of 1.0% and above for the overall population
(n=420,395) (Table 2-10). The Fortin triads included the top eleven single chronic conditions
(hyperlipidaemia, hypertension, diabetes, arthritis &/or rheumatoid arthritis, obesity,
cardiovascular disease, stroke and transient ischaemic attack, and kidney disease or failure)
except ‘asthma, COPD, or chronic bronchitis’, ‘stomach problem’, and ‘chronic hepatitis’
(i.e., eight single conditions in total).
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Table 2-10. The most common triads using the Fortin list – Crude prevalence rates
Rank

1
2
3
4
5
6
7
8
9
10
11
12

Fortin Triads
Hyperlipidaemia/
Hypertension/Diabetes
Hyperlipidaemia/
Hypertension/Arthritis
Hypertension/Diabetes/
Arthritis
Hypertension/Diabetes/
Obesity
Hypertension/Diabetes/
Cardiovascular
Hyperlipidaemia/
Hypertension/
Cardiovascular
Hyperlipidaemia/
Hypertension/Obesity
Diabetes/Arthritis/
Obesity
Hyperlipidaemia/
Hypertension/Stroke
Hypertension/Arthritis/
Obesity
Hypertension/Diabetes/
Stroke
Hypertension/Diabetes/
Kidney

Overall
(n = 420,395)

Chinese
(n=323,941)

Malay
(n=47,541)

Indian
(n=33,870)

Female

Male

Female

Male

Female

Male

(n = 174,750)

(n=149,191)

(n=25,338)

(n=22,203)

(n=17,633)

(n=16.237)

21.9%

18.9%*

22.1%

29.7%

24.8%

30.2%

29.8%

5.5%

6.7%

4.7%

5.3%

4.0%

5.6%

3.3%

5.2%

5.3%

3.9%

7.1%

5.1%

11.4%

7.1%

6.3%

6.9%

5.2%



3.8%

2.7%*

3.1%*

11.1%

3.2%

1.9%*

4.4%

2.2%*

4.5%

2.7%

6.7%

2.5%

1.4%*

4.2%

1.0%*

3.3%

0.7%*

2.9%

2.0%

1.6%

1.8%

4.4%

2.7%

2.3%

1.5%

1.7%

1.4%*

0.8%*

4.5%

2.1%

5.9%

2.5%

1.2%

1.0%

1.8%

0.5%*

0.9%

0.3%*

0.7%

1.1%

1.2%

0.6%*

2.9%

1.4%

2.5%

0.8%

1.1%

1.0%

1.4%

1.0%

1.2%

0.7%

1.2%

1.0%

0.8%

1.2%

1.4%

1.5%

0.8%

0.9%

15,043 participants were excluded from the Others Ethnic Group.  Highest crude prevalence rate in that row;  Clinically
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row

Hyperlipidaemia/hypertension/diabetes was the top triad for all the ethnic groups for both sexes
with a crude prevalence rate of 10.0% and above. These top triad was also the top triad for all
the subgroups stratified by sex and ethnicity with a crude prevalence rate of more than 10.0%.
In addition to this triad, Malay females had one more triad (hypertension/diabetes/obesity), and
Indian females had one more triad (hypertension/diabetes/arthritis) with a crude prevalence
rate of more than 10.0%. In terms of the crude prevalence rate, each of the three ethnic groups
had four triads that surpassed the other ethnic groups.

The Chinese females had five triads with crude prevalence rates that were clinically
significantly lower than other ethnic/sex groups. Both the Malay and Indian males had no
dyads with crude prevalence rates that were clinically significantly lower than other ethnic/sex
groups.
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3.7 Sub-group analysis of the common dyads and triads of
multimorbidity
The Fortin list was found to have a higher standardised prevalence ratet compared with the
CDMP list in Section 3.4 (p44). Therefore, we determined the common dyads and triads of
the three major ethnic groups stratified by sex instead of the overall population using the Fortin
list in this section. Table 2-11, 2-12 and 2-13 show the most common dyads and triads based
on the total Chinese, Malay, and Indian patients age 45 years and above respectively. The most
common dyads and triads were defined by a crude prevalence of 1.0% or more.

3.7.1

Chinese ethnic group (Table 2-11)

‘Hypertension’, ‘stroke and transient ischaemic attack’, and ‘chronic hepatitis’ tended to occur
more in combination with other conditions to form a dyad or triad for Chinese males.
‘Hypertension’ and ‘arthritis &/or rheumatoid arthritis’ tended to occur more in combination
with other conditions to form a dyad or triad for Chinese females. Although ‘asthma, COPD,
or chronic bronchitis’, as a single condition, was ranked number seven in terms of prevalence
rate (Table 2-2), it was not seen at all in the common dyads and triads of the Chinese ethnic
group for both sexes.

3.7.2

Malay ethnic group (Table 2-12)

Both the Malay males and females tended to have more frequent occurrences of ‘kidney disease
or failure’ in combination with other conditions to form a dyad or triad. None of the other
female ethnic groups had ‘kidney disease or failure’ found in any of the triads at all with a
crude prevalence rate of 1.0% and above. ‘Obesity’ was also a distinctly common condition in
combination with other conditions to form a dyad or triad for the Malay females. Out of the
15 triads listed, nine of them consisted of ‘obesity’, of which six of the triads had the highest
prevalence rate when compared to all the other subgroups (hypertension/diabetes/obesity,
hyperlipidaemia/hypertension/obesity,

hypertension/arthritis

&/or

rheumatoid

arthritis/obesity, diabetes/obesity/chronic hepatitis, diabetes/obesity/kidney disease or failure,
diabetes/obesity/asthma, COPD, or chronic bronchitis).

t

Age-sex-ethnicity standardised prevalence rate
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3.7.3

Indian ethnic group (Table 2-13)

‘Diabetes’ and ‘cardiovascular disease’ tended to occur more frequently in combination with
other conditions to form a dyad or triad for both sexes of the Indians. Although ‘kidney disease
or failure’, as a single condition, was ranked number eleven in terms of prevalence rate (Table
2-2), it was not seen at all in the common triads of the Indian ethnic group for both sexes. Only
one dyad for Indian males had this condition. Only the Indian females had ‘thyroid disorder’
in combination with other conditions to form a dyad, none of the other subgroups had this
condition found in combination with other conditions with a crude prevalence rate of 1.0% and
above.
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Table 2-11. The most common dyads and triads for Chinese patients above 45 years old stratified by sex (Fortin List, n = 323,941)
Female (n = 174,750)

Rank
Dyad

%

%

Dyad

%

1

Hyperlipidaemia/Hypertension

40.9

Hyperlipidaemia/Hypertension/Diabetes

18.9

Hyperlipidaemia/Hypertension

45.9

Hyperlipidaemia/Hypertension/Diabetes

22.1

2

Hypertension/Diabetes

19.7

Hyperlipidaemia/Hypertension/Arthritis

6.7#

Hypertension/Diabetes

23.1

Hyperlipidaemia/Hypertension/Arthritis

4.7

3

Hypertension/Arthritis

8.3

#

Hypertension/Diabetes/Arthritis

5.3

Hypertension/Arthritis

5.8

Hypertension/Diabetes/Cardiovascular

4.4

4

Diabetes/Arthritis

6.2

Hypertension/Diabetes/Obesity

2.7

Diabetes/Cardiovascular

4.9

Hyperlipidaemia/Hypertension/Cardiovascular

4.2#

Hypertension/Diabetes/Cardiovascular

1.9

Diabetes/Arthritis

4.7

Hypertension/Diabetes/Arthritis

3.9

5

Hyperlipidaemia/Arthritis

3.4

#

Triad

#

Triad

%

6

Hyperlipidaemia/Diabetes

3.3

Hyperlipidaemia/Hypertension/Obesity

1.6

Hypertension/Cardiovascular

4.6

Hypertension/Diabetes/Obesity

3.1

7

Diabetes/Obesity

2.8

Diabetes/Arthritis/Obesity

1.4

Hyperlipidaemia/Diabetes

4.4

Hyperlipidaemia/Hypertension/Obesity

1.8

8

Arthritis/Obesity

2.8

Hyperlipidaemia/Hypertension/Cardiovascular

1.4

Diabetes/Obesity

3.1

Hyperlipidaemia/Hypertension/Stroke

1.8#

9

Diabetes/Cardiovascular

2.0

Hypertension/Arthritis/Obesity

1.2

Arthritis/Cardiovascular

2.2

Hypertension/Diabetes/Stroke

1.4#

10

Hypertension/Obesity

1.8

Hypertension/Stroke

2.0#

Hypertension/Diabetes/Kidney

1.2

11

Hypertension/Cardiovascular

1.6

Hypertension/Obesity

1.9

Hypertension/Diabetes/Chronic Hepatitis

1.1#

12

Arthritis/Cardiovascular

1.5

Hyperlipidaemia/Arthritis

1.7

13

Arthritis/Chronic Hepatitis

1.1#

Cardiovascular/Stroke

1.7

14

Hypertension/Stroke

1.1

Cardiovascular/Kidney

1.6

15

Diabetes/Stroke

1.0

Diabetes/Stroke

1.5#

16

Arthritis/Obesity

1.5

17

Diabetes/Chronic Hepatitis

1.4#

18

#

Male (n=149,191)

Hypertension/Chronic
Hepatitis

Hyperlipidaemia/Hypertension/Chronic
Hepatitis
Hypertension/Arthritis/Cardiovascular

1.3#

19

Diabetes/Kidney

1.3

20

Obesity/Cardiovascular

1.3

21

Hypertension/Kidney

1.1#

22

Hypertension/Urinary

1.0#

denotes the highest crude prevalence rate for that specific dyad or triad compared with other ethnic/sex subgroups across Table 2-11, Table 2-12 & Table 2-13.

1.1#
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Table 2-12. The most common dyads and triads for Malay patients above 45 years old stratified by sex (Fortin List, n = 47,541)
Female (n=25,338)

Rank
Dyad

%

%

Dyad

%

1

Hyperlipidaemia/Hypertension

46.6#

Hyperlipidaemia/Hypertension/Diabetes

29.7

Hyperlipidaemia/Hypertension

41.0

Hyperlipidaemia/Hypertension/Diabetes

24.8

2

Hypertension/Diabetes

30.6

Hypertension/Diabetes/Obesity

11.1#

Hypertension/Diabetes

25.4

Hypertension/Diabetes/Obesity

6.3

3

Diabetes/Obesity

11.9#

Hypertension/Diabetes/Arthritis

7.1

Diabetes/Obesity

6.6

Hypertension/Diabetes/Arthritis

5.1

4

Diabetes/Arthritis

8.5

Hyperlipidaemia/Hypertension/Arthritis

5.3

Diabetes/Arthritis

6.1

Hypertension/Diabetes/Cardiovascular

4.5

5

Arthritis/Obesity

8.2

Diabetes/Arthritis/Obesity

4.5

Hyperlipidaemia/Diabetes

6.0

Hyperlipidaemia/Hypertension/Arthritis

4.0

6

Hypertension/Arthritis

6.5

Hyperlipidaemia/Hypertension/Obesity

4.4#

Diabetes/Cardiovascular

5.3

Hyperlipidaemia/Hypertension/Cardiovascular

3.3

Triad

#

Triad

%

7

Hyperlipidaemia/Diabetes

5.2

Hypertension/Arthritis/Obesity

2.9

Hypertension/Arthritis

4.8

Hyperlipidaemia/Hypertension/Obesity

2.7

8

Hypertension/Obesity

5.0#

Hypertension/Diabetes/Cardiovascular

2.2

Arthritis/Obesity

3.6

Diabetes/Arthritis/Obesity

2.1

9

Obesity/Asthma

2.4

Hyperlipidaemia/Diabetes/Obesity

1.6

Hypertension/Cardiovascular

3.5

Diabetes/Obesity/Cardiovascular

1.7#

10

Hyperlipidaemia/Arthritis

2.4

Hypertension/Diabetes/Kidney

1.4

Obesity/Cardiovascular

2.9

Hypertension/Diabetes/Kidney

1.5#

11

Obesity/Cardiovascular

2.3

Hyperlipidaemia/Diabetes/Arthritis

1.3

Hypertension/Obesity

2.7

Hypertension/Arthritis/Obesity

1.4

#

12

Diabetes/Cardiovascular

2.3

Diabetes/Obesity/Cardiovascular

1.3

Cardiovascular/Kidney

2.3

Hypertension/Diabetes/Stroke

1.2

13

Obesity/Chronic Hepatitis

1.9#

Diabetes/Obesity/Kidney

1.2#

Arthritis/Cardiovascular

2.1

Diabetes/Arthritis/Cardiovascular

1.1

Diabetes/Obesity/Asthma

1.0

#

Cardiovascular/Stroke

1.7

Hyperlipidaemia/Diabetes/Arthritis

1.0

Diabetes/Obesity/Chronic Hepatitis

1.0#

Diabetes/Kidney

1.6#
1.5

#

14

Obesity/Kidney

1.8

15

Diabetes/Kidney

1.5

16

Cardiovascular/Kidney

1.4

Hyperlipidaemia/Arthritis

17

Hypertension/Cardiovascular

1.1

Diabetes/Stroke

1.3

18

Diabetes/Stroke

1.1

Stroke/Kidney

1.1#

19

Arthritis/Asthma

1.1

Obesity/Chronic Hepatitis

1.1

20

Arthritis/Cardiovascular

1.0

Obesity/Kidney

1.0

21

Cardiovascular/Stroke

1.0

Hypertension/Stroke

1.0

Cardiovascular/Asthma

1.0

22
#

Male (n=22,203)

denotes the highest crude prevalence rate for that specific dyad or triad compared with other ethnic/sex subgroups across Table 2-11, Table 2-12 & Table 2-13.
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Table 2-13. The most common dyads and triads for Indian patients above 45 years old stratified by sex (Fortin List, n = 33,870)
Female (n=17,633)

Rank
Dyad

%

%

Dyad

%

1

Hyperlipidaemia/Hypertension

43.3

Hyperlipidaemia/Hypertension/Diabetes

30.2#

Hyperlipidaemia/Hypertension

41.7

Hyperlipidaemia/Hypertension/Diabetes

29.8

2

Hypertension/Diabetes

31.3#

Hypertension/Diabetes/Arthritis

11.4#

Hypertension/Diabetes

30.3

Hypertension/Diabetes/Arthritis

7.1

3

Diabetes/Arthritis

14.7#

Hypertension/Diabetes/Obesity

6.9

Hyperlipidaemia/Diabetes

10.4#

Hypertension/Diabetes/Cardiovascular

6.7#

4

Arthritis/Obesity

9.6#

Diabetes/Arthritis/Obesity

5.9#

Diabetes/Arthritis

Hypertension/Diabetes/Obesity

5.2

Hyperlipidaemia/Hypertension/Arthritis

3.3

5

Hyperlipidaemia/Diabetes

9.3

Triad

Hyperlipidaemia/Hypertension/Arthritis

5.6
#

6

Diabetes/Obesity

8.3

Hyperlipidaemia/Diabetes/Arthritis

3.1

7

Hypertension/Arthritis

6.8

Hypertension/Diabetes/Cardiovascular

2.7

9.5
#

Triad

%

Diabetes/Cardiovascular

7.9

Diabetes/Obesity

6.0

Hyperlipidaemia/Hypertension/Cardiovascular

2.9

Hypertension/Arthritis

4.1

Diabetes/Arthritis/Obesity

2.5

#

8

Hyperlipidaemia/Arthritis

3.4

Hypertension/Arthritis/Obesity

2.5

Arthritis/Cardiovascular

3.7

Hyperlipidaemia/Diabetes/Arthritis

2.5

9

Diabetes/Cardiovascular

3.1

Hyperlipidaemia/Hypertension/Obesity

2.3

Arthritis/Obesity

3.4

Diabetes/Arthritis/Cardiovascular

2.3#

10

Hypertension/Obesity

2.8

Hyperlipidaemia/Diabetes/Obesity

1.8#

Hypertension/Cardiovascular

3.1

Diabetes/Obesity/Cardiovascular

1.6

11

Obesity/Cardiovascular

2.6

Diabetes/Arthritis/Cardiovascular

1.6

Obesity/Cardiovascular

2.9#

Hyperlipidaemia/Hypertension/Obesity

1.5

Hyperlipidaemia/Arthritis

2.0

Hyperlipidaemia/Diabetes/Obesity

1.4

12

#

Male (n=16.237)

Obesity/Asthma

2.5

#

Arthritis/Obesity/Asthma

1.3

#

#

13

Arthritis/Cardiovascular

2.2

Diabetes/Obesity/Cardiovascular

1.2

Cardiovascular/Stroke

1.9

Hypertension/Diabetes/Stroke

1.2

14

Arthritis/Asthma

2.0#

Arthritis/Obesity/Cardiovascular

1.1#

Cardiovascular/Kidney

1.6

Hyperlipidaemia/Diabetes/Cardiovascular

1.2#

15

Obesity/Thyroid

1.7#

Cardiovascular/Asthma

1.6#

Hypertension/Arthritis/Cardiovascular

1.0

16

Diabetes/Asthma

1.3#

Hypertension/Obesity

1.5

17

Arthritis/Thyroid

1.2#

Diabetes/Stroke

1.4

18

Diabetes/Thyroid

1.2#

Diabetes/Asthma

1.1

Diabetes/Chronic Hepatitis

1.1

#

19

Asthma/Thyroid

1.1

20

Cardiovascular/Asthma

1.1

21

Obesity/Chronic Hepatitis

1.1

denotes the highest crude prevalence rate for that specific dyad or triad compared with other ethnic/sex subgroups across Table 2-11, Table 2-12 & Table 2-13.
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4

Discussion
4.1

Summary of results

This study described the epidemiology of multimorbidity of Singapore’s primary care
population. Patients under 25 years old had very low rates of chronic conditions for both the
CDMP and Fortin lists. The prevalence of chronic conditions increased by several fold from
the ‘25-44’ year age group to the ‘45-64’ year age group and with further increase to the ‘6599’ year age group for both the CDMP and Fortin lists. There were different findings when
using the two different lists to describe the prevalence of chronic conditions and multimorbidity
in the sample population. The two lists will be discussed in more detail in Section 4.3 (p64).
The standardised prevalence ratet of multimorbidity using CDMP MM2+ was 21.9%, 25.9%
for Fortin MM2+, 12.0% for CDMP MM3+, and 17.2% for Fortin MM3+ (Table 2-3). The
standardised prevalence ratesa of all the four age groups were statistically and clinically
different from each other (Table 2-4). There was no clinically significant difference in the
standardised prevalence ratesg of multimorbidity between the sexes (Table 2-5). There were
also no clinically significant differences in the standardised prevalence ratese of multimorbidity
among the three major ethnic groups in Singapore (Table 2-6).

The two most common dyads of chronic conditions based on crude prevalence rates for those
45 years old and above were hyperlipidaemia/hypertension and hypertension/diabetes for all
the different ethnic groups and sexes (Table 2-7 & Table 2-9). The most common triad of
chronic conditions was hyperlipidaemia/hypertension/diabetes (Table 2-8 & Table 2-10).

t

Age-sex-ethnicity standardised prevalence rate
Sex-stratified, age-and-ethnicity standardised prevalence rate
e
Ethnicity-stratified, age-and-sex standardised prevalence rate
g
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4.2

Comparison with other studies

4.2.1

Prevalence rate of multimorbidity

Comparing our results with those of other studies is difficult due to the different conditions,
different number of conditions selected to form the multimorbidity list, data sources, and
reference populations. When using two or more chronic conditions to define multimorbidity,
most estimates from the primary care setting reported prevalence rates between 20-30% for the
entire population and 50-90% for the elderly1,5,23,25,42,43. Ours were 21.9% (CDMP list) and
25.9% (Fortin list) for the entire population (Table 2-3), and 72.5% (CDMP list) and 77.5%
(Fortin list) for the older adult population (age 65-99) (Table 2-4). As such, our estimates of
the standardised prevalence ratest of multimorbidity were comparable to the international
literature.

When using three or more chronic conditions to define multimorbidity, the age-standardised
prevalence rate was 14.0-15.2% in the literature on practice-based populations39,44. Our
estimates of 12.0% (CDMP list) and 17.2% (Fortin list) were comparable to their findings
(Table 2-3).

4.2.2

Age and prevalence rate of multimorbidity

Similar to the prevalence rates of chronic conditions, patients under 25 years old had very low
standardised prevalence ratesa of multimorbidity for both the CDMP and Fortin lists. The
standardised prevalence ratesa of multimorbidity increased progressively from the ‘25-44’ year
age group to the ‘45-64’ year age group and with further increase to the ‘65-99’ year age group
for both the CDMP and Fortin lists. Our findings confirmed the significant positive association
between age and prevalence of multimorbidity, irrespective of the definitions used for
multimorbidity, consistent with that found in a growing world literature1,21,25,26,39,42,45-51.

t
a

Age-sex-ethnicity standardised prevalence rate
Age-stratified, sex-and-ethnicity standardised prevalence rate
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4.2.3

Sex and prevalence rate of multimorbidity

The association between sex and the prevalence of multimorbidity has been less consistent
across studies2. This study found no clinically statistically significant sex differences in the
standardised prevalence rateg of multimorbidity. Other investigators who conducted
multimorbidity studies in primary care also found no sex differences in the occurrences of
multimorbidity21,28,22,40,42,51. Fortin et al.44 observed that more females than males were found
with multimorbidity were found in the general population, whereas the contrary was found in
the practice-based population. However, in the population health index survey (communitydwelling individuals) conducted in Singapore, no sex differences were found in the prevalence
rate of multimorbidity between males and females aged 21 years and above6.

Further

comparison studies locally using the same list of multimorbidity conditions would need to be
conducted to confirm whether there are sex differences between the two settings.
Schafer et al.51 reported that the difference in prevalence rates of multimorbidity between the
sexes depended on the type of multimorbidity conditions considered. They explained that
females seemed to be more vulnerable to anxiety, depression, somatoform disorders, and painrelated morbidity while males appeared to be more vulnerable to cardiovascular and metabolic
diseases. In our study when we looked at the common dyads and triads of multimorbidity in
Sections 3.6-3.7 (p49-59), the males also appeared to be more vulnerable to cardiovascular and
metabolic diseases while the females were more vulnerable to arthritis.

4.2.4

The

findings

Patterns of multimorbidity

in

our

study

showed

that

the

hyperlipidaemia/hypertension and hypertension/diabetes.

most

common

dyads

were

The most common triad was

hyperlipidaemia/hypertension/diabetes. These findings were consistent with results from
international40,49,52 and local studies6.

Hyperlipidaemia/hypertension/arthritis was found to be the second most common triad in the
Chinese ethnic group (both males and females); for the Malay ethnic group,

g

Sex-stratified, age-and-ethnicity standardised prevalence rate
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hyperlipidaemia/hypertension/obesity took precedence; and hypertension/diabetes/arthritis
took precedence for the Indian ethnic group.
Salive9 in his review of multimorbidity in older adults stated that the most common
combinations of chronic conditions could be predicted from the individual chronic condition
prevalence rates. In our study, the different combinations of the most prevalent single chronic
conditions (Table 2-2) were also the common dyads and triads seen. However, the condition
‘asthma’ and ‘stomach problem’ were not included in the most common dyads and triads
indicating that the most prevalent single chronic conditions may not always be able to predict
the most common combinations.
Furthermore, ‘depression’ and ‘anxiety’ were prominently not represented in all the patterns of
this study compared to non-local studies. The conspicuous absence of mental disorders in the
patterns of multimorbidity in this study could be because there is a lower prevalence of mental
illness in Singapore. However, according to Chong et al.53, the prevalence of major depression
in a local population-based mental health survey was 5.8%, bipolar disorder was 1.2%, and
generalised anxiety disorder was 0.9%. The prevalence rates of the above mental disorders
were much lower in the present study – the crude prevalence rate of major depression was
0.2%, bipolar disorder was 0.006%, and generalised anxiety disorder was 0.8% (Table 2-2).

The other likely reason for the absence of mental disorders is the social stigma associated with
these conditions resulting in the decreased help-seeking behaviour by the local population54.
Chong et al.55 found that only 50.1% of respondents with severe disability across any mental
disorder had sought help from some service in the past year. Individuals with moderate or mild
levels of mental disorder had lower rates of consultation. Their study found that the main
sources of help were from religious or other non-medical healers rather than from family
physicians or mental health specialists.
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4.3 Comparison between CDMP and Fortin list with different cutpoints - addressing objective 2
In this section, we discuss the advantages and disadvantages of the CDMP and Fortin lists of
chronic conditions and also that of the different cut-points used for defining multimorbidity.
We will address the controversial issues on multimorbidity research from Chapter One and
attempt to make recommendations on lists and cut-points, based on this study.
4.3.1

The CDMP vs Fortin list

The CDMP list is based on the list of important chronic conditions that have a significant
burden in the Singapore healthcare system where the Singapore Ministry of Health provides
financial subsidy to patients who suffer from these conditions to help reduce their monetary
burden. Therefore, these conditions are chosen based on the country’s health burden and not
strictly from the primary care perspective. A good example is the zero-patient count for
psoriasis from the 787,446 primary care patients in this study (Table 2-2).

A team of well-established multimorbidity researchers developed the Fortin list after studying
various multimorbidity lists used in several countries which targeted the primary healthcare
system36. Conceptually, the Fortin list is more suitable for measuring multimorbidity in
primary care.

Sixteen out of the 19 single conditions in the Fortin list had a prevalence rate of more than
1.0% while only eight out of the 20 conditions in the CDMP list had a prevalence rate of more
than 1.0% (Table 2-2). The Fortin list consisted of categories of conditions and included 37
ICD-10 codes used in NHGP (Appendix 2-2). The CDMP list included 26 ICD-10 codes used
in NHGP (Appendix 2-1). So, even though there were only 19 conditions used in the Fortin
list, more ICD-10 diagnoses were captured than in the CDMP list. Using the Fortin list, the
prevalence rate of multimorbidity was consistently higher than that of the CDMP list (Table 23). There were consistently more dyads and triads that had a prevalence rate of 1.0% and above
when using the Fortin list than when using the CDMP list (Table 2-7 to 2-10). The Fortin list
is more intuitive as it combines conditions like ‘anxiety’ and ‘depression’ into one category
recognising perhaps that about 85% of patients with depression have significant anxiety and
vice versa56. Therefore, in terms of practicality, the Fortin list picked up more chronic and
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relevant conditions by merging frequently co-occurring conditions into one category in primary
care than the CDMP list that kept all the conditions separate.

Although we noticed differences between the gradients in the increase in proportion of patients
with chronic conditions using the two different lists (Figures 2-1 & 2-2), it was evident that
the sudden surge in the proportion (by age) of chronic conditions occurs around the middleage years of individuals. The increase in the number of chronic conditions for the Fortin list
was more gradual, i.e., the steepest slope for two conditions at age 45-49 and for three
conditions at age 50-54 (Figure 2-2 & Appendix 2-4), when compared to the CDMP list. The
steepest slope for two conditions of the CDMP list was at age 50-54, and for three conditions
at age 65-69 years old (Figure 2-1 & Appendix 2-4). In terms of capturing the full breadth of
multimorbidity across the ages, the Fortin list appears to be more sensitive when compared to
the CDMP list.

4.3.2

Cut-off for ‘two or more’ vs ‘three or more’ chronic conditions

As mentioned in Chapter One, one of the concerns of using the cut-off for two conditions is
that a large majority of patients would be classified as having multimorbidity, making the
classification less clinically meaningful10.
When using the CDMP list with an MM2+ cut-off, the standardised prevalence ratet of
multimorbidity was similar to using the Fortin list (CDMP MM2+ 21.9%, Fortin MM2+
25.9%) (Table 2-3). As the surge in the proportion of chronic conditions occur around the
middle-age years of an individual, we looked more carefully at the prevalence rates of
multimorbidity for patients above 44 years old (Table 2-4).

When using the CDMP list with an MM2+ cut-off, more than one in three (37.6% of patients
age 45-64) and close to three in four (72.3% of patients age 65-99) patients were classified as
having multimorbidity for the ‘45-64’ year and ‘65-99’ year age groups respectively. When
using the Fortin list with an MM2+ cut-off, almost one in two (45.3 % of patients age 45-64)
patients and more than three in four (77.3% of patients age 65-99) patients were classified as

t

Age-sex-ethnicity standardised prevalence rate
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having multimorbidity. In general, a large proportion of older adults would be classified as
having multimorbidity when we use the MM2+ cut-off.

When using CDMP list with an MM3+ cut-off, almost one in five (18.4% of patients age 4564) and close to one in two (48.5% of patients age 65-99) patients were classified as having
multimorbidity for the ‘45-64’ year and ‘65-99’ year age groups respectively. When using
Fortin list with an MM3+ cut-off, more than one in four (28.5% of patients age 45-64) patients
and about three in five (60.9% of patients age 65-99) patients were classified as having
multimorbidity.

Compared to MM2+, MM3+ results in a lower prevalence of multimorbidity and likely better
identify patients with higher needs and hence may be more meaningful for clinicians than
MM2+ which is less discriminating57.

In summary, the Fortin list is conceptually more suitable for measuring multimorbidity in
primary care, more practical as it reflects disease categories rather than single conditions like
the CDMP list, and is more sensitive in capturing the full breadth of multimorbidity across the
ages, when compared to the CDMP list. Using MM3+ as the cut-off can identify a smaller
number of patients with higher needs compared to MM2+. Putting these two considerations
together, it would seem that the Fortin list with MM3+ cut-off is the most suitable definition
of multimorbidity in the Singapore primary care setting. Further studies will need to be
conducted to confirm this finding.

4.4 Distinct patterns of chronic conditions and multimorbidity noted in
the different ethnic and sex groups – addressing objective 4
Using the Fortin list, the mean number of chronic conditions in descending order for each ethnic
group was Indian (1.2), Chinese (1.1), Malay (1.0) and Others (0.8) (Table 2-1 Fortin
Conditions). Despite being younger than the Chinese, the Indians (mean age of Chinese = 47.1
years old, Indians = 39.7 years old) had slightly more chronic conditions than the Chinese (1.2
vs 1.1). When looking at the overall dyads and triads with a crude prevalence rate of 1.0% and
more (Table 2-9 & 2-10), the Indian ethnic group was also found to have the greatest number
of dyads and triads with the highest crude prevalence rates when compared to the other ethnic
groups.
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Although the Malay males had the fewest number of dyads or triads that had the highest crude
prevalence rate, they were also the only subgroup that did not differ significantly from all the
other subgroups for every dyad and triad listed in Tables 2-9 and 2-10. Moreover, despite
being younger than the Others group (mean age of Malays = 35.1 years old, Others = 37.1 years
old), the Malays had more chronic conditions than the Others ethnic group (1.0 vs 0.8) (Table
2-1 Fortin Conditions). Therefore, the Malay males seemed to have the highest burden of
multimorbidity compared to the other ethnic groups.

The Chinese males had more dyads and triads with higher crude prevalence rates when
compared to the Chinese females, in general. For the other ethnic groups, it was usually the
females who had more prevalent dyads and triads than the males. Together with having more
dyads and triads with clinically significant lower crude prevalence rates compared to the other
subgroups, this suggests that Chinese females had the lowest burden of multimorbidity among
the subgroups.
The more frequent occurrences of ‘kidney disease or failure’ in combination with other
conditions to form a dyad or triad for the Malay ethnic group is consistent with the findings in
the National Health Survey 2010 where the Malay ethnic group was found to have a higher
renal impairment prevalence (4.1%) compared with the Chinese (2.0%) and the Indians
(2.0%)32.
‘Obesity’ was also a distinctly common condition in combination with other conditions to form
a dyad or triad for the Malay females. This finding is also consistent with that reported by the
Health Promotion Board of Singapore. Among the ethnic groups in Singapore, 20.7% of
Malays, 14.0% of Indians and 5.9% of Chinese were considered obese59.

Looking at the different co-occurring conditions provides a fresh perspective and allows
clinicians to see the fuller picture of the interactions of all these common chronic conditions.
We summarised the overall picture of the patterns of multimorbidity seen in the three major
ethnic groups of Singapore as follows.

The Chinese ethnic group had a higher prevalence rate of hypertension as a risk factor with the
brain being the major end-organ disease target (i.e., stroke and transient ischaemic attack). The
Malay ethnic group had a higher prevalence rate of obesity as a risk factor with the kidney
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being the major end-organ disease target (i.e., kidney disease or failure). The Indian ethnic
group had a higher prevalence rate of diabetes as a risk factor with the heart being the major
end-organ disease target (i.e., cardiovascular disease). Hyperlipidaemia was the most prevalent
single chronic condition and a significant risk factor for all ethnic groups. These findings
would need to be further confirmed by future studies.

4.5

Strengths and Limitations

4.5.1

Strengths

There are several strengths in this study. First, we used a large data set which included all the
patients who visited the National Healthcare Group Polyclinics, which was a good
representation of the primary care population in the public health setting in Singapore. Second,
we provided both crude and standardised rates that provided valuable information for both the
burden of multimorbidity at the polyclinic level and possibly at the public health level. Third,
we used diagnoses from the electronic health records instead of self-reports where the latter
have been found to be inaccurate due to under-reporting or forgetfulness60. Last, we included
the full age range of patients to describe multimorbidity across the whole age spectrum.

4.5.2

Limitations

This study also has several limitations. The study was cross-sectional and the prevalence rate
provided a snapshot of the burden of disease in the population over one year. This may
underestimate the actual prevalence of multimorbidity.

Several reasons may lead one to consider that the prevalence rates were an underestimate. The
first is that patients who had chronic conditions but were seen at longer intervals than one year
would not have been counted.

A second possible reason for an underestimate may be that, like most prevalence studies, we
can only provide information on those conditions already diagnosed. There is a significant
proportion of people in the community with undiagnosed chronic conditions. For example,
26.3% of patients with hypertension, 51.4% of patients with diabetes, and 44.1% of patients
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with hyperlipidaemia were previously undiagnosed in the Singapore National Health Survey
201032. However, the setting of this study is in primary care and the proportion of the
undiagnosed common chronic conditions should be lower than that found in the National
Health Survey 2010 as asymptomatic participants gave consent and were screened for a few
common chronic conditions in the survey hence increasing the chance of chronic condition
detection.

In any case, this suggests that the estimates provided in this study may be

conservative.

Another possible reason for an underestimate may be because in all large database studies, the
findings are dependent on the fidelity with which actual patient diagnoses were recorded. Data
from patients whose chronic conditons were treated outside the polyclinic were subjected to
measurement error if the family physicians at National Healthcare Group Polyclinics did not
update or include in the electronic medical records conditions treated by physicians outside of
the polyclinics. Furthermore, there may be undetermined variation among physicians in the
completeness and accuracy of their electronic medical record coding of chronic conditions10.
Finally, an underestimate may have occurred as not all the ‘chronic’ conditions included may
have been active or relevant for some patients during the study period. For example, a patient
with mild asthma that presents intermittently may not visit the polyclinic at all during the study
period.
Another limitation was the use of the ‘de facto registration’ method which excluded diseasefree persons who were not seeking health care. We could not get the population at risk as the
denominator because the study team did not have the utilisation correction factor. We also
used one-year window period and this time frame might underestimate the denominator
because well patients did not visit in that year; it may overestimate the denominator because
people have died or moved away.

While the main limitation was a potential underestimate of the prevalence, another limitation
may have been that this study did not provide any indication of the severity of individual
chronic conditions. A count of chronic conditions may not be adequate to assess how much
burden an individual patient experience. The lack of information on the severity of individual
chronic conditions is common in prevalence studies and will be explored in the next chapter.
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4.6

Clinical implications

4.6.1

Policy and decision-makers

Although the standardised prevalence rate of multimorbidity provides a good estimation of the
burden of multimorbidity for primary care in Singapore, policymakers should be looking at the
crude prevalence rate for better planning of services at the polyclinic level.

For decision-makers tasked with resource allocation, prevalence estimates in samples from
primary care practices are more informative than estimates from the general population. This
is because population prevalence has consistently been shown to be lower than primary care
prevalence23,44. The population-based study in Singapore by Subramaniam et al.3 (16.3%)
supported this finding obviously. However, whether the other two population studies in
Singapore by Picco et al.4 (51.5%) and Ge et al.6 (35.0%) showed a higher or lower prevalence
rate of multimorbidity compared to this study is difficult to ascertain. This is due to the
differences in the list of conditions used, the age of the reference population, and the
methodology used among the studies. A comparison study using the same list of conditions,
similar reference population, and methods for the two population sources would be necessary
to confirm the relationship between prevalence estimates from primary care and the general
population in Singapore.

The knowledge of the common patterns of multimorbidity will also allow delivery of care to
be more targeted to ensure that the resources provided match the needs of patients with the
same patterns of multimorbidity.

4.6.2

Primary care clinicians and educators

Up to nine single conditions were prominently featured when looking at the common dyads
and triads of multimorbidity found in this study. Primary care practice guidelines could be
developed for these common combinations of conditions to guide doctors in providing whole
person care to patients with multimorbidity without dwelling on every single chronic condition
individually and adding unnecessary treatment burden to patients.
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These common dyads and triads included different combinations of conditions like
hyperlipidaemia, hypertension, diabetes, arthritis, obesity, cardiovascular disease, kidney
disease, stroke, and asthma. With the distinct patterns noted in each ethnic group, emphasis
could be put on managing hypertension, hyperlipidaemia and arthritis in Chinese females;
hypertension, hyperlipidaemia and stroke prevention in Chinese males. For the Malay ethnic
group, emphasis could be put on weight management, hyperlipidaemia and kidney disease
prevention. For the Indian ethnic group, attention could be placed on diabetes prevention and
control, hyperlipidaemia, and cardiovascular disease prevention. Many of these conditions are
cardiometabolic diseases and share common treatment goals. Only arthritis and asthma add to
the discordance of treatment goals with possible pharmacological interactions. Special efforts
involving the expertise of the specialists may be necessary to make the multimorbidity
guidelines more complete.

4.6.3

Researchers

Including chronic diseases that are burdensome to the health care system but may not be
prevalent to the list of conditions used in multimorbidity studies is debatable but essential. In
this study, mental disorders were found not to be prevalent, and asthma did not appear in many
patterns of multimorbidity especially in the Chinese ethnic group. It may be possible that the
low prevalence of mental disorders is due to the social stigma attached to it54. The reason for
low prevalence rates of dyads or triads consisting of asthma is less evident. However, the
undeniable fact is that asthma management in Singapore may need improvement as the
country’s asthma mortality rate is three times that of other developed countries61.

This emphasises the importance of the careful and precise documentation of chronic conditions
by the family physician. Without this, both the doctor and the patient may forget to take into
account other co-occurring and important conditions during a typical episode of care. The
deliberate effort to register chronic conditions is a complex and laborious chore, but one that
helps to make transparent the comprehensive reality of multimorbidity. How to help busy
family physicians to record and update all the chronic conditions a patient has is of critical
importance in the area of health services research62.

There are also other ways to look at the non-random associations of chronic conditions using
statistical tools including factor analysis or cluster analysis
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. Investigators should work
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collaboratively with statisticians to explore other patterns of multimorbidity not discovered by
using the current combinations of the most common conditions as was done in this study64.
Understanding the common patterns of the non-random clustering of some chronic conditions
for specific ethnic groups not only provides insights for public health clinicians to prevent their
development in the first place, but also provides practical evidence for basic science researchers
to look at the reasons for co-occurrence at the molecular level.

4.7

Conclusion and future

This is the first epidemiology study of multimorbidity on a large database of primary care
patients in Singapore. The standardised prevalence rate of multimorbidity based on Fortin’s
list with a cut-off of three conditions was 17.2% for primary care patients age between 0-99.
This study showed that age increases the standardised prevalence rate of multimorbidity.
However, the standardised prevalence rates of multimorbidity between the sexes and among
the three major ethnic groups were not clinically significant even though they were all
statistically significant.

This study has identified some distinct patterns of multimorbidity involving about nine
conditions for the three major ethnic groups in Singapore. Knowing these patterns can allow
clinicians, administrators, researchers and policymakers to work collaboratively to look at the
aetiology, prevention, clinical management, resource allocation, and future research for
handling this monumental problem of multimorbidity.

Since there is currently limited evidence of the effectiveness of interventions to improve care
for patients with multimorbidity65, identifying these patients by consistently documenting all
chronic conditions in the list of multimorbidity for each family practice is the first requisite.
The development of minimally disruptive clinical guidelines for the management of the
common patterns of multimorbidity in the local context should follow next.

Although survivorship with minimal complications is the clinical aim of most clinicians
managing patients with multimorbidity, the quality of life and psychological well-being of
patients with multimorbidity are just as, if not more, important. We will explore the quality of
life and psychological distress of patients with multimorbidity in Chapter Four. We have also
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noted the limitation of this study by not including the severity of individual chronic conditions.
This will be explored with a systematic review in Chapter Three.
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Appendices

Appendix 2-1. CDMP List of Conditions35
S/No

Category of Condition

ICD10 Code & Description
E10.9 (Type 1 diabetes mellitus without complication)
E11.9 (Type 2 diabetes mellitus without complication)
E14.2 (Diabetes mellitus with incipient diabetic nephropathy)

Diabetes
1

E14.3 (Diabetes Mellitus with retinopathy)
E14.31 (Unspecified diabetes mellitus with background retinopathy)
E14.64 (Unspecified diabetes mellitus with hypoglycaemia)
E14.73 (Unspecified diabetes mellitus with foot ulcer due to multiple causes)

2

Hypertension

I10 (Essential (primary) hypertension)

3

Lipids

E78.5 (Hyperlipidaemia, unspecified)

4

Stroke

I64 (Stroke, not specified as haemorrhage or infarction)

5

Asthma

J45.9 (Asthma, unspecified)

6

COPD

J44.9 (Chronic obstructive pulmonary disease, unspecified)

7

Chronic Kidney Disease

N18.9 (Chronic kidney disease, unspecified)

8

Osteoporosis

M81.99 (Other osteoporosis, site unspecified)

9

Rheumatoid Arthritis

M06.99 (Rheumatoid arthritis, unspecified, site unspecified)

10

Osteoarthritis

M15.9 Osteoarthritis (OA) - Generalised)

11

Major Depression

F32.20 (Severe depressive episode without psychotic symptoms, not specified as
arising in the postnatal period)

12

Anxiety

F41.1 (ANXIETY DISORDER, UNSPECIFIED)

13

Dementia

F03 (Unspecified dementia)

14

Benign Prostate
Hypertrophy

N40 (Hyperplasia of prostate)

15

Parkinson's

G20 (Parkinson's disease)

16

Epilepsy

G40.90 (Epilepsy, unspecified, without mention of intractable epilepsy)

17

Psoriasis

L40.8 (Other psoriasis)

18

Schizophrenia

F20.9 (Schizophrenia, unspecified)

19

Bipolar Disorder

F31.9 (Bipolar affective disorder, unspecified)

20

Ischaemic Heart Disease

I25.9 (Chronic ischaemic heart disease, unspecified)
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Appendix 2-2. Fortin List of Conditions36
S/No
1
2

Category of Condition
Any cancer in the last 5 years
Thyroid disorder

3
Diabetes

4
5
6

Obesity
Hyperlipidaemia
Dementia
or
disease

Alzheimer's

7

8
9

10

11

Depression or anxiety

Hypertension
(high blood pressure)

I10 (Essential (primary) hypertension)

Cardiovascular disease
(angina, MI, AF, poor
circulation of lower limbs)
Heart failure
(including valve problems or
replacement)
Stroke and TIA
Asthma, COPD, or
chronic bronchitis

13

Stomach problem
(reflux, heartburn, or gastric
ulcer)
Colon problem
(irritable bowel)

15
16

F03 (Unspecified dementia)
F32.20 (Severe depressive episode without psychotic symptoms, not
specified as arising in the postnatal period)
F32.90 (Depressive episode, unspecified, not specified as arising in the
postnatal period)
F41.1 (Anxiety disorder, unspecified)

12

14

ICD10 Code & Description
C80 (Malignant neoplasm without specification of site)
E03.9 (Hypothyroidism, unspecified)
E05.9 (Thyrotoxicosis, unspecified)
E10.9 (Type 1 diabetes mellitus without complication)
E11.9 (Type 2 diabetes mellitus without complication)
E14.2 (Diabetes mellitus with incipient diabetic nephropathy)
E14.64 (Unspecified diabetes mellitus with hypoglycaemia)
E14.73 (Unspecified diabetes mellitus with foot ulcer due to multiple
causes)
E66.9 (Obesity, unspecified)
E78.5 (Hyperlipidaemia, unspecified)

Chronic hepatitis
Arthritis &/or
rheumatoid arthritis

17
18

Osteoporosis

19
20

Chronic urinary problem
Chronic musculoskeletal
condition causing pain or
limitation

Kidney disease or failure

I25.9 (Chronic ischaemic heart disease, unspecified)
I48 (Atrial fibrillation and flutter)
I70.20 (Atherosclerosis of arteries of extremities, unspecified)
I73.9 (Peripheral vascular disease, unspecified)
I50.0 (Congestive heart failure)
I51.9 (Heart disease, unspecified)
G45.9 (Transient cerebral ischaemic attack, unspecified)
I64 (Stroke, not specified as haemorrhage or infarction)
J44.9 (Chronic Obstructive Pulmonary Disease, Unspecified)
J45.9 (Asthma, unspecified)
K21.9 (Gastro-oesophageal reflux disease without oesophagitis)
K27.9 (Peptic ulcer, unspecified as acute or chronic, without haemorrhage
or perforation)
K58.9 (Irritable bowel syndrome without diarrhoea)
K76.9 (Liver disease, unspecified)
Z22.51 (Carrier of viral hepatitis B)
M06.99 (Rheumatoid arthritis, unspecified, site unspecified)
M15.9 (Osteoarthritis (OA) - Generalised)
M19.99 (Arthritis, Unspecified, Site Unspecified)
M81.99 (Other osteoporosis, site unspecified)
N03.9 (Unspecified nephritic syndrome, unspecified)
N18.9 (Chronic kidney disease, unspecified)
N40 (Hyperplasia of prostate)
No matching ICD code
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Appendix 2-3. Singapore residents by age group, ethnic group and sex, June 201637
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Appendix 2-4. Gradient calculation for Figure 2-1 and Figure 2-2
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CHAPTER THREE
A Systematic review on the Instruments used for
measuring the level of Multimorbidity (SIM)
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Abbreviations
ACE-27
ACG
ACSH
ADG
ADL
AUC
BI
CC-AM
CCC (of ICD-9 Codes)
CCC
CCI
CCI-PSR
CC-MM
CC-MuM
CDS
CGI-S
CIRS
CLS
CMI
COSmm
CPRD
DC
ED
EDC
EI
EMR
EQ-5D-5L
EQ-VAS
ERA
GP
HCC
HM
HPFS Cohort
HRQoL
HSMI
HUI3
IADL
ICD-10
ICD-9
ICPC-2
M3 Index
mCCI
MDMS
MeSH
MM by ADL
MM by HUI3
MN Tier
MWI
NHS

Adult Comorbidity Evaluation
Adjusted Clinical Groups
Ambulatory Care Sensitive Hospitalisation
Aggregated Diagnostic Groups
Activities of daily living
Area Under the Curve
Barthel Index
Chronic conditions – additive modelling
Clinical Classification Categories
Chronic Condition Count
Charlson Comorbidity Index
Charlson Comorbidity Index – Psychosocial Risk
Chronic conditions – minimum modelling
Chronic conditions – multiplicative modelling
Chronic Disease Count
Clinical Global Impression – Severity scale
Cumulative Illness Rating Scale
Comorbidity Linked Score
Cornell Medical Index
Core Outcome Sets of multimorbidity
Clinical Practice Research Datalink
Disease Count
Emergency Department
Expanded Diagnosis Clusters
Elixhauser Index
Electronic Medical Record
EuroQoL-5 Dimensions
EuroQoL-Visual Analogue Scale
Elders Risk Assessment
General Practice
Hierachical Condition Categories
Hybrid Model (Minnesota Tiering and Elders Risk Assessment)
Health Professionals Follow-up Study Cohort
Health-Related Quality of Life
Health Search Morbidity Index
Health Utility Index
Instrumental Activities of Daily Living
International Classification of Diseases, Tenth Revision
International Classification of Diseases, Ninth Revision
International Classification of Primary Care – Second Edition
Multi-Multimorbidity Measure Index
modified Charlson Comorbidity Index
Multidimensional Multimorbidity Score
Medical subject heading
Multimorbidity weighted by Activities of Daily Living scale
Multimorbidity weighted by Health Utility Index
Minnesota Tiering
Multimorbidity-Weighted Index
National Health Service
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NHS II Cohort
NOS
NS
OARS
Organ-CDC
Pra tool
QALY
QOF
QOF-E
QOF-S
QoL
RoB
RUB
RxRisk-V
SF-12
SF-36
SF-6D
SRH
TRIPOD
UK
WHO-ATC
Φc

Nurses’ Health Study II Cohort Study
Newcastle-Ottawa Quality Assessment Scale
Not stated
Older Americans Resources and Services
Organ systems with chronic disease count
Probability of repeated admission risk prediction tool
Quality-Adjusted Life Year
Quality and Outcomes Framework
Extended Quality and Outcomes Framework
Standard Quality and Outcomes Framework
Quality of Life
Risk of Bias
Resource Utilisation Band
A Veterans Association adapted pharmacy-based case-mix instrument
12-item Short Form Survey
36-item Short Form Survey
Short Form Six Dimensions
Self-Rated Health
Transparent Reporting of Multivariable prediction models for individual
prognosis or diagnosis
United Kingdom
World Health Organisation – The Anatomical Therapeutic Chemical
Classification System
Cramer’s V
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Introduction

Given the clinical significance of multimorbidity in primary care, it is essential to consider how
we quantify multimorbidity in community-dwelling individuals. We measured the prevalence
and patterns of multimorbidity in Chapter Two.

Chapter Three will now address the

measurement of the level of multimorbidity.

Before moving on, it is pertinent to elucidate some terms used which are very similar but relate
to different meanings and concepts. The first two terms to clarify are the ‘severity of chronic
condition’ and the ‘level of multimorbidity’. The next two terms to clarify are ‘measuring
multimorbidity’ and ‘measuring the level of multimorbidity’.
A consideration of the complexity of multimorbidity should address the ‘severity of chronic
condition’, that is, the severity of individual conditions and its impact of multimorbidity on
health outcomes1. However, less than a quarter of studies on multimorbidity reported the
severity of individual conditions2. Reporting the severity of individual conditions does not
automatically lead to an understanding of the combined effects of multiple conditions. The
combined effect may be additive or multiplicative or may not even be synergistic at all3. The
‘severity of chronic condition’ refers to the severity of a single chronic condition which has
been widely described in the medical literature and in daily clinical practice4. Most of the time,
it can be measured by well-established clinical guidelines like the New York Heart Association
for functional classification of heart failure; or suggested clinical parameter cut-off like blood
pressure control; or sometimes from patients’ self-reported severity of a condition2. Therefore,
the term ‘severity of chronic condition’ is not to be confused with the term ‘level of
multimorbidity’ which measures the combined effects of the multiple conditions that an
individual has.

In scientific measurements, it is important to describe clearly the purpose of the measurement.
According to de Vet et al.5, the three main purposes of measurement are for diagnosis
(discriminant measurement), evaluation of intervention (evaluation measurement), and
prediction of outcome (predictive measurement).

In Chapter Two, we used the term

‘measuring multimorbidity’ for the purpose of describing the prevalence and patterns of
multimorbidity in the primary care population. For this systematic review, we searched for
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studies that were ‘measuring the level of multimorbidity’. The purpose was to describe the
consequences, i.e., the prediction of future course5, with varying ‘levels of multimorbidity’.
Referring to de Vet et al.’s5 classification, discriminant measurement of multimorbidity was
performed in Chapter Two. For Chapter Three, we looked at the predictive measurements of
the different levels of multimorbidity that were described in the literature.
Smith et al.6 published a list of 17 multimorbidity outcomes agreed to by international experts
of multimorbidity intervention studies with quality of life, mental health outcomes, and
mortality as the three essential core outcomes. These core outcome sets (COSmm) represent
the minimum that should be measured and reported in all clinical studies of multimorbidity. In
this study, we looked at whether the purposes of measuring the level of multimorbidity
concurred with the 17 COSmm recommended by international experts of multimorbidity
intervention studies.

Existing instruments for measuring the level of multimorbidity are heterogeneous in terms of
the number, type, and weighting of conditions considered7. Several instruments have also been
developed from highly selective study populations and may not be suitable for individuals from
a different setting.
Multiple different opinions on what constitutes a useful instrument*** for measurement of the
level of multimorbidity exist in the literature. For example, counting diseases has been
criticised for being less relevant compared to the disability connected with the level of the
conditions when measuring multimorbidity8. This was supported by a systematic review that
reported that interventions for multimorbidity were shown to be most effective when focusing
on functional difficulties rather than on the individual diseases9. Other investigators argued
that the number of conditions was associated with the number of consultations10 and was
inversely associated with continuity of care11, highlighting that healthcare utilisation, costs,
and patient satisfaction were just as important outcomes at both the system and patient levels.
Some criticised that the reductive approaches based on the consequences, rather than the causes
of multimorbidity, have led to an incorrect definition of the problem12. There is currently no

***

We have used the term ‘instruments’ rather than ‘indices’ or ‘scales’ or ‘measures’ as a general term to encompass all the
above in order not to create further confusion as some of the instruments are called a ‘scale’, an ‘index’, or a ‘measure’.
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consensus on these disputes because of the conceptual differences in the understanding and a
lack of standardisation in instruments that measure the level of multimorbidity13.
However, prognostic information (i.e., an outcome) has many meaningful uses14. Patients and
clinicians can use it to plan for treatment priorities. Policy analysts can use it to evaluate the
effectiveness of various treatment options. Administrators can also use it to anticipate patients’
medical service utilisation and nursing needs. This is the reason why this chapter will only
look at instruments measuring the level of multimorbidity with at least a specific purpose or
outcome in mind.

Ideally, a single multimorbidity instrument should be able to predict a variety of relevant
outcomes, such as death, hospital admission, and quality of life, in a variety of patient and
population settings. However, Byles et al.15 reported that no single instrument could predict a
variety of outcomes. For example, an instrument developed to measure mental health is
unlikely to be applicable to measure the physical function outcome. A range of different
instruments for measuring different outcomes will be anticipated.
Huntley et al.16 published a systematic review looking at the instruments for measuring
morbidity burden used in the primary care and general population setting. They found 194
articles describing 17 different measures. Most instruments were diagnosis-based measures,
but medication-based measures were also noted. The measures that were most widely used
and for which there was the most significant evidence of validity were the Charlson index,
disease counts, and the ACG (Adjusted Clinical Groups) System16. They concluded that the
choice of an instrument would depend on the outcome (i.e., purpose) of interest and the type
of data available (i.e., context).
The systematic review by Huntley et al.16 has not been updated since 2009 and the amount of
multimorbidity research has surged tremendously since 2010. Therefore, we proposed an
updated review to list the suitable instruments for the measurement of level of multimorbidity
in community-dwelling individuals.

This study aimed to perform a systematic review of relevant multimorbidity studies that
measured the level of multimorbidity of patients from the primary care or general population
to predict or explore the association with at least one specified outcome published from January
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2010 onwards. Specific objectives were to: (1) provide a list of measurement instruments for
measuring level of multimorbidity in the primary care or general population setting; (2) report
the advantages and disadvantages of using these instruments in predicting the multimorbidityrelated outcomes; (3) provide details of the data source(s) and resource(s) required by each of
the instruments; and (4) compile a list of corresponding instruments for measuring the level of
multimorbidity for the three essential core outcomes identified for COSmm6 (quality of life,
mental health, and mortality).

The systematic review will update investigators or clinicians targeting community-dwelling
individuals with multimorbidity on the available instruments for the measurement of level of
multimorbidity so that they can be better informed on the requirements, strengths and
limitations of these instruments and select or develop one that matches their needs.

2 Methods
A protocol for the systematic review was developed using PRISMA-P guidelines17,18 and was
published on PROSPERO website19. CRD42018105297 dated 6th Sep 2018 is available at
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=105297.

We did not seek ethics approval as the review used published data from secondary sources and
did not involve any interactions with human subjects. We followed the PRISMA statement20
and guidance on the conduct of narrative synthesis in systematic reviews21 for the reporting of
this systematic review. There was no funding for this project.

2.1

Search Strategy

We used OVID to search MEDLINE††† and EMBASE‡‡‡, and EBSCO for CINAHL§§§. We
also manually searched the Journal of Comorbidity for potential articles. The search was from

†††

A bibliographic database of life sciences and biomedical information. It includes bibliographic information for articles
from academic journals covering medicine, nursing, pharmacy, dentistry, veterinary medicine, and health care from 1946 to
present.
‡‡‡ A biomedical research database that covers the most international biomedical literature from 1947 to the present day. All
articles are indexed in depth using Elsevier's Life Science thesaurus Embase Indexing and Emtree®.
§§§ An index of English-language and selected other-language journal articles about nursing, allied health, biomedicine and
healthcare from 1961 to present.
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January 2010 to 14th August 2018. A ‘snowball’ search, which is a hand search of the reference
lists in the selected articles, was performed for comprehensiveness22.

Several different search trials were performed before a structured search strategy that identified
the best combination of Medical Subject Headings (MeSH) terms and keywords using
proximity searching**** was developed23. The final search strategy was developed between the
principal investigator (LES) and a librarian trained in health sciences research (JC) after
multiple iterations.

The MeSH terms were different for each electronic database and the proximity searching terms
were also different among them as reflected in Appendix 3-1. For example, ‘multiple chronic
conditions’ was a MeSH term in MEDLINE and EMBASE but not in CINAHL.

2.2

Inclusion and Exclusion criteria

The inclusion criteria were studies that included: (1) adult patients (ages 18 years and above)
who visited primary care or were from the general population; (2) at least one specified
outcome variable (e.g., mortality, quality of life) that was predicted by or associated with
instruments used for measuring the level of multimorbidity; and (3) full-text articles published
from January 2010 to August 2018.

The exclusion criteria were studies that: (1) selected patients from the hospital or nursing home
only or patient data that were drawn solely from the hospital or the nursing home; or (2)
selected patients with a prerequisite to have certain conditions prior to recruitment; or (3) used
level of multimorbidity as a covariate and not the main independent variable; or (4) were not
written in English.

****

Proximity searching is a form of advanced search to specify two or more separately matching term occurrences are
within a specified distance, where distance is the number of intermediate words or characters.
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2.3

Study selection

LES conducted a preliminary screen of titles and abstracts to exclude records that were
irrelevant. Records such as letters to editors, conference abstracts, protocols, editorials,
reviews, qualitative research, and validation of questionnaires were removed. Abstracts of the
remaining records were screened independently by two reviewers (LES & EH) to identify
potentially relevant articles. Disagreements were resolved through discussion until a consensus
was reached. The full-text articles were then retrieved for the agreed list and independently
assessed for eligibility according to the inclusion and exclusion criteria as stated in Section 2.2
(p90) by the same reviewers.
The two reviewers used Covidence24 (a Systematic Review management tool) independently
that allowed blinding to minimise bias while the article selections were assigned neatly from
each stage of the review process to the next. Disagreements at this stage were resolved through
discussion with a third reviewer (TSH) until a consensus was reached. After agreement on the
list of articles, the reference lists of included articles were hand-searched for additional papers
that adhered to the inclusion and exclusion criteria.

2.4

Data Extraction

Specific data extraction forms were developed, and after being pilot-tested (KHL, MZ & LES),
were used with each article for assessment of study quality and evidence synthesis. KHL and
WFY performed the final data extraction. Weekly meetings were held whereby all the data
extracted were checked by LES. Any discrepancies were discussed and rectified in meetings
among LES, KHL and WFY. Outstanding disagreements on data extracted among the three
were resolved by involving EH and TSH.

The extracted information from each article included (1) characteristics of participants
(including population source, sample size, and the age range); (2) instruments used, definition
of chronic diseases used in the instrument, the cut-off number of chronic conditions for
definition of multimorbidity, and the total number of chronic conditions considered in the
multimorbidity list; (3) type of outcomes measured; (4) results; (5) data sources and resources
used to conduct the study; and (6) other information like financial conflict of interest. We
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collated data as much as possible when multiple articles of the same study were found to avoid
double counting of measurement instruments.

2.5

Assessment of risk of bias

Several rounds of calibration exercises were conducted with extensive discussions and
iterations on the selection of a suitable risk of bias assessment tool. Pilot trials of potentially
eligible articles were conducted by four of the team members – LES, MZ, KHL and EH.
Eventually, the Newcastle-Ottawa Scale (NOS) was modified and used as the assessment tool
to determine the risk of bias of each article25,26. Risk of bias assessment was appraised by three
reviewers (LES, EH & TSH) independently for each included article. Each article was assessed
as having good, fair or poor quality using the modified NOS which examined three broad
categories: a) Selection; b) Comparability; and c) Outcome (Appendices 3-2 & 3-3).

We contacted the authors, as needed, for additional information or clarification for a maximum
of three times spaced one week apart. The clarifications were mainly related to sampling and
data analysis. We contacted 25 authors, and 19 of them replied. Any disagreements on the
risk of bias were resolved among the three reviewers (LES, EH & TSH) through regular
meetings. KHL and WFY were responsible for tracking and updating the final risk of bias
assessment outcome.

2.6

Narrative synthesis of results

It was anticipated that the studies would be heterogeneous and therefore the decision was made
a priori not to combine them for meta-analysis. Instead, we synthesised the evidence in tables
and narrative text based on the data extracted.

Upon completion of the systematic review, we compiled a list of instruments for measuring the
level of multimorbidity that were described in studies with low risk of bias and the outcomes
that were used in the studies with those instruments (Table 3-6). We also compiled a list of the
three essential core outcomes identified for COSmm6 (quality of life, mental health, and
mortality) and listed the corresponding instruments for measuring the level of multimorbidity
from those studies with low risk of bias (Table 3-7). The intention was that the two lists
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compiled from the findings of the systematic review would assist investigators in making
informed choices in selecting appropriate instruments or outcomes for future research on level
of multimorbidity.

94

3 Results
3.1

Search Results

A total of 67 studies involving 74 articles were identified for inclusion in the systematic review.
The search of MEDLINE, EMBASE, CINAHL databases, and the Journal of Comorbidity
provided a total of 9,122 records. After adjusting for duplicates, the remaining records were
screened by looking at the titles and abstracts only. We then screened through the full text of
all those articles that were selected from above. This first round of screening resulted in 55
articles. This number was relevant to the first step but not the final step, so it is not shown in
Figure 3-1.

We hand-searched the lists of references of all the 55 included articles and added potentially
eligible records to the ‘additional records identified through other sources’. Many of these
records were duplicates, but we went through the same process of screening the abstracts and
titles, followed by full-text review and then hand-searching the list of references from the newly
included articles. We repeated the whole process until no more potentially eligible articles
were identified. A total of 134 articles were identified using this ‘snowballing’ process.

Ultimately, 7,481 records were screened, and 7,351 records were discarded during the title and
abstract screening. The full text of all the 130 articles was found, and none was discarded
during this screening process. We perused the full text of 130 articles in detail, and 56 of them
were excluded due to the various reasons stated in Figure 3-1. The final number of included
articles was 74 articles, representing 67 unique studies.

Table 3-1 summarised the risk of bias appraisals for the 35 cohort articles and Table 3-2
summarised the 39 cross-sectional articles. Table 3-3 summarised the 53 articles with a good
risk of bias judgement including a summary of the results. Table 3-4 summarised the 21 articles
with a fair or a poor risk of bias. The summary of results was not provided for Table 3-4 due
to the possibility of bias in the study design or methodology. Table 3-5 described the unique
instruments used for measuring the level of multimorbidity from the 74 included articles. Table
3-6 described the associated outcomes of each instrument that was reported in the 53 articles
with a good risk of bias judgement. Table 3-7 compiled the list of the instruments that were
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used for the three essential core outcomes of multimorbidity identified for COSmm6 from the
53 articles with a good risk of bias judgement.

For the rest of the chapter, we describe the included 67 studies as much as possible rather than
the 74 articles so as not to duplicate and confuse the reader.

3.2

Description of the included studies

There were 67 studies reported in 74 articles because 14 articles were from seven studies (two
separate articles corresponding to each study) namely Barile et al.27,28, Boeckxstaens et al.29,30,
Brilleman et al.31,32, Crooks et al.33,34, Formiga et al.35,36, Payne et al.37,38, and Wallace et al.39,40.

Thirty studies selected participants from the general population and 37 studies selected
participants from primary care. A majority of the studies were for participants 18 years old and
above (n=28) and the second largest group was for older adults age 65 years old and above
(n=20). More than half of the studies were from Europe (n=35), and 14 of these came from the
United Kingdom. North America contributed 26 studies (the United States of America had 20
and Canada had 6). There were two studies from Australia and one study each from Israel,
Japan, New Zealand, and South Africa.

Altogether, there were 117 instruments for measuring the level of multimorbidity used in the
67 studies, of which 33 were unique instruments. The instruments were categorised based on:
1) simple counts of individual conditions; 2) organ or system-based approaches; 3) conditions
that have been weighted and combined into indices; and 4) other approaches including case mix and pharmaceutical-based approaches as described by Sarfati41,42.

A total of 112 outcomes were reported from all the studies. They were broadly categorised
into eleven categories: Activities of Daily Living; Costs; Health care use; Health-related
Quality of life; Mental health; Mortality; Physical activity; Physical function; Quality health
care; Self-rated health; and Others. The top reported outcomes were health care use (n=34),
mortality (n=14), and health-related quality of life (n=14).
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The sample size of the 67 studies ranged from 11343 to more than 9 million44. There were 28
cohort studies, 36 cross-sectional studies, and three mixed studies (i.e., cross-sectional and
cohort). Twenty of these studies (23 articles) used prediction models.

Identification

Figure 3-1. PRISMA Flow Diagram

Records identified
through database
searching
(n = 9,122)

Additional records
identified through other
sources
(n =134)

Screening

Records after duplicates removed
(n = 7,481)
)

Eligibility

Records screened
(n = 7,481)

Full-text articles assessed
for eligibility
(n = 130)

Included

)

Full-text articles included
(n = 74)
-

35 cohort articles &
39 cross-sectional articles

Records excluded by
looking at the titles and
abstracts (n = 7,351)
Full-text articles excluded, with
reasons (n =56)
• No measurement of
multimorbidity (n=17)
• Measurement of
multimorbidity is a covariate
only (n=16)
• Has an index condition for
recruitment (n=11)
• Wrong type of publication
e.g., review, editorial (n=4)
• Not English (n=2)
• Measures multimorbidity
patterns only (n=2)
• Wrong Setting e.g., hospital,
nursing home (n=1)
• No outcome (n=2)
• Irrelevant (n=1)
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Table 3-1 summarised the details of the risk of bias (RoB) assessment using the modified
Newcastle Ottawa Scale (NOS) for 35 cohort articles and Table 3-2 summarised the 39 crosssectional articles. Of the 35 cohort articles, 29 articles were rated ‘good’, four articles were
rated ‘fair’, and two articles were rated ‘poor’. Of the 39 cross-sectional articles, 24 articles
were rated ‘good’, five articles were rated ‘fair’, and ten articles were rated ‘poor’. In total,
there were 47 studies (53 articles) that were rated ‘good’, eight studies (nine articles) that were
graded ‘fair’, and 12 studies (12 articles) that were graded ‘poor’. (The articles are highlighted
in light grey for combined studies and highlighted in dark grey for cohort studies in Tables 31 and 3-2)
All studies that were graded ‘fair’ were due to issues with the ‘selection’ criterion. Studies
graded ‘poor’ were due to issues with a variety of criteria but mainly on the ‘selection’ and
‘comparability’ criteria. A higher proportion of cohort studies compared to cross-sectional
studies were graded ‘good’ with the RoB assessment.

The justification for choosing a specific list of chronic conditions was not clearly stated in
many of these studies. We found only 23 studies (34.3%) that provided at least a brief
statement of what a chronic condition was.

The total number of conditions in the

multimorbidity list ranged from seven45-47 to 14710 conditions in this review but only slightly
more than half of them, i.e., 38 studies (56.7%), provided the full list of the conditions. Finally,
only 23 studies (34.3%) stated clearly the cut-points they used to define multimorbidity. A
large majority of the studies used ‘two or more’ chronic conditions as the cut-off to define
multimorbidity. We identified two studies that used ‘three or more’ chronic conditions 29,30,48
and another two studies that used ‘four or more’ conditions28,30 as the cut-offs to define
multimorbidity. In total, only 14 studies (20.9%) included all three components, i.e., the
definition of chronic condition, list of conditions, and cut-points used to define multimorbidity.
The data sources of the conditions and the reference populations were clearly stated in all the
studies.

Hand-searching by the snowball method contributed 25% (n=19) of the final selected articles.
All the objectives stated in every one of the 67 studies were fully reported. Only 15 articles
declared financial sponsorship or funding from grants. Thirty-six articles declared no financial
support or funding, and 23 of the articles did not make any statement on financial conflict of
interest.

98

Outcome Criteria
Statistical test†
Assessment of outcome
Follow-up was long enough for outcomes to
occur
Adequacy of follow-up of cohorts

Boeckxstaens et al. (2015b)30

Brilleman et al. (2014)31

Brilleman and Salisbury (2013)32

Carey et al. (2013)50

Chapman et al. (2015)51

Crane et al. (2010)52

Crooks et al. (2016)33

Crooks et al. (2015)34

Formiga et al. (2013)53

Formiga et al. (2011a)54

Formiga et al. (2016)35

Fraccaro et al. (2016)55

Haas et al. (2013)56

Hwang et al. (2015)57

Jennings et al. (2015)58

Jia and Lubetkin (2016)59

Jia et al. (2018)60

Lemke et al. (2012)61

Md Yusof et al. (2010)43

Payne et al. (2014)37

Payne et al. (2013)38

Quail et al. (2011)62

Reyes et al. (2014)63

Salisbury et al. (2011)11

Saver et al. (2014)64

Stanley and Sarfati (2017)65

Streit et al. (2014)66

Takahashi et al. (2016)67

Takahashi et al. (2012)47

Tyack et al. (2016)68

Wallace et al. (2016a)39

Wallace et al. (2016b)40

Wei and Mukamal (2018)69

Comparability Criteria
Study controls for age and sex
Study controls for others

Biehl et al. (2016)49

Selection Criteria
Representativeness of the sample
Ascertainment of Multimorbidity
Demonstration that outcome of interest was
not present at the start of the study

Barile et al. (2013)27

Table 3-1. Summary of risk of bias (RoB) appraisal of included cohort articles using the modified Newcastle-Ottawa Quality Assessment Scale
(35 articles)
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Overall RoB Judgementa
G G F G G G G G G G G G G G G G F P P G F G G G G G G G G G G F G G G
Note. G = Good; F = Fair; P = Poor.
†
Statistical test must be clearly described and appropriate before assessing the other items under the Outcome category. a Good rating is given when there are 2 to 3 stars in Selection category (Representativeness of
Sample must be fulfilled) AND 1 to 2 stars in Comparability category AND 2 to 3 stars in Outcome category; Fair rating is given when there are 1 to 2 stars in Selection category AND 1 to 2 stars in Comparability
category AND 2 to 3 stars in Outcome category; Poor rating is given when there are 0 star in Selection category OR 0 star in Comparability category OR 0 to 2 stars in Outcome category.
“*” Study satisfies the criteria; “-” Study did not satisfy the criteria; “” Statistical test is clearly described and appropriate; “X” Statistical test is not described, incomplete or inappropriate.
NB: Articles highlighted in light grey are combined studies (see Table 3-2 with similar highlights) and articles highlighted in dark grey are cohort studies. Those not highlighted are single articles which are also single
studies.
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Agborsangaya et al. (2013)70

Barile et al. (2012)28

Barnett et al. (2012)71

Boeckxstaens et al. (2015a)29

Chen et al. (2011)72

DiNapoli et al. (2017)73

Formiga et al. (2011b)36

Galenkamp et al. (2011)45

Garin et al. (2014)74

Glynn et al. (2011)10

Gunn et al. (2012)75

Hanmer et al. (2010)76

Hu et al. (2017)77

Isaacs et al. (2014)78

Kojima et al. (2011)46

Kristensen et al. (2014)79

Lapi et al. (2015)80

Lawson et al. (2013)81

Li et al. (2016)82

Marengoni et al. (2011)83

McDaid et al. (2013)84

Muggah et al. (2012)44

Mujica-Mota et al. (2015)3

Naessens et al. (2011)85

Østergaard and Foldager (2011)86

Peters et al. (2018)87

Ranstad et al. (2014)88

Renne and Gobbens (2018)89

Ryu et al. (2015)90

Shadmi et al. (2011)91

Sibley et al. (2014)92

Sullivan et al. (2012)93

Ubalde-Lopez et al. (2016)94

van den Bussche et al. (2014)48

van Oostrom et al. (2014)95

Vos et al. (2013)96

Wei et al. (2018)97

Wikman et al. (2011)98

Wister et al. (2015)99

Table 3-2. Summary of risk of bias (RoB) appraisal of included cross-sectional articles using the modified Newcastle-Ottawa Quality
Assessment Scale (39 articles)
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F

G

P

G

G

P

G

G

G

G

P

G

Note. G = Good; F = Fair; P = Poor.
†
Statistical test must be clearly described and appropriate before assessing the other items under the Outcome category. a Good rating is given when there are 3 to 4 stars in Selection category (Representativeness of
Sample must be fulfilled) AND 1 to 2 stars in Comparability category AND 1 star in Outcome category; Fair rating is given when there are 2 stars in Selection category AND 1 to 2 stars in Comparability category
AND 1 star in Outcome category; Poor rating is given when there are 0 to 1 star in Selection category OR 0 star in Comparability category OR 0 star in Outcome category.
“*” Study satisfies the criteria; “-” Study did not satisfy the criteria; “” Statistical test is clearly described and appropriate; “X” Statistical test is not described, incomplete or inappropriate.
NB: Articles highlighted in light grey are combined studies (see Table 3-1 with similar highlights). Those not highlighted are single articles which are also single studies.
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles)

Author (Year),
Country

Study Design

Population
source
(Sample size)

Age

Measure (s) used

Multimorbidity Measurement
Definition of chronic disease
Number of conditions
included in the scale
(MM cut-off)

Outcomes measured

Results

Agborsangaya
et al. (2013)70,
Canada

Cross-sectional

General
Population
(N = 4,946)

≥ 18

a.

DC

NS

a.

16 (2)

1.

HRQoL

1.

Number of conditions negatively
associated with HRQoL*

Barile et al.
(2013)27, USA

Cohort
- Same study as
Barile et al.
(2012)28

General
Population
(N = 27,334)

≥ 65

a.

DC

NS

a.

11 (2)

1.

ADL limitations

1.

DC positively associated with ADL
limitations***

2.

Number of
physically unhealthy
days

2.

DC positively associated with
physically unhealthy days***

3.

Number of mentally
unhealthy days

3.

DC positively associated with
mentally unhealthy days***

1.

Physical HRQoL

1.

Number of conditions positively
associated with number of
physically unhealthy days

2. Mental HRQoL

2.

Number of conditions positively
associated with number of mentally
unhealthy days
Presence of mental health disorder
was positively associated with the
number of physical disorders that an
individual had*

Barile et al.
(2012)28, USA

Cross-sectional
- Same study as
Barile et al.
(2013)27

General
Population
(n = 64,428)

≥ 65

a.

DC

NS

1.

11 (4)

Barnett et al.
(2012)71, UK

Cross-sectional

Primary Care
(N =
1,751,841)

≥0

a.

DC

Chronic diseases selected are
those recommended as core
for any multimorbidity
measure by systematic
review in QOF of the UK GP
contract and long-term
disorders identified as
important by NHS Scotland

1.

40 (2)

1.

Presence of mental
health disorder

1.

Biehl et al.
(2016)49, USA

Cohort

Primary Care
(N = 9,872)

≥ 65

a.
b.

ERA
CCI

Chronic disease as identified
in ICD-9

a.
b.

9 (NS)
NS (NS)

1.

Presence of critical
illness

1a. Both measures positively associated
with critical illness***
1b. CCI performed better in predicting
critical illness
(Continued on next page)
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Author (Year),
Country

Study Design

Brilleman et al.
(2014)31, UK

Cohort
- Same study
as Brilleman
& Salisbury
(2013)32

Population
source
(Sample size)
Primary Care
(N = 86,100)

Age
≥ 18

Measure (s) used
a.
b.
c.
d.
e.

QOF count
CCI
EDC count
ACG
RUB

Multimorbidity Measurement
Definition of chronic disease
included in the scale
Measure (a): Chronic disease as
identified in the clinical domain
of the UK QOF pay for
performance scheme

Number of conditions
(MM cut-off)

Outcomes measured

Results

a.
b.
c.
d.
e.

17 (NS)
17 (NS)
114 (NS)
68 categories (NS)
6 categories (NS)

1.

Primary healthcare
cost

1a. All measures positively associated
with outcome*
1b. EDC count has the best
performance on the goodness of fit

a.
b.
c.
d.
e.
f.

17 (NS)
17 (NS)
114 (NS)
68 categories (NS)
6 categories (NS)
NS (NS)

1.

Mortality
(3-years period)

1.

Best performing model was drugs
count followed by ACG, EDC
count, RUB, QOF count, and CCI

2.

Number of primary
care consultations
(3-years period)

2.

Best performing model was CCI
followed by drugs count, QOF
count, EDC count, and RUB

1.

Mortality
(1-year period)

1a. All measures positively associated
with 1-year mortality risk*

Measure (b): Chronic disease
that are predictive of mortality
Brilleman &
Salisbury
(2013)32, UK

Carey et al.
(2013)50, UK

Cohort
- Same study
as Brilleman
et al. (2014)31

Cohort

Primary Care
(N = 95,188)

Primary Care
(n = 335, 904)

≥ 18

≥ 60

a.
b.
c.
d.
e.
f.

QOF count
CCI
EDC count
ACG
RUB
Prescribed
drugs count

NS

a.

Standard
QOF
Extended
QOF
CCI (Khan)

Measure (a): Based on QOF
disease definition from UK GP
contract

b.
c.

a.
b.
c.

9 (NS)
14 (NS)
17 (NS)

1b. Fitting the weighted score as a 9level variable, extended QOF score
outperformed the rest of the
measures in overall model
performance

Measure (b): Based on QOF
disease definition and
additional 5 severe subgroups
of standard QOF conditions
Measure (c): Chronic diseases
selected based on Read code
list created by Khan

Chapman et al.
(2015)51, UK

Cohort

General
Population
(n = 3,237)

≥ 18

a.
b.

CCI
CCI-PSR

NS

a.
b.

9 categories (NS)
9 categories and 5
psycho-social
factors (NS)

1.

Mortality
(5, 10, 15, 20, 25years period)

1.

CCI-PSR showed substantially
better discrimination across all time
horizons***
(Continued on next page)
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued)
Author (Year),
Country

Study Design

Chen et al.
(2011)72, USA

Cross-sectional

Crane et al.
(2010)52, USA

Cohort

Population
source
(Sample size)
General
Population
(n = 430,912)

Primary Care
(N = 12,650)

Age
≥ 18

≥ 60

Measure (s) used
a.

a.

DC

ERA

Multimorbidity Measurement
Definition of chronic disease
included in the scale

Number of conditions
(MM cut-off)

NS

a.

Chronic diseases identified
from ICD-9 and selected
based on consensus
discussion regarding their
known risk for recurrent
hospitalization and greater
complexity of care

a.

8 (NS)

NS (NS)

Outcomes measured

Results

1.

General Health

1.

Higher DC associated with poorer
general health*

2.

Mental Distress

2.

Higher DC associated with higher
prevalence of mental distress*

3.

Physical Distress

3.

Higher DC associated with higher
prevalence of physical distress*

4.

Activity
limitations

4.

Higher DC associated with more
frequent activity limitations*

1.

Number of
hospital visits
(1-year period)

1a. AUC = 0.705

2.

Number of ED
visits
(1-year period)

1b. Increased with increasing ERA
score**
2a. AUC = 0.64
2b. Increased with increasing ERA
score**

3.

4.

Crooks et al.
(2016)33, UK

Cohort
- Same study as
Crooks et al.
(2015)34

Primary Care
(n = 328,636)

20
to
100

a. Co-morbidity
linked score
b. CCI
c. Elixhauser Index

Measure (a): Chronic
diseases identified from
primary care in the CPRD
and diagnostic ICD-10 from
secondary care in English
HES

a.
b.
c.

NS (NS)
NS (NS)
NS (NS)

Number of
hospital
admissions
(1-year period)
Days hospitalised
(1-year period)

1. Mortality
(1-year period)

3.

Increased with increasing ERA
score**

4.

Increased with increasing ERA
score**

1. Linked score improved
discrimination and fit compared to
CCI and Elixhauser Index

(Continued on next page)
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Multimorbidity Measurement
Author
(Year),
Country

Study Design

Crooks et al.
(2015)34, UK

Cohort
- Same study as
Crooks et al.
(2016)33

DiNapoli et
al. (2017)73,
USA

Population
source
(Sample size)

Definition of chronic disease
included in the scale

Number of
conditions
(MM cut-off)

Outcomes
measured

Age

Measure (s) used

Primary Care
(N = 657,264)

≥ 20

a. CCI (Read)
b. CCI (ICD-10)
c. CCI (Read and
ICD-10)

NS

a.
b.
c.

19 (NS)
19 (NS)
19 (NS)

1. All-cause
mortality (1-5
years)

1. No large difference in the discrimination
of model for overall survival, whichever
codes used to derive CCI

Cross-sectional

Primary Care
(n = 34,786)

≥ 50

a.

NS

a.

NS (NS)

1. Presence of
depressive or
anxiety disorder

1. Odds of having depressive and/or anxiety
disorder increased with each additional
organ system with chronic disease**

Formiga et
al. (2013)53,
Spain

Cohort

Primary Care
(N = 328)

85

a. CCI

NS

a.

Assumed
17 (NS)

1. Mortality
(3-years period)

1. Patients who did not survive had
significantly higher CCI score***

Formiga et
al. (2011a)54,
Spain

Cohort

General
Population
(including
those in
institutions)
(N = 186)

90
to
99

a. CCI

NS

a.

NS (NS)

1. Mortality
(5-years period)

1. Patients who did not survive had
significantly higher CCI score***

Formiga et
al. (2011b)36,
Spain

Cross-sectional
- Same study as
Formiga et al.
(2016)35

Primary Care
(n = 328)

85

a.

NS

a.

NS (NS)

1. Successful
aging

1. Successful aging was associated with
lower values on the CCI*

Formiga et
al. (2016)35,
Spain

Cohort
- Same study as
Formiga et al.
(2011b)36

Primary Care
(N = 328)

85

a.

NS

a.

NS (NS)

1. Mortality
(5-years period)

1. Patients who survived after 5-year
follow-up had significantly lower CCI
score***

Organ
systems with
chronic
disease

CCI

CCI

Results

(Continued on next page)
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Author (Year),
Country
Fraccaro et al.
(2016)55, UK

Study Design

Cohort

Population
source
(Sample size)
Primary Care
(N = 287,459)

Age
≥ 18

Measure (s) used
a.

CCI (Khan)

Multimorbidity Measurement
Definition of chronic disease
Number of conditions
included in the scale
(MM cut-off)
Chronic disease selected
from a validated list of Read
diagnostic codes for
calculating CCI in UK
primary care from Khan et al.
(2010)

a.

22 (NS)

Outcomes measured

Results

1.

Mortality
(1, 5, 10-years
period)

1.

Mortality odds ratio positively
associated with change in CCI at 1,
5, and 10 years follow-up*

2.

Mortality
(3, 6, 12-months
period)

2.

Model consisting of sex, timedependent age, CCI, and CCI
change over consecutive time
windows had the best fit to the data

Galenkamp et
al. (2011)45,
The
Netherlands

Cross-sectional

General
Population
(N = 2,046)

57 to
98

a.

DC

Selection of chronic diseases
was based on their
prevalence in the 55+ age
group in The Netherlands

a.

7 (NS)

1.

SRH

1.

SRH declines with each increase in
number of co-occurring diseases***

Garin et al.
(2014)74, Spain

Cross-sectional

General
Population
(N = 3,625)

≥ 50

a.

DC

NS

a.

11 (NS)

1.

QOL

1.

QoL decreased with increasing
number of chronic conditions***

2.

Disability

2.

Disability increased with increasing
number of chronic conditions***

1.

Primary Care
Consultations
(1-year period)

1.

Mean primary care consultations
increased with increasing number of
conditions***

2.

Hospital
outpatient visits
(1-year period)

2.

Mean outpatient visits increased
with increasing number of
conditions***

3.

Hospital
admissions
(1-year period)

3.

Higher number of conditions
increased the odds of hospital
admissions**

4.

Healthcare cost

4.

Total healthcare cost increased
significantly with increasing
number of chronic conditions***
(Continued on next page)

Glynn et al.
(2011)10,
Ireland

Cross-sectional

Primary Care
(n = 3,309)

> 50

a.

DC

Health problems that require
ongoing management over a
period of years/decades

a.

147 (2)
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Author
(Year),
Country
Haas et al.
(2013)56,
USA

Study Design

Cohort

Population
source
(Sample size)
Primary Care
(N = 83,187)

Age
≥ 18

Measure (s) used
a.
b.

c.
d.
e.
f.
g.

Hwang et al.
(2015)57,
USA

Cohort

General
Population
(N = 42,038)

≥0

a.
b.

ACG
Minnesota
Health Care
Home Tiering
HCC
ERA
CCC
CCI
Hybrid Model

ACE-27
ACE-27
count

Multimorbidity Measurement
Definition of chronic disease
Number of conditions
included in the scale
(MM cut-off)
NS

Measures (a) and (b) consist
of 26 common patient
conditions

a.
b.
c.
d.
e.
f.
g.

a.
b.

93 categories (NS)
5 levels (NS)
70 (NS)
NS (NS)
6 categories (NS)
17 (NS)
NS (NS)

26 (NS)
26 (NS)

Outcomes measured

Results

1.

Hospitalisation
(1-year)

1.

ACG model outperformed other
models when predicting
hospitalisation

2.

ED visits
(1-year)

2.

ACG model outperformed other
models when predicting ED visits

3.

Readmission
within 30 days
(1-year)

3.

ACG model outperformed other
models when predicting 30-days
readmissions

4.

Healthcare
expenditure
(1-year)

4.

ACG model outperformed other
models when predicting healthcare
expenditure

1.

Healthcare
expenditure

1a. Increasing number of comorbidity
(Φc = 0.36) and comorbidity
severity (Φc = 0.30) increased the
likelihood of being persistent high
healthcare users
1b. Exploratory predictive model of
persistent high-user group reported
an AUC value of 0.923

Kristensen et
al. (2014)79,
Denmark

Cross-sectional

Primary Care
(N = 139,527)

>0

a.

Lapi et al.
(2015)80,
Italy

Cross-sectional

Primary Care
(n = 26,903)

≥ 15

a.

RUB

HSMI

NS

a.

6 levels (NS)

1.

Fee-for-services
expenditures

1.

RUB explained about 18% of the
variance in expenditures

Chronic disease is defined as
being diagnosed with 1 of
the selected conditions in the
study at least once in an 18month period

a.

73 (NS)

1.

Total mean
healthcare cost per
year

1.

HSMI explained 50.17% of the
variation in costs

(Continued on next page)
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Author
(Year),
Country

Study Design

Population
source
(Sample size)

Age

Measure (s)
used

Multimorbidity Measurement
Definition of chronic disease included in
the scale

Number of conditions
(MM cut-off)

Outcomes measured

Results

Lawson et
al. (2013)81,
UK

Cross-sectional

General
Population
(n = 7,054)

≥ 20

a.

DC

Chronic conditions that are
longstanding, as defined by “anything
that has troubled you over a period of
time”

a.

40 (2)

1.

Preference_
Weighted
HRQoL

1.

Increasing number of
conditions was associated with
reduction in Preference
Weighted HRQoL scores***

Lemke et
al. (2012)61,
USA

Cohort

General
Population
(n =
4,707,001)

≥0

a.
b.

CCI
ACG

NS

a.
b.

17 (NS)
NS (NS)

1.

Inpatient
Hospitalisations

1.

ACG-based models were
superior to the prior
hospitalization model and
Charlson inpatient
hospitalization model (AUC
0.80 vs 0.75 vs 0.78)

Marengoni
et al.
(2011)83,
Sweden

Cross-sectional

General
Population
(n = 1,099)

≥ 75
(baseline)

a.

DC

Disease was classified as chronic if it
met 1 or more of the following
characteristics: (1) state of permanence,
(2) caused by non-reversible
pathological alternation, (3) requiring
rehabilitation and (4) requiring a long
period of care

a.

30 (2)

1.

Disability

1.

Increasing number of diseases
was associated with increasing
prevalence of disability***

McDaid et
al. (2013)84,
Ireland

Cross-sectional

a.

DC

NS

a.

8 (2)

1.

Disability

1.

2.

QoL

2.

3.

SRH

Higher DC associated with
higher risk of disability***
Higher DC associated with
poorer QoL***
Higher DC associated with
poorer SRH***

1.

Unplanned
hospital
admissions
(1-year period)

≥ 77
(follow-up)

General
Population
(N = 6,159)

≥ 50

3.

Payne et al.
(2014)37,
UK

Cohort
- Same study as
Payne et al.
(2013)38

Primary Care
(N = 180,815)

≥ 20

a.

DC

Conditions established by clinical expert
consensus, sought to include morbidities
recommended as core for any
multimorbidity measure by a previous
systematic review, diseases included in
the UK primary care ‘payment-forperformance’ contract (QOF) and those
considered important for health service
planning by NHS Scotland. These
conditions may significantly impact
quality of life.

a.

40 (NS)

1.

Number of clinical conditions
positively associated with
unplanned hospital admissions
in a 12-month follow-up
period***

(Continued on next page)
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Author (Year),
Country

Study Design

Payne et al.
(2013)38, UK

Cohort
- Same study
as Payne et
al. (2014)37

Quail et al.
(2011)62,
Canada

Cohort

Population
source
(Sample size)
Primary Care
(N = 180,815)

General
Population
(N = 662,423)

Age
≥ 20

≥ 20

Measure (s) used
a.

a.
b.
c.

Crosssectional

General
Population
(N = 151,731)

≥0

NS

NS

e.

DC
CCI (Quan)
Elixhauser
(Quan)
Number of
different
dispended
drugs
CDS

a.

RUB

NS

d.

Ranstad et al.
(2014)88,
Sweden

DC

Multimorbidity Measurement
Definition of chronic disease
Number of conditions
included in the scale
(MM cut-off)
a.

a.
b.
c.
d.
e.

a.

40 (NS)

NS (NS)
17 (NS)
31 (NS)
NS (NS)
NS (NS)

NS (NS)

Outcomes measured
1.

Unplanned
hospital admission
(1-year period)

2.

Potentially
preventable
unplanned
admission
(1-year period)

Results
1.

Number of physical conditions
positively associated with unplanned
admission in a year***

2.

Number of physical conditions
positively associated with preventable
admission in a year***

1.

Mortality
(1-year period)

1.

The addition of Elixhauser Index (Quan)
to the base model yielded the largest
improvement in c-statistic, followed by
CCI (Quan) in predicting mortality

2.

One or more
hospitalisations

2.

DC performed best in predicting one
more or hospitalisations

3.

Two or more
hospitalisations

3.

DC performed best in predicting two or
more hospitalisations

1.

Registered active
listing in primary
care

1a. Patients of high multimorbidity level are
more likely to be actively listed in
primary care*
1b. Multimorbidity level predicted active
listing in primary care, significantly
increasing for RUB 0-4***

2.

Registered active
listing in all
healthcare

2a. Patients of high multimorbidity level are
more likely to be actively listed in all
healthcare*
2b. Multimorbidity level predicted active
listing in all healthcare significantly***
increasing for RUB 0-4
(Continued on next page)
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Multimorbidity Measurement
Definition of chronic
disease included in the
Number of conditions
scale
(MM cut-off)

Author
(Year),
Country

Study Design

Reyes et al.
(2014)63,
Spain

Cohort

Primary Care
(Men only)
(N = 186,171)

≥ 65

a.

CCI

NS

a.

17 (NS)

1.

Hip fractures

1.

Patients with CCI ≥ 3 had increased
risk of hip fracture as compared to
patients without co-morbidities***

Cross-sectional

Primary Care
(N = 21,736)

≥ 18

a.

DC

NS

a.

80 (NS)

1.

Deficits of perceived
general health

1.

Disease burden was associated with
higher risk of deficits in perceived
general health*

2.

Depressive
symptoms

2.

Disease burden was associated with
higher risk of deficits in depressive
symptoms*

1.

Primary Care
consultation rates
(3-years period)

1.

Number of QOF conditions positively
associated with consultation rates***

2.

Continuity of care
(3-years period)

2.

QOF morbidity inversely associated
with continuity of care*

1.

Acute ACSH

1.

Models containing flags for
comorbidity showed greater
predictive power for acute ACSH

2.

Chronic ACSH

2.

Models containing flags for
comorbidity showed greater
predictive power for acute ACSH

1.

Number of primary
care physician visits

1.

2.

Number of specialist
visits

ADGs explained 23% to 54% of the
variance in health care resource
utilization as compared to CCI, which
explained only 11%-18%.

3.

Number of
hospitalisation

Ryu et al.
(2015)90,
USA

Salisbury et
al. (2011)11,
UK

Saver et al.
(2014)64,
USA

Shadmi et
al. (2011)91,
Israel

Cohort

Cohort

Cross-sectional

Population
source
(Sample size)

Primary Care
(N = 99,997)

General
Population
(N = 106,930)

General
Population
(n = 279,241)

Age

≥ 18

≥ 65

≥ 18

Measure (s) used

a.

QOF count
EDC count

a. CCI (Romano)
+ Hypertension

a.
b.

ADG
CCI

Measure (b): Chronic
disease defined as one
that normally lasts ≥ 6
months

NS

NS

a.
b.

a.

a.
b.

17 (2)
114 (NS)

19 (NS)

32 (NS)
19 (NS)

Outcomes measured

Results

(Continued on next page)
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Multimorbidity Measurement
Study Design
Author (Year),
Country
Stanley & Sarfati
(2017)65, New
Zealand

Streit et al.
(2014)66,
Switzerland

Sullivan et al.
(2012)93, USA

Cohort

Cohort

Crosssectional

Population
source
(Sample size)
Primary Care
(n =
1,000,166)

Primary Care
(N = 1,002)

General
Population
(N = 47,178)

Age

Measure (s) used

≥ 18

a.
b.
c.

50
to
80

≥ 18

a.
b.

a.

M3 Index
CCI
Elixhauser
(van
Walraven)

CCI
DC

DC

Definition of chronic disease
included in the scale

Number of
conditions
(MM cut-off)

Measure (a): Chronic diseases
were identified from ICD-10
and based on the impact on
quality and quantity of life,
requiring complex healthcare
management for coordination,
and lasting for ≥ 3 months

a.
b.
c.

Measure (b): Derived list of
chronic diseases based on a
large study by Higashi et al.
(2007) and the CCI. Psychiatric
conditions were also included
based on consensus

a.
b.

CCC of ICD-9 codes
- Chronic conditions is defined
as lasting for more than 1 year

a.

55 (NS)
17 (NS)
31 (NS)

19 (NS)
17 (NS)

118 (2)

Outcomes measured

Results

1.

Mortality
(1-year period)

1.

M3 Index improved predictive
performance for 1-year mortality risk
over CCI and Elixhauser

2.

Overnight
hospitalisation
(1-year period)

2.

M3 Index improved predictive
performance for overnight
hospitalisation over CCI and Elixhauser

1.

Quality of
cardiovascular
preventive care

1.

No association found between
multimorbidity measures and outcome

2.
2.

Quality of
preventive care

No association found between
multimorbidity measures and outcome

1.

Preference-based
HRQoL

1a. The number of chronic conditions was
negatively associated with EQ-5D-5L
scores***
1b. Inclusion of chronic co-morbidity to the
baseline models explained more
variance in EQ-5D-5L index scores than
did age or other socio-demographic
characteristics

Takahashi et al.
(2016)67, USA

Cohort

Primary Care
(n = 42,368)

≥ 18

a.

b.

Minnesota
Tiering
(ACG)
Enhanced
model

NS

a.

42 (NS)

b.

42 (NS)

1.

Hospitalisation /
ED visits

1a. Patients identified as high-risk in the
enhanced model were much more likely
to experience hospital utilization than
those in the Minnesota medical tiering
model***
1b. Enhanced model (AUC = 0.711) is
better at predicting hospitalization/ED
visits as compared to Minnesota
Medical Tiering (AUC = 0.667)
(Continued on next page)

110
Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued)
Author (Year),
Country

Study Design

Takahashi et al.
(2012)47, USA

Cohort

Ubalde-Lopez
et al. (2016)94,
Spain

Cross-sectional

Population
source
(Sample size)
Primary Care
(N = 12,650)

General
Population
(N = 372,370)

Age
> 60

Female
(Mean):
35.9

Measure (s) used
a.

a.

ERA

MDMS

Multimorbidity Measurement
Definition of chronic disease
Number of conditions
included in the scale
(MM cut-off)

Outcomes measured

NS

1.

Mortality
(2-years period)

1.

Being in the uppermost quartile
of the ERA index significantly
increased the risk for mortality in
the subsequent 2 years***

2.

Nursing home
placement
(2-years period)

2.

Being in the uppermost quartile
of the ERA index significantly
increased nursing home
placement in the subsequent 2
years***

1.

Sickness
absence
episodes taken
in last 2 years

1a. Higher risk of new episodes was
observed among men as MDMS
levels increased*

NS

a.

a.

7 (NS)

14 (2)

Male
(Mean):
37.9
van den
Bussche et al.
(2011)48,
Germany

Cross-sectional

Primary Care
(N = 123,224)

≥ 65

Results

1b. Similar trend was observed
among women but trend was
statistically significant
a.

DC

Chronicity of conditions was
assessed using the “Expert
Report for the Selection of 50
to 80 Diseases to be included
in the morbidity based risk
adjustment scheme” in the
German Statutory Health
Insurance. A person was
defined as chronically ill if
she/he had at least one of the
46 chronic conditions in at
least three quarters within the
one-year observation period
2004.

a.

46 (3)

1.

Frequency of
contacts with
physicians (1year)

1.

Number of chronic conditions is
positively associated with the
number of contacts with
physicians***

2.

Number of
different
ambulatory
physicians
contacted (1year)

2.

Number of chronic conditions is
positively associated with the
number of physicians
contacted***

(Continued on next page)

111
Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued)
Author (Year),
Country

Study Design

van Oostrom et
al. (2014)95,
The
Netherlands

Cross-sectional

Population
source
(Sample size)
Primary Care
(N = 32,583)

Age

Measure (s) used

≥ 55

a.

DC

Multimorbidity Measurement
Definition of chronic disease
included in the scale
NS

Number of conditions
(MM cut-off)
a.

28 (2)

Outcomes measured

Results

1.

Number of
contacts with
general practice

1.

The number of chronic diseases
was positively associated with the
number of contacts for all types of
contacts in the general practice***

2.

Number of
medications
prescribed

2.

The number of chronic diseases
was positively associated with the
number of medications
prescribed***

3.

Number of
referrals

3.

The number of chronic diseases
was positively associated with the
number of referrals***

Wallace et al.
(2016a)39,
Ireland

Cohort
- Same study as
Wallace et al.
(2016b)40

Primary Care
(N = 862)

≥ 70

a.
b.

Pra tool
Modified
Pra tool

NS

a.
b.

NS (NS)
NS (NS)

1.

Emergency
hospital admission
(1-year period)

1.

Both measures demonstrated poor
discrimination performance in
predicting emergency hospital
admission in a year

Wallace et al.
(2016b)40,
Ireland

Cohort
- Same study as
Wallace et al.
(2016a)39

Primary Care
(N = 862)

≥ 70

a.
b.

DC
Barnett
conditions
DC
CCI
Prescribed
drugs count
RxRisk-V

Measure (a): ICPC-2 definition of
chronic disease was used

a.
b.
c.
d.
e.

NS (2)
40 (2)
19 (NS)
NS (NS)
N3S (NS)

1.

Emergency
admission
(2-years period)

1.

All measures demonstrated poor
discrimination for the emergency
admission in 2 years

2.

Functional decline
(2-years period)

2.

All measures demonstrated poor
discrimination for functional
decline

c.
d.
e.

Measure (b): Chronic conditions
were selected based on health
impact and prevalence

(Continued on next page)
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued)
Author (Year),
Country

Study Design

Wei et al.
(2018)97, USA

Cross-sectional

Wei &
Mukamal
(2018)69, USA

Cohort

Population
source
(Sample size)
General
Population
(N = 20,509)

General
Population
(N = 219,950)

Age
≥ 51

≥ 36

Measure (s) used
a.

a.
b.
c.

MWI

MWI
DC
CCI

Multimorbidity Measurement
Definition of chronic disease
Number of conditions
included in the scale
(MM cut-off)
NS

NS

a.

a.
b.
c.

81 (NS)

81 (NS)
81 (2)
19 (NS)

Outcomes measured
1.

Subjective
physical
functioning

2.

Grip strength

3.

Results
1.

MWI negatively associated with
physical functioning***

2.

MWI negatively associated with
grip strength***

Gait speed

3.

No association found between
MWI and gait speed

4.

Cognitive
performance

4.

Higher MWI associated with
poorer cognitive performance***

5.
5.

ADL limitations

Higher MWI associated with
increased ADL limitations***

6.

IADL limitations

6.

Higher MWI associated with IADL
limitations***

1.

Mortality
(10-years period)

1a.

All three measures of
multimorbidity were positively
associated with mortality***

1b. MWI performed best in predicting
mortality as compared to DC and
CCI in all three cohorts as well as
combined cohorts
2.
2.

Future physical
functioning

All three measures of
multimorbidity were negatively
associated with future physical
functioning***
(Continued on next page)



The youngest participant was from the NHS II cohort, aged 25 in 1989. Data collection for this study started in 2000 (NHS and HPFS cohorts) and 2001 (NHS II cohort) and hence, the age of the participants
recruited in this study is 36 years old and above.
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued)
Author (Year),
Country
Wikman et al.
(2011)98, UK

Wister et al.
(2015)99,
Canada

Study Design

Crosssectional

Crosssectional

Population
source
(Sample size)
General
Population
(n = 11,532)

General
Population
(n = 16,369)

Age
≥ 50

≥ 65

Measure (s) used
a.

a.
b.
c.

d.

DC

Multimorbidity
additive scale
Multimorbidity
weighted by HUI3
Multimorbidity
weighted by ADL
Scale
Multimorbidity
weighted by HUI3
betas

Multimorbidity Measurement
Definition of chronic disease
included in the scale

Number of conditions
(MM cut-off)

NS

a.

Conditions that are slow in
progression, long in duration,
and typically limit function,
productivity and quality of
life.

a.
b.
c.
d.

8 (NS)

19 (NS)
19 (NS)
19 (NS)
19 (NS)

Outcomes measured

Results

1.

QoL

1.

Number of chronic conditions
was negatively associated to
QoL***

2.

Affective wellbeing

2.

Number of chronic conditions
was negatively associated to
affective well-being***

1.

Life satisfaction

1.

All measures are negatively
associated with life
satisfaction***

2.

Perceived health
status

2.

All measures are negatively
associated with perceived health
status***

Note. ACE-27 = Adult Comorbidity Evaluation-27; ACG = Adjusted Clinical Groups; ACSH = Ambulatory Care Sensitive Hospitalisation; ADG = Aggregated Diagnosis Groups; ADL = Activities of Daily Living;
AUC = Area Under the Curve; BI = Barthel Index; CCC = Chronic Condition Count; CCC (of ICD-9 codes) = Clinical Classification Categories; CCI = Charlson Comorbidity Index; CCI-PSR = Charlson Comorbidity
Index-Psychosocial Risk; CDS = Chronic Disease Score; CPRD = Clinical Practice Research Datalink; DC = Disease Count (Unweighted); ED = Emergency Department; EDC = Expanded Diagnosis Clusters; EMR =
Electronic Medical Record; EQ-VAS = EuroQoL-Visual Analogue Scale; EQ-5D-5L = EuroQoL-5 Dimensions; ERA = Elder Risk Assessment; GP = General Practice; HCC = Hierarchical Condition Categories;
HRQoL = Health-related Quality of Life; HUI3 = Health Utility Index; IADL = Instrumental Activities of Daily Living; ICD-10 = International Classification of Diseases, Tenth Revision; ICD-9 = International
Classification of Diseases, Ninth Revision; ICPC-2 = International Classification of Primary Care, second edition; MDMS = Multidimensional Multimorbidity Score; MM = Multimorbidity; MWI = MultimorbidityWeighted Index; NHS = National Health Service; NS = Not Stated; Pra tool = Probability of repeated admission risk prediction tool; QOF = Quality and Outcomes Framework; QoL = Quality of Life; RUB = Resource
Utilisation Band; RxRisk-V = A Veterans Association adapted pharmacy-based case-mix instrument; SRH = Self-Rated Health; UK = United Kingdom; Φc = Cramer’s V
* p ≤ .05. ** p ≤ .01. *** p ≤ .001.
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Table 3-4. Summary of included studies with poor and fair risk of bias judgement (20 studies including 21 articles)
Multimorbidity Measurement
Definition of chronic disease included in
the scale

Author (Year),
Country

Study Design

Boeckxstaens et
al. (2015a)29,
Belgium

Cross-sectional
- Same study as
Boeckxstaens
et al. (2015b)30

Primary Care
(N = 567)

≥ 80

a.
b.
c.

DC
CCI
CIRS

NS

a.
b.
c.

22 (3)
19 (5)
58 (3)

1.
2.

Disability
Frailty

Boeckxstaens et
al. (2015b)30,
Belgium

Cohort
- Same study as
Boeckxstaens
et al. (2015a)29

Primary Care
(N = 567)

≥ 80

a.
b.
c.

DC
mCCI
CIRS

NS

a.
b.
c.

22 (3/4)
19 (5/4)
58 (3/3)

1.

Mortality
(3-years period)

2.

Hospitalisation
(3-years period)

3.

Functional decline
(19-months period)

Population source
(Sample size)

Age

Measure(s) used

Number of conditions
(MM cut-off)

Outcomes measured

Gunn et al.
(2012)75,
Australia

Cross-sectional

Primary Care
(n = 7,620)

18
to
76

a.

DC

Chronic diseases selected were the
commonly seen chronic physical
conditions seen in Australian GP and the
National health priority areas

a.

12 (2)

1.

Depressive symptoms

Hanmer et al.
(2010)76, USA

Cross-sectional

General
Population
(n = 94,794)

22
to
106

a.
b.
c.

Additive
Minimum
Multiplicative
Models

Chronic disease defined as conditions that
are chronic in nature and should affect the
respondent’s health at the point when they
completed the survey

a.
b.
c.

15 (NS)
15 (NS)
15 (NS)

1.

SF-6D health utility

Hu et al.
(2017)77,
Canada

Cross-sectional

Primary Care
(N = 265)

≥ 65

a.

Age-adjusted
CCI

NS

a.

NS (NS)

1.

Frequency of family physician visits

Isaacs et al.
(2014)78, South
Africa

Cross-sectional

Primary Care
(N = 4,184)

18
to
101

a.

DC

Any condition requiring long-term (> 1
month) medication with repeat
prescriptions

a.

NS (2)

1.

Prescription cost

Jennings et al.
(2015)58, USA

Cohort

Primary Care
(N = 1,776)

≥ 75

a.

Elixhauser
Comorbidity
Count

NS

a.

NS (NS)

1.

Number of fall-related injuries in 2 years

(Continued on next page)




Multimorbidity cut-off of the multimorbidity measure in relation to hospitalisation in 3-years period.
Multimorbidity cut-off of the multimorbidity measure in relation to mortality risk in 3 years.
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Table 3-4. Summary of included studies with poor and fair risk of bias judgement (20 studies including 21 articles) (Continued)
Multimorbidity Measurement
Definition of chronic disease included in the
scale

Author (Year),
Country

Study Design

Jia and
Lubetkin
(2016)59, USA

Cohort

General
Population
(N = 2,380)

≥ 65

a.

DC

Chronic diseases are selected based on their
inclusion in other national data sets, prevalence
among elderly, being a leading cause of death
and having a high mortality rate

a.

9 (NS)

1.

QALY

Jia et al.
(2018)60, USA

Cohort

General
Population
(N = 96,481)

≥ 65

a.

DC

NS

a.

15 (NS)

1.

QALY

Kojima et al.
(2011)46, Japan

Cross-sectional

Primary Care
(N = 262)

≥ 65

a.

DC

NS

a.

7 (NS)

1.

Fall tendency

Li et al.
(2016)82, UK

Cross-sectional

General
Population
(N = 27,806)

16
to
68

a.

DC

Conditions can range across different longterm, illnesses, and health problems

a.

13 (2)

1.

HRQoL

Cohort

General
Population
(N = 113)

64
to
85

a.
b.
c.

CCI
CMI
Count of
prescribed
drugs

NS

a.
b.
c.

19 (NS)
NS (NS)
NS (NS)

1.

Mortality
(7-years period)

Muggah et al.
(2012)44,
Canada

Cross-sectional

General
Population
(N = 9,901,410)

≥ 20

a.

DC

NS

a.

9 (NS)

1.

Ambulatory care use

Mujica-Mota et
al. (2015)3, UK

Cross-sectional

Primary Care
(n = 831,537)

≥ 18

a.

DC

NS

a.

13 (2)

1.

HRQoL

Naessens et al.
(2011)85, USA

Cross-sectional

General
Population
(N = 33,324)

18
to
64

a.

DC

Chronic diseases as identified in ICD-9

a.

NS (NS)

1.

Healthcare cost

Østergaard and
Foldager
(2011)86,
Denmark

Cross-sectional

Primary Care
(n = 4,271)

≥ 18

a.
b.

CGI-S
DC

NS

a.
b.

3 levels (NS)
9 (2)

1.

Presence of major
depressive episode

Md Yusof et al.
(2010)43, UK

Population source
(Sample size)

Measure(s)
used

Age

Number of conditions
(MM cut-off)

Outcomes measured

(Continued on next page)
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Table 3-4. Summary of included studies with poor and fair risk of bias judgement (20 studies including 21 articles) (Continued)
Author (Year),
Country

Study Design

Population source (Sample
size)

Age

Measure(s) used

Multimorbidity Measurement
Definition of chronic disease included
in the scale

Number of conditions
(MM cut-off)

Outcomes measured

Peters et al.
(2018)87, UK

Cross-sectional

Primary Care
(N = 848)

18
to
101

a.

DC

NS

a.

11 (NS)

1.

QoL

Renne and
Gobbens
(2018)89, The
Netherlands

Cross-sectional

Primary Care
(N = 241)

≥ 70

a.

DC

Chronic diseases selected were the
most frequently present in the older
Dutch population

a.

9 (2)

1.

QoL

Sibley et al.
(2014)92,
Canada

Cross-sectional

General Population
(N = 16,357)

≥ 65

a.

DC

Conditions lasting for 6 months or
more and diagnosed by a health
professional

a.

13 (2)

1.

Self-reported falls in last 12 months

Tyack et al.
(2016)68,
Australia

Cohort

Primary Care
(N = 351)

≥ 18

a.

DC

Chronic disease defined as requiring
complex care management involving
multiple providers and ideally
coordinated care, and where they may
be acute as well as chronic episodes

a.

25 (NS)

1.

HRQoL

Cross-sectional

Primary Care
(Women only)
(N = 315)

70
to
74

a.

DC

List of conditions developed under the
auspices of Statistics Netherlands

a.

21 (NS)

1.

SRH

Vos et al.
(2013)96, The
Netherlands

Note. CCI = Charlson Comorbidity Index; CGI-S = Clinical Global Impression – Severity Scale; CIRS = Cumulative Illness Rating Scale; CMI = Cornell Medical Index; DC = Disease Count (Unweighted); EQ-5D-5L
= EuroQoL 5 Dimensions 5 Levels; GP = General Practice; HRQoL = Health-related Quality of Life; ICD-9 = International Classification of Diseases, Ninth Revision; mCCI = modified Charlson Comorbidity Index;
NS = Not Stated; QALY = Quality-adjusted Life Year; QoL = Quality of Life; SF-6D = Short-Form Six-Dimension.
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required
Description
Category
A
A1

A2

COUNT OF INDIVIDUAL CONDITIONS
By Condition
1
DC
Disease Count

System or
Condition
based
Condition

Items

7 - 147

Weightage

Unweighted

Scoring
Method

Condition
count

Score
Range

0 to 147

Data source(s) &
resources required

Number of
studies
using the
instrument

EMR, GP records, Health
service database, Hospital
discharge abstract,
Insurance claims or
Questionnaires telephone, face-to-face,
mailed

42

By Category

2

B

Instrument

Instrument
(Full Name)

CCC

Chronic Condition
Count

Condition

6 categories

Cumulative Illness
Rating Scale

System

14
categories

18
categories

17 organ
systems

Unweighted

Based on
AHRQ's
clinical
classification
software and
number of
conditions for
each category

0 to 5

EMR

1

Summative

0 to 56

Structured questionnaire
followed by encoding
research assistants

1

Sum of 'yes'

0-195

Self-reported
questionnaire

1

Sum of organ
systems

0 to 17

EMR

1

ORGAN OR SYSTEM-BASED APPROACHES
3

CIRS

4

CMI

Cornell Medical
Index

System Regarded
only for
historical
purposes and
for research
since 2001.

5

Organ CDC

Organ systems with
chronic disease
count

Organ system

0-4, based on
clinical
judgement
195 yes-no
questions
collecting
pertinent
medical and
psychiatric
data
Unweighted
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued)
Description
Category
C

Instrument

Instrument
(Full Name)

System or
Condition
based

Items

Weightage

Scoring
Method

Score
Range

Data source(s) &
resources
required

Number of
studies
using the
instrument

WEIGHTED INDICES
6

ACE-27

Adult Comorbidity
Evaluation

Condition

27 conditions

1-3, based on severity of
most severe condition

Highest score of
single item

Condition

Original 17
conditions.
Modified - range
from 9 conditions
and 5
psychosocial
factors to 19
conditions

1-6; based on impact on
1-year mortality (RR) original

Sum of
weighted
conditions

CCI (Original
and modified)

Charlson
Comorbidity Index

8

CC-AM

Chronic conditions
additive modelling

Condition

15 conditions

Weighted based on SF6D

9

CC-MM

Chronic conditions
minimum modelling

Condition

15 conditions

Weighted based on SF6D

10

CC-MuM

Chronic conditions
multiplicative
modelling

Condition

15 conditions

Weighted based on SF6D

Condition

98 combined
codes of subchapters in the
Read code and the
ICD10 code
blocks

Based on impact for
mortality (hazard ratio)

Condition

21 to 31
conditions

Based on impact on inhospital mortality

7

11

CLS

Comorbidity Linked
Score

12

EI

Elixhauser Index
(original and
modified)

By adding the
health utility
scores of the
conditions
By using the
minimum single
condition utility
score
By multiplying
the health utility
scores of all the
conditions

0 to 3

0 to 37

Insurance Claims'
database
Administrative
database (e.g., Billing,
Insurance Claims),
EMR (primary care or
integrated with
secondary care),
Medical chart review,
Interviews (patients,
caregivers, nurse or
physicians) or postal
questionnaire.

1

22

Variable

Questionnaire on
health conditions

1

Variable

Questionnaire on
health conditions

1

Variable

Questionnaire on
health conditions

1

Sum of beta
coefficients of
each category

1 to 10

Linked patients'
records of all primary
care events, hospital
admissions and causes
of death.

1

Summing of
beta coefficients

-19 to 89

Insurance Claims' or
Medical services
database

3
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued)
Description
Category
C

Instrument

Instrument
(Full Name)

System or
Condition
based

Data source(s) &
resources required

Number of
studies
using the
instrument

Items

Weightage

Scoring
Method

Score
Range

6 to 9 conditions

Weighted, based
on impact on
future
hospitalisation

Sum of weighted
regression
coefficients

Original: -1
to 43. Some
modified
from -7 to
43.

EMR and administrative
database

4

The most severe
manifestation of
a given disease
process
principally
defines
its impact on
costs. Therefore,
more severe
manifestations of
a condition
dominating (and
zeroing out the
effect of) less
serious ones.
Other diseases
are summed
additively.

NS

EMR & HCC software
licensing

1

WEIGHTED INDICES (continued)
13

ERA

Elders Risk
Assessment

Condition

14

HCC

Hierachical
Condition Categories

Condition

70 condition
categories

Based on
Medicare
capitation
payments for
health
expenditure

15

M3 Index

Multi-Morbidity
Measure Index

Condition

55 conditions

Weighted based
on 1-year
mortality

Summing of beta
coefficients

0.01 to 2.47

Linked patients' records

1

Condition

7 chronic
conditions, 2
health
behaviours for
1st dimension &
5 symptoms for
2nd dimension

Weighted but
not based on any
specific outcome

Sum of the value
for the weighted
absolute
contributions of
each of the
dimensions.

Men 9 to 100
Women 7 to 100

Standardised medical
evaluation (Intervieweradministered)

1

16

MDMS

Multidimensional
multimorbidity score
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued)
Description
Category
C

Instrument

Instrument
(Full Name)

System or
Condition
based

Items

Weightage

Scoring
Method

Score
Range

Data source(s) &
resources required

Number of
studies
using the
instrument

WEIGHTED INDICES (continued)
17

MM by ADL

Multimorbidity
weighted by ADL
Scale

Condition

19
conditions

18

MM by HUI3

Multimorbidity
weighted by Health
Utility Index

Condition

19
conditions

19

MM by HUI3
betas

Multimorbidity
weighted by Health
Utility Index betas

Condition

19
conditions

20

MWI

MultimorbidityWeighted Index

Condition

81
conditions

21

QOF-E

Extended QOF
(weighted)

Condition

14
conditions

22

QOF-S

Standard QOF
(weighted)

Condition

9
conditions

Weighted based on
OARS functional
status scale
measuring ADL
Weighted based on
correlation with
health utility index
Weighted based on
correlation with
health utility index
and adjusted for age
and sex
Weighted based on
impact on SF-36
physical functioning
scale
0-6, based on impact
on 1-year mortality
(RR)
1-3, based on impact
on 1-year mortality
(RR)

Sum of
weighted
conditions

0 to 1.8

Face-to-face or
telephone interviews

1

Sum of
weighted
conditions

0 to 2.46

Face-to-face or
telephone interviews

1

Summing
of beta
coefficients

0 to 1.18

Face-to-face or
telephone interviews

1

Sum of
weights

Variable

Intervieweradministered or mail
questionnaire

2

Not
described

EMR

1

0 to 17

EMR

1

Sum of
weighted
conditions
Sum of
weighted
conditions
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued)
Description
Category
D
D1

Instrument

Instrument
(Full Name)

System or
Condition
based

Items

Weightage

93 mutually
exclusive
ACGs. Some
are modified to
68 ACGs

Incorporated into
ACGs based on
impact on resource
use (proprietary)

Scoring
Method

Score
Range

Data source(s) &
resources required

Number of
studies
using the
instrument

OTHER APPROACHES
Case-Mix

23

ACG

Adjusted Clinical
Groups

Condition

24

ADG

Aggregated
Diagnostic Groups

Condition

32 groups

25

HM

Hybrid Model (MN
Tier + ERA)

Condition

NS

26

HSMI

Health Search
Morbidity Index

Condition

73 chronic and
acute conditions

27

MN Tier

Minnesota Tiering

Condition

NS

28

RUB

Resource
Utilisation Band

Condition

6 mutually
exclusive bands

Based on duration,
severity, diagnostic
certainty, aetiology,
and need for
specialty care
Only MN tier 4 +
MN tier 3 with
ERA > 10
Based upon yearly
health care costs
directly derived
from primary care
setting
Grouping patients
into 'complexity
tiers' based on the
number of major
condition categories
Based upon ACG
algorithm on impact
on resource use
(proprietary)

Variable

N/A

EMR & ACG software
licensing

3

Variable

NS

EMR & ACG software
licensing

1

Variable

NS

EMR, HCC software
licensing & administrative
data

1

Sum of
regression
coefficients
(range
from -0.06
to 1.04)

Variable

EMR

1

Condition
count

Tier
0 to 4

EMR or administrative
data & MN Tiering
software licensing

2

Variable

N/A

EMR & ACG software
licensing

3
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued)
Description
Category
D
D2

System or
Condition
based

Items

Weightage

Scoring Method

Score
Range

Data
source(s) &
resources
required

Number of
studies
using the
instrument

OTHER APPROACHES (Continued)
Pharmaceutical-based
29

CDS

Chronic Disease
Score

Condition

17 conditions

Weighted 1-5

Sum of weights
based on
pharmacological
database

Weighted

Medication count

Variable

Self-reported
questionnaire

4

4 categories

0 to 1

GP medical
record + linked
pharmacy
claims database

1

1

1

0 to 35

Prescription
drug database

1

30

Drug Count

Drug Count

NA

Variable.
Some may be
based on
pharmacologi
c-therapeutic
classification
system

31

Modified Pra

Modified Pra tool
using RxRisk-V

NA

Pra tool +
RxRisk-V

Weighted due
to RxRisk-V

WHO-ATC
classification
system

Weighted
according to
the diagnostic
group of drugs
to predict
future health
care costs

Sum of weights

NA

GP medical
record + linked
pharmacy
claims database

NA

1-6; based on
clinical
judgement of
GP

Rating of severity
was only carried out
for physical illness
in general and not
for each individual
disease

1 to 6

GP
Questionnaire

32

D3

Instrument

Instrument
(Full Name)

RxRisk-V

RxRisk-V

NA

Clinical Judgement

33

CGI-S

Clinical Global
Impression Severity Scale

NA
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3.3

Description of all the instruments used

Table 3-6 summarised all the 27 instruments that were identified from the studies with low risk
of bias.

3.3.1

Count of Individual Conditions

Disease count was based on the unweighted count of all the conditions an individual had
usually from a pre-specified number of chronic conditions. It was used in 42 out of the 67
studies (62.7%). Disease counts were positively associated with activity limitations, continuity
of care, disability, healthcare cost, healthcare utilisation, medications, mental disorders, and
mortality; and negatively associated with general health, physical function, quality of life, and
self-rated health. The only outcome that was not associated with disease count was preventive
care66 (Table 3-6).

The data sources and resources used ranged from medical records (manual to electronic) or
administrative records like billing reports to insurance reports, self-administered questionnaires
by using mail, or telephone to interviewer-administered questionnaires. As such, information
collected could be from participants’ recall or medical records (Table 3-5).
Under the category of count of individual conditions, Chronic Condition Count56 (CCC) was a
unique instrument.

The difference between disease count and CCC was that although the

number of conditions was counted for CCC, they were further divided into six categories based
on a clinical classification software developed by the United States government agency. The
score ranged from zero to five. Only one study used this instrument, and the investigators
retrieved all the information from the electronic medical records.

3.3.2

Organ or system-based approaches

There were three instruments in this category. They were Cumulative Illness Rating Scale
(CIRS)29,30, Cornell Medical Index (CMI)43, and Organ Systems with chronic disease count
(Organ-CDC)73 represented by one study each.
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The CIRS is a system-based instrument divided into 14 categories100. Weightage is applied to
each category with a scoring of zero to four based on clinical judgement. The score ranges
from 0-56 and requires the summation of individual scores from each category.

Cornell Medical Index was created in 1949 and has been declared by the Cornell Medical
Centre to be no longer of clinical use since 2001. It was a self-reported questionnaire.
(https://library.weill.cornell.edu/archives/about-us/cornell-medical-index)

The Organ-CDC has 17 organ systems summed to form a score range of zero to seventeen.
Data were collected from electronic medical records. The instrument was found to be
associated with the presence of depressive or anxiety disorder73.

The two studies that used the instruments CIRS and Cornell Medical Index were not rated
‘good’ after the risk of bias assessment, and therefore the outcomes being examined in these
two studies were not reported in our summary Table 3-6. The outcomes examined for these
two instruments were disability29,30, frailty29,30, functional decline29,30, and mortality30,43.

3.3.3

Weighted Indices

There were seventeen unique weighted instruments found in the included studies. The original
Charlson Comorbidity Index (CCI) with its different modifications was the most frequently
used instrument and was found in 22 studies. Trailing behind were four studies using the Elder
Risk Assessment (ERA), three studies using Elixhauser Index (EI), and two studies using
Multimorbidity-Weighted Index (MWI). The other 13 studies had a unique weighted index
each. Some of these indices were used in prediction models.

The CCI was based on disease count, but the 17 conditions were weighted originally based on
its impact on one-year mortality101. The final score was derived by the summation of all the
weighted conditions.

The score ranges from 0-37.

There were many variations and

modifications of the score including the addition of psychosocial factors. The data sources and
resources used ranged from medical records (manual to electronic), or administrative records
like billing reports or insurance reports, to self-administered questionnaires by using mail,
telephone, or interviewer-administered.

As such, information collected could be from
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participants’ recall or from medical records. The instrument was found to be associated with
multiple outcomes other than one-year mortality (Table 3-6).

The ERA was based on disease count, but the conditions were weighted based on the impact
on future hospitalisation52. The instrument had six to nine conditions, and the final score was
derived from the sum of the weighted regression coefficients. The data sources were obtained
from electronic medical records or administrative data. The instrument was found to be
associated with critical illness49, healthcare expenditure56, mortality47, and readmission56.
The EI was developed from large administrative inpatient datasets102. It was based on disease
count with conditions ranging from 21 to 31 due to its many variations. The conditions were
weighted based on hospital mortality. The final score was also from the sum of the weighted
regression coefficients. Like the above two indices, association with outcomes other than
hospital mortality were found.

The MWI was a newer instrument that had 81 conditions weighted based on the impact on
physical functioning97. The final score was from the sum of the weights. The investigators
used an interviewer-administered or mailed questionnaire. The instrument was also associated
with cognitive performance97, grip strength97 , and mortality69. There was no association found
between MWI and gait speed97.

Most of the other instruments were novel like MWI where the investigators built multivariable
prognostic models from a set of potential predictor conditions (including non-clinical factors)
and weighted the conditions based on an outcome of clinical interest. The most common
outcomes chosen were mortality and physical function. Others included health expenditure56,
health utility index99, and severity of the most severe condition57. However, Multidimensional
multimorbidity score (MDMS)94 was unique in that it was weighted but not based on any
specific outcome.
Ubalde-Lopez et al.94 used statistical methods to develop MDMS based on seven chronic
conditions and two health behaviours. The conditions were weighted but were not based on
any specific outcome. The instrument required a standardised medical evaluation. The
investigators reported that MDMS was found to be positively associated with sickness absence
for males, but no association was found for females.
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3.3.4

Other Approaches

Other approaches included case-mix, pharmaceutical-based, and using clinical judgement for
measuring the level of multimorbidity.

For case-mix, Adjusted Clinical Groups (ACG) and Resource Utilisation Band (RUB) were
the most commonly used. Most of the case-mix instruments required proprietary software
licenses from the United States of America. Large data sets from electronic medical records
or administrative data were also needed (Table 3-5).

The second group in this category was related to pharmaceutical data. The most frequent type
was the unweighted drug count. The other three (Chronic disease score, Modified Pra tool
using RxRisk-V, and RxRisk-V) were all weighted indices. Except for the drug count that was
based on a self-report questionnaire, the rest required a prescription drug database to obtain the
data.

Clinical global impression - severity score (CGI-S) was an exceptional instrument that was not
based on any of the above but solely based on clinical judgement of the attending physician.
The study looked at the outcome of the presence of major depressive episode86.

3.3.5

Prediction Models

Twenty studies (with 23 articles) used different multimorbidity instruments together with nonclinical predictors like social deprivation, age, sex, marital status into a multivariable regression
analysis to predict outcomes including emergency department visits, health-related quality of
life, hospitalisations, mortality, number of primary care consultations, primary healthcare cost,
readmission (Appendix 3-4).

The c-statistic (concordance index), area under the receiver operating curve (AUC), and the
square of the correlation between the observed outcome and the predicted risk (R2) are the
general statistics tests to summarise the discrimination between individuals with and without
the outcome event in the regression model103. Of the 20 studies (23 articles), ten articles used
c-statistic, five articles used AUC, and four articles used R2. Additionally, two articles used
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Akaike information criterion (AIC) and another two used Bayesian information criterion (BIC)
for model selection.

The predictive ability of the instruments varied widely. Performances varied according to the
specific instrument used and the outcome measured. The c-statistic†††† ranged from 0.55 to
0.931. In general, models that compared different outcomes consistently showed better cstatistic when the model was used to predict mortality33,34,62,65. Similar variability was noted
with AUC‡‡‡‡ that ranged from 0.640 to 0.923, and R2 §§§§ that ranged from 0.11 to 0.793.

3.4 Instruments used for measuring the three core outcomes in
intervention studies
Table 3-7 identified the instruments that were used to explore the association with the three
essential core outcomes selected for the core outcomes set of multimorbidity research
(COSmm)6.

Three categories of instruments were used for measuring mortality. The three

categories were counts of individual conditions (DC), weighted indices (CCI, CLS, EI, ERA,
M3 Index, MWI, QoF-E & QoF-S), and other approaches including case-mix (ACG & RUB)
and pharmaceutical-based approaches (CDS & Drug Count). For mental health as an outcome,
only two categories of multimorbidity measures were identified.

They were counts of

individual conditions (DC), and organ or systems-based approaches (Organ-CDC). Finally,
for the quality of life, only counts of individual conditions (DC) was identified. Disease count
was the only instrument identified for all three outcomes.

††††

Concordance index (c-statistic): 0.50-0.69 (poor), 0.70-0.79 (good), >0.80 (excellent)
There are no recommended cut-offs for Area Under the receiver operating Curve (AUC)
§§§§ There are no recommended cut-offs for observed outcome and the predicted risk (R2)
‡‡‡‡
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measured
Association between Outcomes and Multimorbidity
Multimorbidity Measures

Positive Association

Negative Association

No Association

Affective well-being 98
Future physical functioning 69
General health 72
Life satisfaction 99
Perceived health status 99
Self-rated Health 45,84

Quality of cardiovascular preventive care 66
Quality of preventive care 66

Count of Individual Conditions
By Condition
Disease Count
(Many different groupings ranging from 7 45-47 to 147 10
conditions and some are further categorised 56)

Activities of Daily Living (ADL) limitations 27
Activity limitations 72
Continuity of care (3-years) 11
Deficits of perceived general health 90
Depressive symptoms 90
Disability 74,83,84
Emergency hospital admission (2-years) 40
Frequency of contacts with physicians (1-year) 48
Functional decline (2-years) 40
Healthcare costs 57,57
Hospital admissions (1-year) 37 38 62
Hospital outpatient visits (1-year) 67
Hospitalisation/Emergency Department Visits 67
Mental distress 72
Mortality (1-year) 62, (3-years) 32, (10-years) 69
Number of contacts with general practice (1-year) 95
Number of medications prescribed (1-year) 95
Number of mentally unhealthy days 27,28
Number of physically unhealthy days 27,28
Number of different ambulatory physicians contacted (1-year) 48
Number of primary care consultations (1-year) 32, (3-years) 32
Number of referrals (1-year) 95
Physical distress 72
Presence of mental health disorder 10
Primary care consultations (1-year period) 11, (3-years) 11
Primary healthcare cost 31
Potentially preventable unplanned admission (1-year period) 38

By Category
Chronic Condition Count

Healthcare costs 56
Hospital admissions (1-year) 56
Number of emergency department visits (1-year) 56
Readmission within 30 days (1-year) 56
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measure (Continued)
Association between Outcomes and Multimorbidity
Multimorbidity Measures

Positive Association

Negative Association

No Association

-

-

Organ or system-based approaches
Organ systems with chronic disease

Presence of depressive or anxiety disorder 73

Weighted Indices
Adult Comorbidity Evaluation-27 (ACE-27)

Healthcare expenditure 57

Charlson Comorbidity Index (CCI)

Ambulatory care sensitive hospitalisations (acute &
chronic) 64

Future physical functioning 69
Successful aging 36

Quality of cardiovascular preventive care 66
Quality of preventive care 66

Emergency department visits (1-year) 56
Emergency hospital admission (2-years) 40
Functional decline (2-years) 40
Healthcare expenditure 56
Hip fractures 63
Hospitalisation (1-year) 56,61,62,65,91
Mortality (1-year) 50,55,62,65, (5-years) 51,55, (10-years) 51,55,
(15, 20, 25-years) 51
Number of primary care consultations (3-years) 32
Number of primary care physician visits (1-year) 91
Number of specialist visits (1-year) 91
Potentially preventable unplanned admission (1-year) 37
Presence of critical illness 49
Primary healthcare cost 31
Mortality (1-year) 33,34, (3-years) 32,53, (5-years) 34,54,35,
(10-years) 69
Readmission within 30 days (1-year) 56
Comorbidity Linked Score

Mortality (1-year) 33

-

-

Elders Risk Assessment (ERA)

Healthcare expenditure 56
Mortality (2-years) 47
Number of days hospitalised (1-year) 52
Number of emergency department visits (1-year) 52,56
Number of hospital admissions (1-year) 52,56
Number of hospital visits (1-year) 52
Nursing home placement (2-years) 47
Presence of critical illness 49
Readmission within 30 days (1-year) 56

-

-
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measure (Continued)
Association between Outcomes and Multimorbidity
Multimorbidity Measures

Positive Association

Negative Association

No Association

-

-

-

-

-

Sickness absence episodes taken in 2 years (female) 94

Weighted Indices (Continued)
Elixhauser Index (Original and Modified)

Hospitalisation (1-year) 62,65
Mortality (1-year)

Hierachical Condition Categories (HCC)

33,62,65

Hospitalisation (1-year) 56
ED visits (1-year) 56
Readmission within 30 days (1-year) 56
Healthcare expenditure (1-year) 56

Multi-Morbidity Measure (M3) Index

Hospitalisation (1-year) 65
Mortality (1-year) 65

Multidimensional Multimorbidity Score (MDMS)

Sickness absence episodes taken in 2 years (male) 94

99

Multimorbidity weighted by Activities of Daily Living
(ADL) Scale

-

Life satisfaction
Perceived health status 99

-

Multimorbidity weighted by Health Utility Index
(HUI3)

-

Life satisfaction 99
Perceived health status 99

-

Multimorbidity weighted by Health Utility Index
(HUI3) betas

-

Life satisfaction 99
Perceived health status 99

-

Multimorbidity-Weighted Index (MWI)

ADL limitations 97
IADL limitations 97
Mortality (10-years) 69

Quality and Outcomes Framework (QOF)
(Standard)

Mortality (1-year) 50

Quality and Outcomes Framework (QOF)
(Extended)

Mortality (1-year) 50

Cognitive performance 97
Future physical functioning 69
Grip strength 97
Subjective physical functioning 97

Gait speed 97

-

-

-

-

Other Approaches
Case-Mix
Adjusted Clinical Groups (ACG)

Hospitalisation (1-year) 61
Mortality (3-years) 32
Number of primary care consultations (3-years) 32
Primary healthcare cost 31
Readmission within 30 days (1-year) 56
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measure (Continued)
Association between Outcomes and Multimorbidity
Multimorbidity Measures

Positive Association

Negative Association

No Association

-

-

Other Approaches (Continued)
Case-Mix (Continued)
Aggregated Diagnostic Groups (ADG)

Hospitalisation (1-year) 91
Number of primary care physician visits (1-year) 91
Number of specialist visits (1-year) 91

Hybrid Model (Minnesota Tiering + ERA)

Emergency department visits (1-year) 56
Healthcare expenditure 56
Hospitalisation (1-year) 56
Readmission within 30 days (1-year) 56

-

-

Health Search Morbidity Index (HSMI)

Healthcare cost (primary care) 80

-

-

56,67

Minnesota Tiering (MN Tier)

Emergency department visits (1-year)
Healthcare expenditure 56
Hospitalisation (1-year) 56,67
Readmission within 30 days (1-year) 56

-

-

Resource Utilisation Band (RUB)

Fee-for-service expenditures 79
Primary healthcare cost 31
Mortality (3-years) 32
Number of primary care consultations (3-years) 32
Registered active listing in primary care 88
Registered active listing in all healthcare 88

-

-

-

-

Pharmaceutical-based
Chronic Disease Score (CDS)

Hospitalisation (1-year) 62
Mortality (1-year) 62

Prescribed drug count

Emergency hospital admission (2-years) 40
Functional decline (2-years) 40
Hospitalisation (1-year) 62
Mortality (1-year) 62, (3-years) 32
Number of primary care consultations (3-years) 32

Pra Tool Modified

Emergency hospital admission (1-year) 39

-

-

RxRisk-V

Emergency hospital admission (2-years) 40
Functional decline (2-years) 40

-

-
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Table 3-7. Summary of the three essential core outcomes* of multimorbidity and their
corresponding instruments
Outcomes
Mortality

Corresponding multimorbidity measures
Counts of Individual Conditions
Disease count 32,62,69
Weighted Indices
Charlson Comorbidity Index 32 50 51,33-35 53-55,62,65,69
Co-morbidity linked score 33
Elderly Risk Assessment 47
Elixhauser Index (original and modified) 33,62,65
Multi-Morbidity Measure (M3) Index 65
Multimorbidity Weighted Index (MWI) 69
Quality and Outcomes Framework (Standard and Extended) 50
Other approaches
Case-Mix
Adjusted Clinical Groups 32
Resource Utilisation Band 32
Pharmaceutical-based
Chronic Disease Score 62
Drug Count 32,62

Mental Health

Counts of Individual Conditions
Disease count 72,90
Organ or system-based approaches
Organ systems with chronic disease 73

Quality of Life

Counts of Individual Conditions
Disease count 27,28,70,74,81,84,98

* The outcomes were based on the Core Outcome Set for Multimorbidity Research (COSmm) by Smith et al. 6
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4

Discussion
4.1

Summary of findings

Thirty-three unique instruments for measuring the level of multimorbidity were identified from
all the included studies using the classification by Sarfati41. The most commonly used
instrument in the count of individual conditions category was ‘Disease Count’. In the organ or
system-based approaches category, three instruments were found but they were not commonly
used. The weighted indices category had the most variety of different instruments (up to 17),
and within this category, Charlson Comorbidity index (with its different variations) was the
most commonly used.

Finally, for the ‘other approaches’ category, case-mix and

pharmaceutical-based instruments were also commonly used. The full list and description of
the instruments are provided in Table 3-5.

Disease count is the only instrument that was associated with all three essential core outcomes
identified for COSmm, i.e., quality of life, mental health, and mortality (Table 3-7). In
summary, all the study findings showed the association between the explanatory variables and
outcomes were in the same direction and did not conflict with each other (Table 3-6). The
outcomes not found to have any association with the instruments for measuring the level of
multimorbidity were preventive care66, sickness absence episodes (female)94, and gait speed97.

4.2

Comparison with previous research

We identified five other review articles describing the instruments for measuring the level of
multimorbidity in the literature: Huntley et al.16, Sharabiani et al.104, Yurkovich et al.105,
Diederichs et al.106, and de Groot et al.13 Huntley et al.16 was mentioned in the introduction as
the review that this study was updating. It was also the only study that targeted participants
from the primary care or general population. Sharabiani et al.104 (2012) and Yurkovich et al.105
(2015) were reviews of multimorbidity instruments using administrative data, Diederichs et
al.106 (2011) was a review that looked specifically at weighted indices for measuring the level
of multimorbidity, and de Groot et al.13 (2003) was the oldest study that looked at all
instruments using all kinds of data.

134
Huntley et al.16, consistent with this systematic review, listed the most frequently used
instruments for measuring the level of multimorbidity while the other four reviews13,104-106
recommended the most suitable instruments. We found the most common instruments used
for measuring the level of multimorbidity in primary care similar to the systematic review done
by Huntley et al. However, several of the instruments including Duke Severity of Illness
Checklist (DUSOI) and Functional Comorbidity Index (FCI) identified in their paper were not
found in this systematic review.

The original DUSOI has been adapted and renamed the Duke and World Organisation of
Family Doctors Severity of Illness Checklist (DUSOI/WONCA) in 2011107. However, a quick
search for use of the instrument in PubMed***** showed the last publication using the
instrument was in 2004108. An article on FCI in chronic rhinosinusitis was published in 2016109,
and another study showed that FCI had higher inter-rater reliability in patients with acute lung
injury in 2012110. The reasons for not identifying these instruments in this review may be
because of the lack of interest on the instrument by the research community for DUSOI in the
recent years, or that the search strategy in the review excluded studies that have an index
condition or were not from the primary care or general population like the FCI.
Under the ‘count of individual conditions’ category, disease count was found to be one of the
most frequently used instruments in this review and Huntley et al.’s16. For this review, there
were multiple and variable outcomes associated with this measure. These outcomes included
disability, healthcare costs, hospitalisation, mental health, mortality, quality of life, and selfrated health.
Under the ‘organ or system-based approaches’ category, the Cumulative Illness Rating Scale
was the only instrument recommended by one review13. The outcomes were, activities of daily
living (ADL), instrumental ADL, and medication usage. However, the predictive validities
were only small to fair for positive correlation.
For the category on ‘weighted indices’, three instruments were highlighted by the six reviews
(including this review): Charlson Comorbidity Index (CCI), Elixhauser Index (EI), and Elders
Risk Assessment (ERA). CCI was recommended by two of the reviews. Multiple outcomes

*****

The free search engine provided by the United States National Library of Medicine at the National Institutes of Health.
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were found to be associated with CCI, but mortality and hospitalisation were the main ones.
The EI was recommended by two of the reviews. Sharabiani et al.104 recommended that EI
was the best predictor for long-term mortality. Yurkovich et al.105 recommended using the
Quan and van Walraven versions of the EI, or the Romani version of CCI for measuring
mortality. The ERA was not found by any of the other reviews but was one of the common
instruments found in this systematic review. The outcomes predicted were hospitalisation and
mortality.

Diederichs et al.106 looked exclusively at the development of weighted

multimorbidity indices in the general population but did not make any particular
recommendation as the authors pointed out the heterogeneity of existing indices and the need
for a new, established instrument to assess multimorbidity.
Under the ‘other approaches’ category, RxRisk-V was recommended by Yurkovich et al.105 for
evaluating health care utilisation, in which medication data were available. Adjusted Clinical
Group (ACG) was a frequently used instrument for various outcomes including healthcare
resources, health care costs, health care utilisation, hospitalisation, and mortality found in this
study and by Huntley et al.16

4.3

Advantages and disadvantages of selected instruments

4.3.1

Disease count

Summing the number of conditions from among a list of candidate chronic conditions provides
an ordinal score111. This method has the advantage of simplicity and ease of data ascertainment
with minimal resources required. Despite its simplicity, the disease count was not only
associated with the three essential core outcomes (quality of life, mental health, and mortality)
but also six others outcomes (activities of daily living, costs, health care use, physical activity,
physical function, and self-rated health) suggested by the Core Outcome Set for Multimorbidity
Research (COSmm) by Smith et al.6

However, using disease count to measure the level of multimorbidity does not appear
appropriate conceptually. For example, the same category - ‘secondary malignancies’ includes
diagnoses that have a nearly nine-fold difference in mortality, and grouping all ‘secondary
malignancies’ into one category oversimplifies the differences within this category seen in the
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Elixhauser Index102. Moreover, analytic strategies often incorrectly force a linear relationship
with the ordinal scale, ignoring the fact that an additional unit of increase in ‘disease count’
will most likely have a diminishing impact. Finally, a summed measure also ignores potentially
important relationships between diseases that might differ from their simple sum111.

The other disadvantage noted in this systematic review is that many investigators using disease
counts as an instrument did not state clearly on what basis certain chronic conditions were
included or excluded, the total number of conditions in the multimorbidity list, and the cutpoints used to define multimorbidity.

This lack of information makes the comparison with

other studies difficult, and also impossible to replicate or confirm previous findings.

4.3.2

Weighted Indices

Calculation of weights was usually based on three methods. The first method was by directly
getting self-reported information from patients, for example, directly asking patients whether
a particular condition interfered with their daily activities on a Likert scale. The second method
was by deriving weights from the literature according to the individual impact of diseases on
different outcomes. This was the commonest method and utilised in prognostic models to build
complex multivariable regression models whereby the weights were calculated from hazard
ratios, odds ratios, or regression coefficients112. A third method was to apply weights by
defining specific criteria, based on clinical parameters such as fasting glucose for a physiologic
index of comorbidity113 or cholesterol level for Chronic Disease Score (CDS)114. In the next
chapter of this thesis, the Chronic Disease Control Score (CDCS) used the third method as an
independent variable for measuring the level of multimorbidity.

The common weighted indices identified in this systematic review were Charlson Comorbidity
Index, Elders Risk Assessment, Elixhauser Index and Multimorbidity-weighted Index. All of
them belonged to the second method of weighting diseases. The other 13 weighted indices
identified in this systematic review were novel and were also developed using this second
method. These instruments have been found by other included studies in this systematic review
to be associated with four outcomes from the Core Outcome Set for Multimorbidity Research
(COSmm) suggested by Smith et al.6 These outcomes included activities of daily living, costs,
health care use, physical function.
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The advantage of these weighted indices is that the weights allow the adaptation of an index to
a specific outcome.

An investigator could recalibrate the correct weight by creating a

prognostic model to produce a contextualised instrument for a different setting. Prognostic
models can provide clinically relevant risk stratification and help to allocate resources115.

One disadvantage of such indices is the number of resources required to develop a new
instrument. Even adopting well-established indices would still require validation studies
meaningful to the local context. This is made more difficult as there is also a lack of transparent
reporting of multivariable prediction models for individual prognosis or diagnosis
(TRIPOD)103.

Moreover, calculated weights are greatly influenced by the population,

outcomes used, and the instrument’s original conception and purpose. Therefore, addressing
different outcomes may necessitate using different instruments.

4.3.3

Case-Mix

The ease of obtaining and using the data needed to characterise multimorbidity make the ACG
system a preferred method for analyses in different domains and suitable for comparison across
areas within and between countries116. The advantage of the instrument is its good track record
in the United States and several other countries. However, the instrument is proprietary, and
the exact algorithm of the instrument is not open to the public and may not be suitable in certain
nuance settings. Another disadvantage is the financial costs involved in obtaining the license.

4.3.4

Pharmaceutical-based instruments

Medication-based indices include versions of the Chronic Disease Score114, which later became
known as the RxRisk117, and its adaptation for use in the veteran population, the RxRisk-V118.
The advantage of using these instruments is when prescription datasets are easily obtainable.

Drug count is one of the common instruments reported in this systematic review. Like disease
count, the main advantage is its ease of use with minimal resources required. In this systematic
review, it was found to be associated with health care use and physical function. However, it
was also not clearly described in many studies regarding which type of drugs were counted and
which were not.
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4.4

Data sources

Data sources for using these various instruments rely on medical record information, patient
self-report, clinical judgment, or large administrative databases. Regardless of the data source,
errors can be introduced. For patient self-report, patients with cognitive impairment may
under-report symptoms and may be seen less frequently by their physicians, resulting in an
under-recognition or under-treatment of conditions111. Administrative data may not truly
reflect the exact list of chronic conditions of patients as that is not the primary purpose of
collecting the data. It has been shown that health administrative data based on billing system
underestimated the prevalence of many chronic conditions119.

Some of these instruments mentioned have been developed exclusively for use with
administrative data such as Elixhauser Index102, whereas others have been developed in other
contexts but adapted for use with administrative data such as the Charlson Comorbidity
Index101. Many weighted indices require medical records or administrative data which may not
be readily available. It is time-consuming to engage research team members in the examination
of individual clinical notes.

The available data in a particular setting may strongly influence the ultimate instrument chosen
for multimorbidity research. As there is currently no consensus on the gold standard for
sources of data, it is difficult to assess which data source performs the best. The next chapter
of this thesis will explore the agreement between self-reported data and the electronic medical
records.

4.5

Clinical Implications

Seventeen multimorbidity outcomes were identified by a Delphi panel of international experts
of multimorbidity intervention studies6. However, only ten out of the seventeen outcomes were
reported in the 67 studies identified in this systematic review. None of the other seven outcome
measures (adherence, communications, prioritisation, self-management behaviour, selfefficacy, shared decision-making, and treatment burden) was explored in any of the 67 studies
included in this systematic review. Most of these outcomes were patient-centred outcomes.
The outcome that was investigated the most was health care utilisation. In the search strategy
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for this systematic review, there was no restriction on the type of studies to be included or not.
However, we only found observation studies (cohort and cross-sectional) and did not find any
interventional studies. This could be the reason why the other seven outcome measures were
not reported, but it is also reflective of the lack of interventional studies on multimorbidity in
primary care and the general population generally. There is still much to do to improve on the
body of knowledge of multimorbidity when most investigators in the last ten years measured
multimorbidity without including some of the important outcome measures of multimorbidity.

Ideally, a single instrument for measuring the level of multimorbidity should be able to predict
a variety of relevant outcomes, but Byles et al.15 reported that a single index could not predict
a variety of outcomes, in different patient groups and settings. The investigators suggested that
prediction of multiple outcomes within one study may not necessitate more than one instrument
if the same instrument could still be utilised by using different weights for the same items in
calculating the scoring systems. Such multiple-scoring instruments may be the way forward
for validation of prognostic models for different outcomes and different populations with
established multimorbidity instruments.

The choice of conditions included in such an

instrument should include those with a high prevalence in the population being served and with
a severe impact on affected people. The definition of high prevalence and severe impact would
have to be defined by each health care setting or geography. However, for pragmatic reasons,
the final selection of the conditions to be included in such a multiple-scoring instrument may
have to take into account the availability of relevant and reliable data.

Interestingly, in a systematic review of studies on hospitalisation risk prediction models, more
than half of the studies did not include multimorbidity in the modelling120. However, the
authors noted that the studies with the best-performing models were those that considered
multimorbidity. It was observed that well-performing prediction models were distinguished
by taking into account multi-dimensional scales instead of multimorbidity scores alone121.
Therefore, in building the predictor variables for the model, relevant clinical and non-clinical
profiles should be considered on top of a level of multimorbidity measurement instrument.

Multimorbidity is a complex phenomenon, and the current definition maybe overly simplistic
and not able to ideally capture the complexity of multimorbidity. The complex interactions of
several co-occurring chronic conditions often include the additional consideration of social,
psychological, and emotional factors.

Social networks and support, coping strategies,
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individual preferences, and living conditions would have to be considered in the assessment of
multimorbidity122.

In conclusion, a certain degree of reductionism will have to be accepted because a
multimorbidity measurement instrument will not be able to encompass all the nuances of the
different interactions of chronic conditions on an individual living in his/her unique milieu.
Moreover, most of the studies in this systematic review were from Europe and North America
with very few Asian studies. Applying the findings to the local setting of Singapore should not
be taken wholesale. The current instruments should not be the only tool for investigators and
clinicians to assess all the dimensions of multimorbidity. Ultimately, the most suitable
instrument will depend on the specified outcome of interest, the study population, and the type
of data and resources available.

4.6

Strengths and limitations of the study

One of the main strengths of this systematic review was that we involved a health science
librarian at the start of the review and had several rounds of iterations and cross-checks before
finalising the search strategy.

We also published our protocol before embarking on the review and adhere to what we
proposed to report without changes during the systematic review process123. We followed the
PRISMA statement20 for systematic review of observational studies and guidance on the
conduct of narrative synthesis in systematic reviews21 for the reporting of this systematic
review.

The systematic review had several limitations. Grey literature was not included in this review,
which may have introduced study selection bias124. However, we excluded grey literature
based on evidence suggesting that the quality of research in the grey literature is lower and
more difficult to appraise compared with research in journal articles124. We excluded abstracts,
as abstracts with positive findings tend to be accepted for presentation at conferences more
frequently than those with negative or null findings124. Another limitation was that we only
included articles that were published in the English language.
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Although our search strategy was comprehensive, it was far from complete. The use of
electronic databases has been found to retrieve only half of all relevant studies125. We did not
contact authors directly for a suggestion of studies. We also did not identify a list of
instruments from the preliminary search and then perform an additional search using the same
databases as suggested by Yurkovich et al.105 However, given the consistency of our results,
it is unlikely that missed studies would significantly alter the main findings of our review.
As there was a lack of consensus for qualitative assessment tool for observational studies126,
we chose Newcastle Ottawa Scale (NOS) and then modified it with careful consideration after
testing two other risk of assessment tools. The modified NOS may not be a perfectly reliable
tool for risk of assessment, but the Cochrane Collaboration has recommended it for assessing
nonrandomised studies127.

4.7

Conclusion

In this systematic review, we found 33 instruments for measuring the level of multimorbidity
of community-dwelling individuals that predict or explore the association with at least one
specified outcome. Disease count and weighted indices like the Charlson Comorbidity Index,
the Elders Risk Assessment, and Elixhauser Index were commonly used for measuring the level
of multimorbidity. Other approaches to measuring the level of multimorbidity included casemix or pharmaceutical-based instruments.

We compiled a list of these instruments and discussed the advantages and disadvantages of the
commonly-used instruments. A certain degree of reductionism will have to be accepted for
each instrument as no one single instrument for measuring the level of multimorbidity will be
able to encompass all different dimensions of multimorbidity. There has been a rise in the
development of novel weighted indices by using prognostic models or validation of an existing
well-established instrument. The reporting of such studies would need to follow the TRIPOD
guidelines to allow potential users to replicate and confirm the findings103.

There are continuing interests in measuring the level of multimorbidity with disease count and
drug count.

A clear description of the instruments is required in the publication of
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multimorbidity studies to counter the frequent lack of information currently seen so as to
contribute to robust multimorbidity research in future.

There is currently an absence of a gold standard for where to obtain chronic disease
information. Most data sources are from medical record information, patient self-report,
clinical judgment, or large administrative databases. Ultimately, the most suitable instrument
will depend on the specified outcome of interest, the study population, and the type of data and
resources available.

Finally, we compiled a list of instruments that were used to explore the association with the
three essential core outcomes selected for the core outcomes set of multimorbidity research
(COSmm)6. Disease count was the only instrument identified for all three outcomes.
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Appendices

Appendix 3-1. Search Strategy
Table 1. Medline Search 1946 to August 13, 2018
#
1
2
3
4
5

6
7
8

9
10
11

12
13
14

Searches
exp comorbidity/ or multiple chronic conditions/
(multimorbid* or multi-morbid* or comorbid* or co-morbid*).ab,ti,kw.
((multiple or coexist* or co-exist* or concurrent* or simultaneous*) adj2 (disease* or
illness* or diagnos* or condition* or morbid* or disorder*)).ab,ti,kw.
1 or 2 or 3
primary health care/ or "continuity of patient care"/ or exp general practice/ or ambulatory
care/ or physicians, family/ or physicians, primary care/ or community health services/ or
general practitioners/
((ambulatory or community or general or family or primary) adj2 (care or health* or
practi* or physician* or medicine or center* or centre* or facilit* or clinic*)).ab,ti,kw.
5 or 6
epidemiologic measurements/ or risk assessment/ or "Outcome Assessment (Health
Care)"/ or patient reported outcome measures/ or health status indicators/ or "severity of
illness index"/ or sickness impact profile/ or diagnosis-related groups/ or case mix/
((health status or risk or outcome* or sickness impact) adj2 (appraisal* or assessment* or
evaluation* or measur* or index* or indic* or profile*)).ab,ti,kw.
((severity or burden) adj2 (illness* or diseas* or disorder* or condition* or
diagnos*)).ab,ti,kw.
(charlson comorbidity index or charlson index or charlson score or elixhauser* or
cumulative illness rating scale* or CIRS or adjusted clinical group* or ACG* or disease
count or Duke severity* or DUSOI or casemix or case-mix).ab,ti,kw.
8 or 9 or 10 or 11
4 and 7 and 12
limit 13 to (english language and yr="2010 -Current")

Table 2. Embase Classic+Embase 1947 to August 13, 2018
#
Searches
1
comorbidity/ or multiple chronic conditions/
2
(multimorbid* or multi-morbid* or comorbid* or co-morbid*).ab,ti,kw.
3
((multiple or coexist* or co-exist* or concurrent* or simultaneous*) adj2 (disease* or
illness* or diagnos* or condition* or morbid* or disorder*)).ab,ti,kw.
4
1 or 2 or 3
5
primary health care/ or patient care/ or primary medical care/ or general practice/ or
general practitioner/ or ambulatory care/ or family medicine/ or community care/ or
community health services/
6
((ambulatory or community or general or family or primary) adj2 (care or health* or
practi* or physician* or medicine or center* or centre* or facilit* or clinic*)).ab,ti,kw.
7
5 or 6
8
risk assessment/ or outcome assessment/ or patient reported outcome/ or health status
indicator/ or disease activity score/ or global disease burden/ or organ dysfunction score/
or "severity of illness index"/ or sickness impact profile/ or general health status
assessment/ or disease severity/ or diagnosis related group/ or charlson comorbidity index/
or comorbidity assessment/ or elixhauser comorbidity index/ or case mix/
9
((health status or risk or outcome* or sickness impact) adj2 (appraisal* or assessment* or
evaluation* or measur* or index* or indic* or profile*)).ab,ti,kw.
10 ((severity or burden) adj2 (illness* or diseas* or disorder* or condition* or
diagnos*)).ab,ti,kw.
11 (charlson comorbidity index or charlson index or charlson score or elixhauser* or
cumulative illness rating scale* or CIRS or adjusted clinical group* or ACG* or disease
count or Duke severity* or DUSOI or casemix or case-mix).ab,ti,kw.
12 8 or 9 or 10 or 11
13 4 and 7 and 12

Results
95224
147739
45667
247802
229791

350963
461463
516146

344511
72588
18192

808827
4172
2173

Results
196646
244599
66050
378500
578870

453501
811904
1257685

438484
106531
32221

1613925
9317
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14 limit 13 to (english language and yr="2010 -Current")
Table 3. CINAHL – since inception to August 14, 2018
#
1
2
3
4
5

6
7
8

9
10
11

12
13
14

Searches
(MH “comorbidity”)
multimorbid* or multi-morbid* or comorbid* or co-morbid*
(multiple or coexist* or co-exist* or concurrent* or simultaneous*) N2 (disease* or
illness* or diagnos* or condition* or morbid* or disorder*)
1 or 2 or 3
(MH “primary health care”) or (MH “family practice”) or (MH “ambulatory care") or
(MH “ambulatory care facilities") or (MM “community health services”) or (MM
“community health centers”) or (MH “physicians, family”) or (MH “continuity of patient
care")
(ambulatory or community or general or family or primary) N2 (care or health* or practi*
or physician* or medicine or center* or centre* or facilit* or clinic*)
5 or 6
(MH “risk assessment”) or (MH "Outcome Assessment") or (MH “patient-reported
outcomes) or (MH “health status indicators”) or (MH "severity of illness indices") or (MH
“sickness impact profile”) or (MH “diagnosis-related groups”) or (MH “case mix”)
(health status or risk or outcome* or sickness impact) N2 (appraisal* or assessment* or
evaluation* or measur* or index* or indic* or profile*)
(severity or burden) N2 (illness* or diseas* or disorder* or condition* or diagnos*)
(charlson comorbidity index or charlson index or charlson score or elixhauser* or
cumulative illness rating scale* or CIRS or adjusted clinical group* or ACG* or disease
count or Duke severity* or DUSOI or casemix or case-mix)
8 or 9 or 10 or 11
4 and 7 and 12
limit 13 to (english language and yr="2010 -Current")

6113

Results
30423
49461
9374
57381
83299

205406
211994
69377

165689
51231
4820

211895
1454
800
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Appendix 3-2. Coding Description for the Modified Newcastle-Ottawa Scale for Cohort Studies
Category
Selection
1) Representativeness of the sample

2) Ascertainment of multimorbidity

3) Demonstration that outcome of
interest was not present at start of
study

Description
This item assesses the representativeness of sample in the community, not from some general population.
a) Truly representative* (e.g., everyone from the database)
b) Somewhat representative* (with at least 2 criteria but selection method was convincing due to random sampling)
c) Selected group (e.g., only certain socio-economic groups or areas)
d) No description of sampling strategy
This item assesses the method by which multimorbidity was confirmed.
a) Secure record* (e.g., GP questionnaire)
b) Structured interview* (e.g., interviewer-administered questionnaire)
c) Written self-report (e.g., mailed survey, if items are unable to be confirmed by objective measure)
d) No description / Other
A statement of no history of disease earns a star. In the case of mortality studies, outcome of interest is still the presence of a disease, rather than
death.
a) Yes*
b) No

Comparability
1) Study controls for age and sex

2) Study controls for other factors
Outcome
1) Statistical test

2) Assessment of outcome

Covariates must be adjusted for in the analysis. Statements of no differences between groups or that differences were not statistically significant are
not sufficient for establishing comparability. Note: If the relative risk for the exposure of interest is adjusted for the covariates listed, then the groups
will be considered to be comparable on each variable used.
a) Yes*
b) No
a) Yes*
b) No
Statistical test(s) must be clearly described and appropriate before assessing the other items under the Outcome category.
a) Clearly described and appropriate
b) Not described, incomplete or inappropriate
This item assesses the method by which the outcome of interest was confirmed. For some outcomes, reference to the medical record is sufficient to
satisfy the requirement for confirmation. This may not be adequate for other outcomes where reference to specific tests or measures would be
required.
a) Independent or blind assessment* (e.g., interviewer-administered questionnaire)
b) Record linkage* (e.g., identified through ICD codes on database records)
c) Self-report (i.e., no reference to original medical records)
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d) No description / Other
3) Was follow-up long enough for
outcomes to occur?
4) Adequacy of follow-up of cohorts

An acceptable length of time was at least 1 year of follow-up.
a) Yes*
b) No
This item assesses the follow-up of the sample to ensure that losses are not related to the outcome.
a) Complete follow-up - all subject accounted for*
b) Subjects lost to follow-up unlikely to introduce bias* (Number lost ≤20% or description of those lost suggested no different from those followed.)
c) Follow-up rate less than 80% and no description of those lost
d) No statement

Thresholds for converting the modified Newcastle-Ottawa scales to Good, Fair, and Poor Quality:
• Good Quality - 2-3 stars in Selection category (Representativeness of Sample item must be fulfilled) AND 1-2 stars in Comparability category AND 2-3 stars in Outcome category.
• Fair Quality - 1-2 stars in Selection category AND 1-2 stars in Comparability category AND 2-3 stars in Outcome category.
• Poor Quality - 0 star in Selection category OR 0 stars in Comparability category OR 0-2 stars in Outcome category.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available
from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Modifications from original NOS include:
• ‘Statistical test’ was added to the Outcome category
• ‘Representativeness of sample’ item under Selection category and ‘Statistical test’ item under Outcome category must both be fulfilled for study to be considered Good Quality.
• ‘Selection of the non-exposed cohort’ item was removed from Selection category as most studies did not describe a non-exposed cohort, and this review sought to compare the different
levels of multimorbidity within the group.
• ‘Representativeness of the exposed cohort’ item under Selection category was renamed ‘Representativeness of the sample’ since the ‘non-exposed cohort’ was removed above.
• ‘Ascertainment of exposure’ under the Selection category was renamed as ‘Ascertainment of multimorbidity’ to specify that multimorbidity is the exposure in this review.
• ‘Study controls for age and sex’ and ‘Study controls for other factors’ were revised to be items under Comparability category
• The thresholds for converting the scales to quality were amended accordingly due to the above modifications.
Consensus:
• The study team decided that a period of one-year was a reasonable period of follow-up under ‘Was follow-up long enough for outcomes to occur?’ item under Outcome category.
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Appendix 3-3. Coding Description for the Modified Newcastle-Ottawa Scale for Cross-sectional Studies
Category
Selection
1) Representativeness of the sample

2) Ascertainment of multimorbidity

3) Sample Size

4) Non-respondents

Description
This item assesses the representativeness of sample in the specified population, not from some general population.
e) Truly representative* (e.g., everyone from the database, random sampling)
f) Somewhat representative* (with at least 2 criteria but selection method was convincing due to random sampling)
g) Selected group (e.g., only certain socio-economic groups or areas)
h) No description of sampling strategy
This item assesses the method by which multimorbidity was confirmed.
e) Secure record* (e.g., Clinical records, GP questionnaire)
f) Structured interview* (e.g., interviewer-administered questionnaire)
g) Written self-report (e.g., mailed survey, if items are unable to be confirmed by objective measure)
h) No description / Other
If there is no description, a reported sample size of 800 and above is satisfactory.
c) Justified and satisfactory*
d) Not justified
Acceptable response rates for surveys through various methods†
• In-person: 57%
• Mail: 50%
• Average: 33%
• Email: 30%
• Internet: 29%
• Telephone: 18%
• In-app: 13%
a) Comparability between respondents and non-respondents characteristics is established, and the response rate is satisfactory. *
b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory.
c) No description of the response rate or the characteristics of the responders and the non-responders

Comparability
3) Study controls for age and sex

4) Study controls for other factors

Confounders must be adjusted for in the analysis. Statements of no differences between groups or that differences were not statistically significant
are not sufficient for establishing comparability. Note: If the relative risk for the exposure of interest is adjusted for the confounders listed, then the
groups will be considered to be comparable on each variable used in the adjustment.
c) Yes*
d) No
c) Yes*
d) No

157
Outcome
5) Statistical test

Statistical test(s) must be clearly described and appropriate before assessing the other items under the Outcome category.
c) Clearly described and appropriate
d) Not described, incomplete or inappropriate
6) Assessment of outcome
This item assesses the method by which the outcome of interest was confirmed. For some outcomes, reference to the medical record is sufficient to
satisfy the requirement for confirmation. This may not be adequate for other outcomes where reference to specific tests or measures would be
required.
e) Independent or blind assessment*
f) Record linkage* (e.g., identified through ICD codes on database records)
g) Self-report (i.e., no reference to original medical records)
h) No description / Other
Thresholds for converting the modified Newcastle-Ottawa scales to Good, Fair, and Poor Quality:
• Good Quality – 3-4 stars in Selection category (Representativeness of Sample item must be fulfilled) AND 1-2 stars in Comparability category AND 1 star in Outcome
category.
• Fair Quality - 2 stars in Selection category AND 1-2 stars in Comparability category AND 1 star in Outcome category.
• Poor Quality - 0 star in Selection category OR 0 stars in Comparability category OR 0 stars in Outcome category.
†Lindermann N. What’s the average survey response rate? [2018 benchmark]. SurveyAnyplace. Available from: https://surveyanyplace.com/average-survey-response-rate/.
Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD Overlap Syndrome (ACOS): a systematic review and meta-analysis. PLoS ONE.
2015;10(9):e0136065. Doi:10.1371/journal.pone.0136065.
Modifications from original NOS include:
• ‘Ascertainment of exposure’ item under Selection category was renamed as ‘Ascertainment of multimorbidity’ to specify that multimorbidity is the exposure in this review.
• The ratings for the ‘Ascertainment of exposure’ item under Selection category were revised to ‘secure record, structured interview, written self-report, no description/other’
to align with the Modified NOS for cohort studies in this review.
• ‘Study controls for age and sex’ and ‘Study controls for other factors’ items were revised to be items under Comparability category.
• ‘Was follow-up long enough for outcomes to occur’ item under Outcome category was renamed as ‘Statistical test’. This item must be fulfilled for the study to be considered as
Good Quality.
• The thresholds for converting the scales to quality were amended accordingly due to the above modifications.
Consensus:
• The study team decided on a list of acceptable response rates for various survey methods for the ‘Non-respondents’ item under Selection category.
• The study team decided that a sample size of 800 was reasonable under ‘Sample size’ item under Selection category.
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23
articles)
Author
(Year),
Country
Cohort Studies
Brilleman et al.
(2014)31, UK

Multimorbidity
Measurement(s)
a.
b.
c.
d.
e.
f.
g.
h.

ACG
CCI
CCI dummy
EDC count
EDC dummy
QOF count
QOF dummy
RUB

Outcomes
measured
1.

Primary
healthcare cost

Models used in the study

Statistics

Model 1:

Age and sex

BIC = 1320939

Model 2:

Age, sex, and deprivation

BIC = 1320555

Model 3:

Age, sex, and practice

BIC = 1322027

Model 4:

Age, sex, deprivation, and practice

BIC = 1321883

Model 5:

Model 4 and QOF dummy

BIC = 1302791

Model 6:

Model 4 and QOF count

BIC = 1305547

Model 7:

Model 4 and CCI dummy

BIC = 1310235

Model 8:

Model 4 and CCI

BIC = 1311982

Model 9:

Model 4 and EDC dummy

BIC = 1295660

Model 10:

Model 4 and EDC count

BIC = 1302546

Model 11:

Model 4 and ACG

BIC = 1308944

Model 12:

Model 4 and RUB

BIC = 1312522

Conclusion
1.

Under OLS estimation, the EDC measures performed best
followed by the QOF and ACG measures. The CCI measures
had the worst performance but still improved markedly on
models containing only age, sex, deprivation and practice
effects.

(Continued on next page)
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23
articles)(Continued)
Author
(Year),
Country
Brilleman &
Salisbury
(2013)32, UK

Multimorbidity
Measurement(s)
a.
b.
c.
d.
e.
f.

ACG
CCI
EDC count
Prescribed drugs
count
QOF count
RUB

Outcomes
measured
1.

2.

Mortality
(3-years period)

Number of
primary care
consultations
(3-years period)

Models used in the study

Statistics

Model 1:

Age, sex, and deprivation

BIC = 20250

Model 2:

Model 1 and QOF count

BIC = 19854

Model 3:

Model 1 and CCI

BIC = 19443

Model 4:

Model 1 and EDC count

BIC = 19979

Model 5:

Model 1 and RUB

BIC = 19946

Model 6:

Model 1 and prescribed drugs count

BIC = 19693

Model 1:

Age, sex, age-by-sex interaction,
deprivation, and GP practice

BIC = 650373

Model 2:

Model 1 and QOF count

BIC = 638720

Model 3:

Model 1 and CCI

BIC = 644908

Model 4:

Model 1 and EDC count

BIC = 629766

Model 5:

Model 1 and ACG

BIC = 628438

Model 6:

Model 1 and RUB

BIC = 631863

Model 7:

Model 1 and prescribed drugs count

BIC = 620799

Conclusion
1.

Measures of multimorbidity made little difference to the fit of
a model predicting 3-year mortality. Nonetheless, the CCI
was the best performing measured followed by the number of
prescribed drugs.

2.

All of the multimorbidity measures had moderate predictive
validity in relation to consultation in primary care, in which
the number of prescribed drugs had the greatest predictive
validity followed by the ACG based measures (ACG, EDC
count, and RUB).
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Author
(Year),
Country
Carey et al.
(2013)50, UK

Chapman et al.
(2015)51, UK

Multimorbidity
Measurement(s)
a.
b.
c.

a.
b.

Standard QOF
Extended QOF
CCI (Khan)

CCI
CCI-PSR

Outcomes
measured
1.

1.

Mortality
(1-year
period)

Mortality
(5, 10, 15, 20,
25-years
period)

Models used in the study

Statistics

Model 1:

Age and sex

C-statistics = 0.776

Model 2:

Age, sex, and Standard QOF count

C-statistics = 0.806

Model 3:

Age, sex, and Standard QOF weighted
score

C-statistics = 0.823

Model 4:

Age, sex, and Standard QOF weighted
score (9 levels)

C-statistics = 0.826

Model 5:

Age, sex, and CCI count

C-statistics = 0.809

Model 6:

Age, sex, and CCI weighted score

C-statistics = 0.816

Model 7:

Age, sex, and CCI weighted score (9
levels)

C-statistics = 0.818

Model 8:

Age, sex, and Extended QOF count

C-statistics = 0.813

Model 9:

Age, sex, and Extended QOF weighted
score

C-statistics = 0.826

Model 10:

Age, sex, and Extended QOF weighted
score (9 levels)

C-statistics = 0.829

CCI Model:

CCI-PSR
Model:

Age, sex, chronic asthma/emphysema,
arthritis/rheumatism, cancer, diabetes,
gastrointestinal disease, heart disease,
kidney disease, and stroke
CCI model, income, education, type A
personality, communalism, and lie scale

AUC = 0.75 (5-yrs)
AUC = 0.74 (10-yrs)
AUC = 0.74 (15-yrs)
AUC = 0.76 (20-yrs)
AUC = 0.77 (25-yrs)

Conclusion
1.

A simple count of the morbidities in each of the
multimorbidity measurements produced significant
improvement from a basic model adjusting for age and
sex.

2.

Fitting the weighted score as a nine-level variable further
improved discrimination, with the standard QOF score
outperforming the Charlson index. The extended QOF
score produced only a modest improvement in overall
model performance.

1.

Across 5-, 10-, 15-, 20-, and 25-year time horizons, the
CCI-PSR showed substantially better discrimination than
the CCI.

AUC = 0.83 (5-yrs)
AUC = 0.83 (10-yrs)
AUC = 0.83 (15-yrs)
AUC = 0.84 (20-yrs)
AUC = 0.84 (25-yrs)
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Author
(Year),
Country
Crane et al.
(2010)52, USA

Crooks et al.
(2016)33, UK

Multimorbidity
Measurement(s)
a.

a.
b.
c.

ERA

Co-morbidity
linked score
CCI
Elixhauser Index

Outcomes
measured

Models used in the study
ERA Model:

Age, marital status, number of days
hospitalised in 2003 or 2004,
history of diabetes, history of
CAD/MI/CHF, history of stroke,
history of COPD, history of cancer,
and history of dementia

Statistics

1.

Number of
hospital visits
(1-year period)

AUC = 0.705

2.

Number of ED
visits
(1-year period)

3.

Number of
hospital
admissions
(1-year period)

AUC not reported

4.

Number of days
hospitalised
(1-year period)

AUC not reported

1.

Mortality
(1-year period)

Conclusion
1.

Results suggest that the ERA index is an effective risk
identification model to identify population of older,
community-dwelling adults who are at increased risk of
hospitalisation and ED encounters.

1.

The linked score had significantly improved discrimination
and fit compared to the CCI and the Elixhauser Index

AUC = 0.640

Elixhauser:

Elixhauser Index, age, sex, and
recent hospitalisation

C-statistics = 0.868

CCI:

CCI, age, sex, and recent
hospitalisation

C-statistics = 0.872

Linked score
(Categorical):

Linked score (Categorical), age,
sex, and recent hospitalisation

C-statistics = 0.879

Linked score
(Continuous):

Linked score (Continuous), age,
sex, and recent hospitalisation

C-statistics = 0.878
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Author
(Year),
Country
Crooks et al.
(2015)34, UK

Fraccaro et al.
(2016)55, UK

Multimorbidity
Measurement(s)
a.
b.
c.

a.

CCI (Read)
CCI (ICD-10)
CCI (Read and
ICD-10)

CCI (Khan)

Outcomes
measured
1.

1.

All-cause
mortality

Mortality
(6-month
period)

Models used in the study

Statistics

Model 1:

Sex

C-statistics = 0.513

Model 2:

Age and sex

C-statistics = 0.844

Model 3:

Age, sex, and CCI (Read)

C-statistics = 0.861

Model 4:

Age, sex, recent hospitalisation,
and CCI (Read)

C-statistics = 0.868

Model 5:

Age, sex, and CCI (ICD-10)

C-statistics = 0.870

Model 6:

Age, sex, recent hospitalisation,
and CCI (ICD-10)

C-statistics = 0.872

Model 7:

Age, sex, CCI (Read and ICD-10)

C-statistics = 0.869

Model 8:

Age, sex, recent hospitalisation,
and CCI (Read and ICD-10)

C-statistics = 0.873

Model 1:

Age, sex, and baseline CCI

AIC = 362230

Model 2:

Sex, time-dependent age, and CCI

AIC = 358054

Model 3:

Sex, baseline CCI, time-dependent
age, and CCI

AIC = 357290

Model 4:

Sex, baseline CCI, time-dependent
age, and cumulative CCI change

AIC = 357290

Model 5:

Sex, time-dependent age, CCI, and
CCI change over consecutive time
windows

AIC = 357000

Conclusion
1.

There was no large difference in the discrimination of the
model for overall survival, whichever codes were used to
derive the CCI. Including a marker for a recent hospital
admission resulted in a slightly improved discrimination for
each Charlson derivation.

1.

Model 5 had the best fit to the data but had equivalent
discrimination to the other time-dependent models.
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Author
(Year),
Country
Haas et al.
(2013)56, USA

Multimorbidity
Measurement(s)
a.
b.

c.
d.
e.
f.
g.

Hwang et al.
(2015)57, USA

1.
2.

ACG
Minnesota
Health Care
Home Tiering
HCC
ERA
CCC
CCI
Hybrid Model

ACE-27
ACE-27 count

Outcomes
measured
1.

Hospitalisation

2.

ED visits

3.

Readmission
within 30 days

4.

1.

Models used in the study
ACG

Minnesota Health Care Home Tiering

Healthcare
expenditure

Healthcare
expenditure

Statistics
C-statistics = 0.73 (Hospitalised)
C-statistics = 0.67 (ED visits)
C-statistics = 0.81 (Readmission)
C-statistics = 0.76 (Expenditure)
C-statistics = 0.71 (Hospitalised)
C-statistics = 0.66 (ED visits)
C-statistics = 0.79 (Readmission)
C-statistics = 0.74 (Expenditure

HCC

C-statistics = 0.67 (Hospitalised)
C-statistics = 0.58 (ED visits)
C-statistics = 0.74 (Readmission)
C-statistics = 0.70 (Expenditure)

ERA

C-statistics = 0.71 (Hospitalised)
C-statistics = 0.61 (ED visits)
C-statistics = 0.78 (Readmission)
C-statistics = 0.72 (Expenditure)

CCC

C-statistics = 0.69 (Hospitalised)
C-statistics = 0.61 (ED visits)
C-statistics = 0.77 (Readmission)
C-statistics = 0.72 (Expenditure)

CCI

C-statistics = 0.68 (Hospitalised)
C-statistics = 0.59 (ED visits)
C-statistics = 0.75 (Readmission)
C-statistics = 0.70 (Expenditure)

Exploratory predictive model consists of
age, sex, rurality of residence, logarithms
of total, inpatient, medication, outpatient,
and professional expenditures, number
and overall severity of patient conditions
defined by ACE-27 score, and each of
the 26 individual comorbidities in ACE27

AUC = 0.923

Conclusion
1.

The ACG model outperformed the other 5 models in
predicting hospitalisation.

2.

In models predicting ED visits, the ACG model had the
best predictive ability.

3.

The ACG model outperformed other models when
predicting 30-day readmissions

4.

When predicting healthcare expenditures for the top 10%
high-cost users, the performance of the ACG model was
superior to that of other models

1.

The model, using year 1 data to determine if an individual
would be classified into the persistent high-user group for
the following 3 years, indicates a very high level of
accuracy in predicting membership in a high-user group.

(Continued on next page)

164
Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23
articles)(Continued)
Author
(Year),
Country
Lemke et al.
(2012)61, USA

Multimorbidity
Measurement(s)
a.
b.

CCI
ACG

Outcomes
measured
1.

Inpatient
hospitalisations

Models used in the study

Statistics

Model 1:

Prior Inpatient Hospitalisation
Age, sex, count of hospitalisations
within the previous 12 months

AUC = 0.75

Model 2:

Charlson Inpatient Hospitalisation
Age, sex, prior hospitalisations,
emergency department episodes not
resulting in inpatient hospitalisations,
outpatient visits, markers for dialysis
services, nursing services and major
procedures and 17 Charlson
comorbidities

AUC = 0.78

Model 3:

ACG Inpatient Hospitalisation
Age, sex, diagnosis-based morbidity
categories and disease cluster markets,
medication-based morbidity groups,
count of previous hospitalisations

AUC = 0.80

Model 4:

ACG ICU/CCU Hospitalisation
Age, sex, diagnosis-based morbidity
categories and disease cluster markets,
medication-based morbidity groups,
count of ICU/CCU hospitalisation

AUC = 0.85

Model 5:

ACG Extended Hospitalisation
Age, sex, diagnosis-based morbidity
categories and disease cluster markets,
medication-based morbidity groups,
count of extended hospitalisation

AUC = 0.87

Conclusion
1.

ACG-based predictive model for inpatient
hospitalisation was superior to the prior
hospitalisation model and the Charlson
inpatient model

2.

The difference between the ACG and
Charlson inpatient models was statistically
significant (p<0.0001)
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Author
(Year),
Country
Quail et al.
(2011)62,
Canada

Multimorbidity
Measurement(s)
a.
b.
c.
d.
e.

DC
CCI (Quan)
Elixhauser Index
(Quan)
Number of
dispensed drugs
Chronic Disease
Score

Outcomes
measured
1.
2.
3.

Death
One or more
hospitalisations
Two or more
hospitalisations

Models used in the study

Statistics

Age, age2, sex, income
quintile, and geography

C-statistic = 0.880 (Death)
C-statistic = 0.652 (≥1 hospitalisations)
C-statistic = 0.706 (≥2 hospitalisations)

Model 1 + Number of
different diagnoses

C-statistic = 0.901 (Death)
C-statistic = 0.722 (≥1 hospitalisations)
C-statistic = 0.782 (≥2 hospitalisations)

Model 3:

Model 1 + Charlson
Comorbidity Index (Quan)

C-statistic = 0.905 (Death)
C-statistic = 0.671 (≥1 hospitalisations)
C-statistic = 0.731 (≥2 hospitalisations)

Model 4:

Model 1 + Elixhauser (Quan)

C-statistic = 0.913 (Death)
C-statistic = 0.682 (≥1 hospitalisations)
C-statistic = 0.748 (≥2 hospitalisations)

Model 1
(Base Model):

Model 2:

Model 5:

Model 1 + Number of
dispensed drugs

C-statistic = 0.894 (Death)
C-statistic = 0.688 (≥1 hospitalisations)
C-statistic = 0.744 (≥2 hospitalisations)

Model 6:

Model 1 + Chronic Disease
Score

C-statistic = 0.889 (Death)
C-statistic = 0.672 (≥1 hospitalisations)
C-statistic = 0.729 (≥2 hospitalisations)

Conclusion
In predicting all outcomes, the addition of a
comorbidity measure to the base model yielded a
statistically significant improvement in the cstatistic.
1.

Elixhauser Index (Quan) performed best in
improving the c-statistic, followed by CCI.

2.

Disease count (number of different
diagnoses) was the best performing
comorbidity measure for one or more
hospitalisations

3.

Disease count (number of different
diagnoses) was the best performing
comorbidity measure Disease count
(number of different diagnoses) was the
best performing comorbidity measure for
two or more hospitalisations
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Author
(Year),
Country
Saver et al.
(2014)64, USA

Multimorbidity
Measurement(s)
a.

CCI (Romano)
+ Hypertension

Outcomes
measured

Models used in the study

Statistics

1.

Acute ACSH

Model 1:

Age, sex, and race

C-statistics = 0.68

2.

Chronic ACSH

Model 2:

Model 1, rural-urban
residence, state of residence,
availability of healthcare
services, continuity of care,
household income,
education, original source of
Medicare eligibility, number
of outpatient visits in prior
year, and previous year
ACSHs

C-statistics = 0.72

Model 3:

Conclusion
1.

Model with limited set of comorbidity flags (model 3 and
model 4) had far grater predictive power for acute and
chronic ACSHs.

1.

M3 Index outperformed both CCI and Elixhauser in
predicting mortality

2.

M3 Index performed better than CCI and Elixhauser when
considering overnight hospitalisation.

C-statistics = 0.87
Model 2, comorbidity flags
(CHF, COPD, diabetes,
hypertension and, for acute
ACSHs, dementia), and
precious year ACSHs

Model 4:

C-statistics = 0.87
Model 1 and comorbidity
flags (CHF, COPD, diabetes,
hypertension and, for acute
ACSHs, dementia)

Stanley and
Sarfati
(2017)65, New
Zealand

a.
b.
c.

M3 Index
CCI
Elixhauser
(van Walraven)

1.

Mortality
(1-year period)

Model 1:

Age and sex

2.

Overnight
hospitalisation
(1-year period)

Model 2:

Age, sex, and CCI

Model 3:

Age, sex, and Elixhauser

Model 4:

Age, sex, and M3 Index

C-statistics = 0.887 (Mortality)
C-statistics = 0.656
(Hospitalised)
C-statistics = 0.921 (Mortality)
C-statistics = 0.683
(Hospitalised)
C-statistics = 0.922 (Mortality)
C-statistics = 0.676
(Hospitalised)
C-statistics = 0.931 (Mortality)
C-statistics = 0.703
(Hospitalised)
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Author
(Year),
Country
Takahashi et al.
(2016)67, USA

Wallace et al.
(2016a)39,
Ireland

Multimorbidity
Measurement(s)
a.

a.
b.

DC using
Minnesota
Medical Tiering
(ACG)

Pra tool
Modified Pra tool

Outcomes
measured
1.

1.

Hospitalisation /
ED visits

Emergency
hospital
admission
(1-year period)

Models used in the study
Minnesota
Medical
Tiering

Statistics
AUC = 0.667

Enhanced
Model

Age, sex, BMI, marital status,
insurance, prior ED visits, prior
hospitalisations, more than 3
specialists seen in 2010, mental
health disorders, substance-related
disorders, narcotic prescription
order, epilepsy, hyperlipidemia,
warfarin prescription order

AUC = 0.711

Pra tool

Age, sex, presence of diabetes,
presence of coronary heart disease,
hospital admission in previous
year, > 6 physician visits in
previous year, self-rated health,
and availability of an informal
caregiver

C-statistics = 0.65

Modified Pra

Conclusion
1.

The enhanced model is better at predicting
hospitalisation/ED visits than models that utilise only
Minnesota medical tiering as it takes into consideration
previous hospitalisation, specific high-risk illnesses, mental
health conditions, and high-risk medication use (eg,
warfarin, narcotics) that are not universally accounted for
in other models.

1.

Both models demonstrated poor model discrimination for
the outcome for emergency admission during the 1-year
follow-up period.

C-statistics = 0.67
Pra tool and RxRisk-V
(Continued on next page)
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Author
(Year),
Country
Wallace et al.
(2016b)40,
Ireland

Multimorbidity
Measurement(s)
a.
b.
c.
d.
e.

Wei and
Mukamal
(2018)69, USA

a.
b.
c.

DC
Barnett conditions
DC
CCI
Prescribed drugs
count
RxRisk-V

MWI
DC
CCI

Outcomes
measured
1.

Emergency
admission
(2-years period)

2.

Functional
decline
(2-years period)

1.

Mortality (10years period)

Models used in the study

Statistics

Conclusion

Model 1:

Age, sex, deprivation, and
DC

C-statistics = 0.61 (Admission)
C-statistics = 0.55 (Functional)

1.

All measures demonstrated poor discrimination in
predicting emergency admission.

Model 2:

Age, sex, deprivation, and
Barnett DC

C-statistics = 0.63 (Admission)
C-statistics = 0.55 (Functional)

2.

All measures demonstrated poor discrimination in
predicting emergency admission.

Model 3:

Age, sex, deprivation, and
CCI

C-statistics = 0.58 (Admission)
C-statistics = 0.60 (Functional)

Model 4:

Age, sex, deprivation, and
RxRisk-V

C-statistics = 0.63 (Admission)
C-statistics = 0.61 (Functional)

Model 5:

Age, sex, deprivation, and
prescribed drugs count

C-statistics = 0.62 (Admission)
C-statistics = 0.57 (Functional)
1.

MWI performed best in predicting mortality as
compared to DC and CCI, with the greatest Cstatistics in all cohorts as well as the combined
cohorts.

MWI

C-statistics = 0.67 (NHS Cohort)
C-statistics = 0.70 (HPFS Cohort)
C-statistics = 0.64 (NHS II Cohort)
C-statistics = 0.68 (Combined)

DC

C-statistics = 0.65 (NHS Cohort)
C-statistics = 0.68 (HPFS Cohort)
C-statistics = 0.62 (NHS II Cohort)
C-statistics = 0.66 (Combined)

CCI

C-statistics = 0.64 (NHS Cohort)
C-statistics = 0.64 (HPFS Cohort)
C-statistics = NA (NHS II Cohort)
C-statistics = 0.64 (Combined)
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Author
(Year),
Country

Multimorbidity
Measurement(s)

Cross-Sectional Studies
Kristensen et
a. RUB
al. (2014)79,
Denmark

Outcomes
measured
1.

Fee-for-services
expenditures

Models used in the study
Model 1:

Age, age squared, and sex

Model 3:

R2 = 0.437

Model 4:

Model 2 and chapter
components markers

R2 = 0.372

Model 6:
Health Search
Morbidity Index
(HSMI)

1.

Morbidity measures were significant patient-related feefor-services expenditures drivers.

1.

The HSMI explained 50.17% of the variation in costs.

R2 = 0.316
Model 2 and ICPC-2
chapter markers

Model 5:

a.

R2 = 0.133

Conclusion

Model 1 and RUB markers
Model 2:

Lapi et al.
(2015)80, Italy

Statistics

1.

Total mean
healthcare cost
per year

Model 1:

Model 2, ICPC-2 chapter
markers, and chapter
components markers
Model 5 and volume
markers
Interaction between age
and sex, province of
patient’s residence, and
GP

R2 = 0.444

R2 = 0.793
R2 = 50.17

R2 = 50.16

Model 2:
Interaction between age
and sex, and region of
patient’s residence

R2 = 49.71

Model 3:
Province of patient’s
residence and GP

R2 = 50.51

Model 4:
Model 1 and cubic
fractional polynomial
transformation of age
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Author
(Year),
Country
Ranstad et al.
(2014)88,
Sweden

Multimorbidity
Measurement(s)
RUB

Outcomes measured
1.

2.

Shadmi et al.
(2011)91, Israel

ADGs
CCI

Models used in the study

Statistics

Registered active
listing in primary
care

Model 1:

Multimorbidity, primary care

AIC = 141110.9

Model 2:

Multimorbidity, all healthcare

AIC = 145361.5

Registered active
listing in all
healthcare

Model 3:

Interaction between number of
consultations and multimorbidity,
primary care

AIC = 140007.6

Model 4:

Interaction between number of
consultations and multimorbidity,
all healthcare

AIC = 144595.7

Model 1:

Age and sex

R2
R2
R2
R2

= 0.13 (Primary care visits)
= 0.12 (Specialist visits)
= 0.13 (Diagnostic tests)
= 0.05 (Hospitalisations)

Model 2:

Age, sex, CCI

R2
R2
R2
R2

= 0.18 (Primary care visits)
= 0.13 (Specialist visits)
= 0.15 (Diagnostic tests)
= 0.11 (Hospitalisations)

Model 3:

Age, sex, ADGs

R2
R2
R2
R2

= 0.54 (Primary care visits)
= 0.45 (Specialist visits)
= 0.37 (Diagnostic tests)
= 0.24 (Hospitalisations)

1.

Number of primary
care physician
visits

2.

Number of
specialist visits

3.

Performance of
diagnostic tests

4.

Number of
hospitalisations

Conclusion
1.

Multimorbidity level predicted active listing,
significantly increasing for RUB0-4 in primary
care

2.

Multimorbidity level predicted active listing,
significantly increasing for RUB0-4 in all
healthcare

1.

ADGs explained the largest percent of variance
or in health care resource use, ranging from 23%
to 54% in primary care physician visits,
specialist visits, performance of diagnostic tests,
and hospitalisations
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Author
(Year),
Country
Sullivan et al.
(2012)93, USA

Multimorbidity
Measurement(s)
DC

Outcomes measured
1.

Preference-based
HRQoL

Models used in the study

Statistics

Model 1:

Age, number of chronic conditions

Pseudo R2 = 0.2316

Model 2:

Age, income, sex, race, education,
ethnicity, physical activity,
smoking status

Pseudo R2 = 0.1462

Model 3:

Number of chronic conditions

Pseudo R2 =0.1994

Model 4:

Age, income, sex, race, education,
ethnicity, physical activity,
smoking status, number of chronic
conditions

Pseudo R2 =0.2360

Conclusion
1.

The inclusion of chronic co-morbidity to the
baseline models explained more of the variance
in EQ-5D-5L index scores than did age or other
sociodemographic characteristics

Note. ACE-27 = Adult Comorbidity Evaluation-27; ACG = Adjusted Clinical Groups; ACSH = Ambulatory Care Sensitive Hospitalisation; AUC = Area Under the Curve; BIC = Bayesian Information Criterion; CAD
= Coronary Artery Disease; CCC = Chronic Conditions Count; CCI = Charlson Comorbidity Index; CCI-PSR = Charlson Comorbidity Index-Psychosocial Risk; CCU = Critical Care Unit; CHF = Congestive Heart
Failure; COPD = Chronic Obstructive Pulmonary Disease; DC = Disease Count (Unweighted); ED = Emergency Department; EDC = Expanded Diagnosis Clusters; ERA = Elder Risk Assessment; GP = General
Practice; HCC = Hierarchical Condition Categories; HSMI = Health Search Morbidity Index; ICD-10 = International Classification of Diseases, Tenth Revision; ICPC-2 = International Classification of Primary Care,
Second Edition; ICU = Intensive Care Unit; MI = Myocardial Infarction; OLS = Ordinary Least Squares; QOF = Quality and Outcomes Framework; RUB = Resource Utilisation Band.
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and its association with Depression, Anxiety and
Quality of Life (MDAQ)
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Abbreviations
ADC-EMR
ADC-SR
BI
BMI
BP
CDCS
CMC
DBP
EMR
EQ-5D
GAD-7
HbA1c
HDB
HUDC
IQR
LD
LDL-C
MAR
MCAR
MI
MNAR
NHGP
OR
PABAK
PHQ-9
PI
SBP
SD
SE
SPSS
STROBE
UI
VAS
VIF
W
κ

Additional Disease Count - Electronic Medical Record
Additional Disease Count - Self-reported
Bias index
Body Mass Index
Blood pressure
Chronic Disease Control Score
Chronic Medication Count
Diastolic Blood Pressure
Electronic Medical Records
EuroQol Office Quality of life scale
Generalised Anxiety Disorder Scale
Glycated Haemoglobin
Housing Development Board
Housing and Urban Development Company
Inter-quartile range
Listwise Deletion
Low-density lipoprotein
Missing at random
Missing completely at random
Multiple Imputation
Missing not at random
National Healthcare Group Polyclinics
Odds ratio
Prevalence-adjusted bias-adjusted kappa
Patient Health Questionnaire Depression Scale
Prevalence index
Systolic Blood Pressure
Standard deviation
Standard error
IBM Statistical Analysis Software
Strengthening the Reporting of Observational Studies in Epidemiology
EuroQol Office Quality of life scale - Utility Index
EuroQol Office Quality of life scale - Visual Analogue Scale
Variance inflation factor
Width
Cohen's kappa statistic
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1 Introduction
A clear association between illness burden and psychological distress has been reported in the
literature1.

It is believed that psychological distress arises through progressive loss of

independence, self-esteem, and self-identity as the number of chronic conditions increase2.
Chapter two reported that the most common co-occurring chronic conditions found in primary
care patients in Singapore are hyperlipidaemia, hypertension, and diabetes with a prevalence
rate of 21.9% in the primary care setting (Chapter Two Table 2-10 p54). If every chronic
condition is poorly-controlled in a patient with multimorbidity, it is logical to assume that the
illness burden would have been higher or worse than a patient whose multiple chronic
conditions were well-controlled for every condition. Moreover, it has been shown that
reducing numerous risks simultaneously is beneficial because risk factors for cardiovascular
disease tend to cluster and interact which exerts a greater combined risk3.

Clinical practice guidelines on the control of clinical parameters of single diseases are widely
available in the medical literature. Based on the guidelines of specialty societies, optimal
thresholds for some of these clinical parameters were combined from separate clinical practice
guidelines as composite measures for reducing cardiovascular disease and were widely
accepted as standards of care since the end of the 20th century4. These standards of care quickly
became performance measures for clinicians5. The Ministry of Health (MOH) in Singapore
also followed suit with the MOH’s Diabetes Mellitus Clinical Practice Guidelines published in
20066.

One success story of using a composite score for both clinical outcomes of patients with
multimorbidity and provider’s performance measures of clinicians was reported in Taiwan7.
However, adhering to the current clinical practice guidelines in caring for an older person with
multimorbidity may result in undesirable effects8. There is concern that performance measures
may direct healthcare providers’ focus on improving outcomes of single diseases, rather than
to manage the interactions of multiple chronic conditions9. This is made worse when clinicians
are blind to the extent to which treatment burden can unintentionally drag people down10.
Findings from a qualitative study reported that patient’s perspectives of living with
multimorbidity speak more to lower quality of life and functional challenges than to disease-
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specific issues11. The inverse relationship between the level of multimorbidity and quality of
life has been reported by multiple other studies using different methodologies12-21. Patients
with multimorbidity were also more likely to be screened positive for depression22. Clinical
depression was two to three times more likely in people with multimorbidity compared to
people without multimorbidity23-25.

However, clinically depressed patients with

multimorbidity were inconsistently picked up in primary care26.

Although multimorbidity is commonly observed in Singapore, very few investigators have
looked into the phenomenon locally, and even fewer studies were conducted to look at patientreported outcomes like depression, anxiety, and quality of life. One exception is Quah et al.27
who surveyed older adults in the primary care setting locally and found that multimorbidity
was associated with lower quality of life. Many of the multimorbidity studies that contributed
to the burgeoning literature on the topic were conducted in North America or Europe.
However, findings reported elsewhere may not apply to the local context.
The entity of ‘diseases’ used by doctors do not always explain the individuals’ illness, and
patient needs and symptom experience are not necessarily an indication of an underlying
disease28. Many multimorbidity studies were conducted by directly obtaining self-reported
medical conditions from the patients. Several studies have reported variable concordance rates
that were reported by patients and what were recorded in their medical notes29-31. A growing
body of literature has raised concerns about the reliability of respondent recall, poor respondent
understanding, and labelling of medical conditions when self-reporting of medical conditions
was used in such studies29,32.

Therefore, in this study, we proposed to look at the association of a composite score for
measuring the level of multimorbidity derived from clinical data among patients with the triad
of hyperlipidaemia, hypertension, and diabetes in primary care and determine its association
with patient-reported outcome measures like depression, anxiety and quality of life. Our
primary research hypothesis was that with a higher level of multimorbidity, patients would
experience a higher degree of depression and anxiety symptoms, and a lower quality of life.
The second objective of the study was to describe the prevalence of depression and anxiety,
and the average score of quality of life in individuals with the commonest triad of
multimorbidity in primary care. Our third objective was to determine the factors associated
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with depression, anxiety or poor quality of life for patients with the commonest triad of
multimorbidity. Our final objective of this study was methodological as we determine the
concordance rate between self-reported medical conditions by patients and medical conditions
recorded in their clinical records.

2 Methods
This was a cross-sectional interviewer-administered questionnaire study conducted in the
primary care population at one of the National Healthcare Group Polyclinics (NHGP) between
August 2014 and June 2016. The study team received approval from the ethics review board
(National Healthcare Group Domain Specific Review Board Reference number 2013/01053)
on 5 June 2014, and the first patient was recruited on 12 August 2014. We followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
guidelines33 in reporting this study. This study received funding from an intramural grant.

2.1

Setting

Hougang Polyclinic is one of the nine polyclinics in the National Healthcare Group Polyclinics
(NHGP) in the north-eastern part of Singapore. Hougang Polyclinic provides a comprehensive
range of health services for the family, functioning as a one-stop health centre providing
treatment for acute medical conditions, management of chronic diseases, women and child
health services, and dental care. It operates with close to 180 staff including 24 doctors and 18
nurses servicing up to 1,200 patients daily from 8 am to 4.30 pm. It is opened for half a day
every Saturday and closed on Sunday.

2.2

Sampling

The full inclusion criteria were listed as follows:
a. Patients who were 21 years old and below 80 years old
b. Patients with current co-existence of at least three chronic conditions, i.e., hyperlipidaemia,
hypertension, and diabetes mellitus Type 1 or 2
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c. Patients who were seen in Hougang Polyclinic at least twice in the last six months††††† for
chronic disease management (information obtained from diagnosis codes) prior to
commencement of the study
d. Patients who were able to understand spoken English, Mandarin, Malay or Tamil and
provided written informed consent
e. Patients who consented to allow the study team to access their medical notes at Hougang
Polyclinic

A random sample of the eligible population in Hougang polyclinic was selected using the IBM
Statistical Analysis software version 21 (SPSS). Potential participants from this selected list
were approached before/during/after their scheduled appointments at Hougang Polyclinic and
invited to go to a nearby interview room where the research assistant would explain the research
study. All eligible participants were given the opportunity to ask questions and given ample
time to think about participation. Informed consent was obtained when the patient was
agreeable to participate in the study. This consent also permitted the research team to obtain
further data like recent biomedical results, medication list and other medical conditions from
the electronic medical records (EMR). We excluded pregnant women and patients who were
cognitively not capable of providing consent. The team members excluded pregnant women
because the outcome measures on depression, anxiety and quality of life may be strongly
influenced by pregnancy rather than multimorbidity.

2.3

Conduct of the interview

All our research assistants and coordinators met regularly and practised interviewing on each
other under the supervision of the principal investigator to ensure that the assistance provided
and answers to anticipated questions raised by participants were standardised as much as
possible before embarking on the actual research to reduce interviewer bias.

We used all four official languages of Singapore to conduct the interviews according to the
choice of the participants. The principal research assistant was proficient in English and
Mandarin only. For Malay and Tamil-speaking participants, we made special arrangements to

†††††

We selected patients who visited two visits in the last six months as a proxy to represent patients who have
chosen Hougang Polyclinic as the designated polyclinic for management of their chronic medical conditions.
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bundle the appointments together so that other research assistants proficient in those languages
would meet potential participants at Hougang Polyclinic on a pre-arranged date and time. We
also arranged a convenient time for participants to return to the polyclinic for the interview if
their agendas were not able to accommodate the interview during their polyclinic scheduled
appointments.

The study questionnaire was programmed on the QuickTapSurvey (www.quicktapsurvey.com)
app on a tablet computer. The questionnaire included all the demographic questions, outcome
variables described in 2.4, and the independent variables described in section 2.5. Data were
entered by the research assistant directly into the tablet computer. Each interview took
approximately 30 minutes. All patient information was de-identified upon completion of the
relevant data collection from the EMR before analysis was commenced.

2.4

Outcome variables

The three outcome variables were Patient Health Questionnaire Depression Scale (PHQ-9)34,35,
Generalised Anxiety Disorder Scale (GAD-7)36, EuroQol Office Quality of life scale (EQ-5D3L) Utility index (UI)37 and EuroQol Office Quality of life scale (EQ-5D-3L) Visual Analogue
Scale (VAS)37 score. Both EQ-5D-3L UI and VAS were continuous variables.
(1) The PHQ-934 is a nine-item depression measure where respondents were asked whether
they were bothered by a series of problems in the past two weeks and if so, how often, using
a four-point scale from ‘not at all’ to ‘nearly every day’. Individual scores from each item
were summed, and a higher total score indicated greater depression as shown in Appendix
4-1. The PHQ-9 is a valid and reliable measure of depression screening in Singapore38.
Using the cut-off score of 10, the PHQ-9 has a sensitivity of 88% and a specificity of 88%
for major depression35. We chose values equal to or greater than five as being indicative
of symptoms of depression39,40. PHQ-9 was a dichotomous variable (‘<5’ as equivalent to
‘minimal depressive symptoms’ and ‘>=5’ as ‘mild to severe depressive symptoms’)
(2) The GAD-736 is a seven-item anxiety measure where respondents were asked whether they
were bothered by a series of problems in the past two weeks and if so, how often, using a
four-point scale from ‘not at all’ to ‘nearly every day’. Individual scores of each item were
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summed, and a higher score indicated greater anxiety as shown in Appendix 4-2. Though
designed primarily as a screening and severity measure for generalised anxiety disorder,
the GAD-7 also has moderately good operating characteristics for three other common
anxiety disorders – panic disorder, social anxiety disorder, and post-traumatic stress
disorder. Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a
specificity of 82% for generalised anxiety disorder36. We chose values equal to or greater
than five as being indicative of symptoms of anxiety to account for emotional
morbidity39,40. GAD-7 was a dichotomous variable (‘<5’ as equivalent to ‘minimal anxiety
symptoms’ and ‘>=5’ as ‘mild to severe anxiety symptoms’)
(3a) The EQ-5D-3L37 is a standardised measure of health status comprising a descriptive
system - Utility Index (UI) and a Visual Analogue Scale (VAS).

The Utility Index (UI) assessed five domains (i.e., mobility, self-care, usual activities,
pain/discomfort, anxiety/depression) and participants were asked to rate their health on that
day of the interview on a three-point scale (no problem/moderate problem/extreme
problem). Responses to these five domains were converted into one of 243 different health
state descriptions which ranged between no problems on all five dimensions (11111) and
severe/extreme problems on all five dimensions (33333). (Appendix 4-3)

The utility of EQ-5D health states was originally elicited using the time trade-off method
from a representative sample of the United Kingdom general population to value a number
of potential EQ–5D states (the time trade-off seeks to establish by how much one would be
willing to reduce one’s life expectancy in order to obtain full health)41. The EQ-5D-3L UI
used in this study was based on a representative sample of a Singapore general population
that has been validated and ranged from -0.769 to 1.00042. Negative values represent health
states worse than being dead, ‘0’ representing being dead, and ‘1.000’ representing a state
of full health.

(3b)

The EQ-5D-3L VAS recorded the participant’s self-rated health on a vertical, visual

analogue scale where the endpoints were labelled ‘best imaginable health state’ (100) and
‘worst imaginable health state’ (0). (Appendix 4-4)
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2.5

Independent variables

All the demographic information was obtained during the interview. These included the year
of birth (age was calculated from the interview date), sex, ethnicity, first language, marital
status, education level, housing type, ownership status of current housing, and monthly
household income. We obtained the body mass index (BMI) within 12 months before the
interview as a continuous variable from the EMR. We measured the level of multimorbidity
in four ways – Chronic Disease Control Score (CDCS), Additional Disease Count - SelfReported (ADC-SR), Additional Disease Count - Electronic Medical Record (ADC-EMR) and
Chronic Medication Count (CMC). ‘Disease count’ and ‘Chronic Medication Count’ are
described in the systematic review of the literature found in Chapter Three of this thesis. We
refer to these four measures as the ‘instruments for measuring the level of multimorbidity’ from
hereon. All the instruments for measuring the level of multimorbidity were not pre-existing
clinical measurements and were created for this study by referring to the instruments listed in
the systematic review in Chapter three. Appendix 4-5 summarises a list of all the independent
and outcomes variables.

We grouped the independent variables into the following categories after exploring the data set
using SPSS. The age range was grouped into four categories ‡‡‡‡‡ – ‘< 55’, ‘55-64’, ‘65-74’,
and ‘≥ 75’ according to the Singapore population census classification43. We grouped ‘sex’
into two categories – ‘Male’ and ‘Female’, and ‘ethnicity’ into two categories – ‘Chinese’ and
‘Non-Chinese’. ‘First language’ was grouped into four categories – ‘English’, ‘Mandarin’,
‘Chinese dialects’, and ‘Others’. ‘Marital status’ was grouped into two categories – ‘Married’,
and ‘Single/Separated/Divorced/Widowed’.

‘Education level’ was grouped into four

categories – ‘No formal education’, ‘Primary’, ‘Secondary’ and ‘Post-Secondary’. ‘Housing
type’ was grouped into four categories – ‘HDB§§§§§ 1/2/3 room’, ‘HDB 4 room’, ‘HDB 5 room
& HUDC******’, and ‘Private Housing’. ‘Ownership status of current housing’ was grouped
into two categories – ‘Owner’ and ‘Non-owner’. Finally, we grouped ‘Monthly household

‡‡‡‡‡

Policymakers in Singapore prefer to have age as a categorical variable instead of a continuous variable
Housing Development Board (public housing in Singapore) – the type of HDB flat has been used as a proxy for
measuring socioeconomic status in Singapore. An HDB 1-room flat is typically about 23 square metres and a HDB 5-room
flat is typically about 110 square metres in area.
******
Housing and Urban Development Company (for Singaporeans who can afford something better than the typical public
housing but still find private housing unaffordable)
§§§§§
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income’ into five categories – ‘< SGD†††††† 2,000’, ‘SGD 2,000-3,999’, ‘SGD 4,000-5,999’,
‘SGD ≥ 6,000’, and ‘Income not disclosed’.

The level of multimorbidity was measured in four ways. The first was CDCS, a composite
score on whether all three conditions – hyperlipidaemia44,45, hypertension46,45, and diabetes47,45
were optimally controlled strictly according to each of their respective clinical practice
guidelines. The clinical parameters obtained were based on the last single clinical parameter
measured that was closest to the date of the interview. This was based on the latest single
clinical parameter of glycated haemoglobin (HbA1c) within six months prior to the interview,
low-density lipoprotein (LDL-c) within twelve months before or four weeks after the interview,
systolic blood pressure (SBP), and diastolic (DBP) recorded in the electronic medical record
(EMR) within six months before the interview. CDCS was grouped into four categories –
‘1’,’2’,’3’, and ‘4’ (Appendix 4-6). ‘1’ means that all of the three conditions (hyperlipidaemia,
hypertension and diabetes) were optimally controlled; ‘2’ means that one of the three
conditions was sub-optimally controlled and the other two were optimally controlled; ‘3’
means that two of the three conditions were sub-optimally controlled and the other one was
optimally controlled; and ‘4’ means that all three conditions were sub-optimally controlled.

The second measure for the level of multimorbidity, the Additional Disease Count - SelfReported (ADC-SR), was based on the total number of other chronic condition (i.e., excluding
hyperlipidaemia, hypertension, and diabetes) that was reported by the participant to the
interviewer.
The third measure for the level of multimorbidity, the Additional Disease count – Electronic
Medical Records (ADC-EMR), was based on the total number of other chronic condition (i.e.,
excluding hyperlipidaemia, hypertension, and diabetes) that was ever coded in the EMR of that
participant. The list of 15 chronic conditions was based on the Chronic Disease Management
Program‡‡‡‡‡‡ list of chronic conditions stipulated by the Ministry of Health, Singapore in
201445 (Appendix 4-7). This was one of the two lists of chronic conditions for measuring the
prevalence of multimorbidity in Chapter Two of this thesis.

We used O’Halloran and

colleagues’ definition of chronicity of a disease as lasting at least six months, having a
††††††

SGD – Singapore Dollar (1.00 Singapore dollare = 0.99 Canadian dollar)
The number of chronic conditions has increased over the years. There were 18 conditions in 2014 and 20 conditions in
2018. Chapter Two used 20 conditions.
‡‡‡‡‡‡
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documented pattern of recurrence or deterioration, and having an impact on an individual’s
quality of life48.

After exploring the data set using SPSS, we found that the frequency distributions for ADCSR and ADC-EMR were heavily right-skewed with clustering at 0 (Appendix 4-8). As such,
they were grouped into three categories – ‘0’,1’, and ‘2 or more’ additional chronic conditions.

The fourth measure for the level of multimorbidity, the Chronic Medication Count (CMC), was
based on the total number of chronic medications currently prescribed in the EMR. We
excluded medications prescribed for acute conditions and also excluded supplements except
for patients with known nutritional deficiency recorded in the clinical notes, e.g., iron
supplements for patients with anaemia. CMC was a count variable (Appendix 4-8).

2.6

Sample size calculation

A regression model was used to answer the primary research hypothesis on whether a higher
level of multimorbidity was associated with a higher degree of depression and anxiety
symptoms, and a lower quality of life. We also used the same regression model for determining
the association between the sociodemographic variables and the outcome variables. We used
the ‘rules of thumb’ for determining sample size for regression equations using six or more
predictors49. VanVoorhis and Morgan49 suggested that approximately 30 or more participants
per variable would be adequate to achieve 80% power, especially when the dependent variable
may be skewed or the effect size expected is small. We decided to use 50 participants per
variable to account for the above as the outcome variable (EQ-5D) is expected to be negatively
skewed with clustering at ‘1’ for utility index and ‘80-90’ for visual analogue scale50.
Therefore, a sample size of 700 was required for a regression with 14 independent variables.

For the prevalence of depression and anxiety, the sample size calculation was based on Jani et
al.’s22 report that the prevalence of having depressive and anxiety symptoms in a population
with multimorbidity was 24.3% by using the Hospital Anxiety and Depression Score. By using
a 5% significance level and 10% total width of confidence interval with an estimated proportion
of 25% (round up from 24.3% from Jani et al.’s study), a sample size of 288 was required to
estimate the prevalence in this study51.
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For the quality of life outcome, where we determined the mean score of the utility index and
visual analogue scale of EQ-5D, the sample size calculation was based on Abdin et al.’s52 report
that the mean EQ-5D index score for the Singapore population was 0.95 with a standard error
(SE) of 0.002 and a total sample size of 5,594. From the study, we calculated the standard
deviation (SD) using the formula SD=SE*√n (i.e., SD=0.002*√5594=0.150)51. Using a total
width (W) of the mean EQ-5D UI score as 0.020, the standardized width would be 0.133 (i.e.,
W/SD = 0.020/0.150=0.133). By using a confidence level of 95%, and a 0.150 standardised
width (round up from 0.133), a sample size of 683 was required51.

Finally, for determining the concordance between self-reported and medical records
conditions, the sample size calculation was based on Wu et al.’s30 report that the concordance
rate kappa statistic (κ) between self-reported medical conditions and those recorded in clinical
notes ranged between 0.4 to 0.6 (fair to moderate concordance). By using table 3 from Temel
and Erdogan’s paper53 on sample size determination in agreement studies, we required a sample
size of 847 when we chose a confidence level of 95%, a power of 80% with a disagreement
probability of 0.1 based on an expected κ of 0.4.

The largest sample size from all the above calculations was used to account for enough power
to answer all the research questions in the study. Taking into account 5% missing data whereby
listwise deletion could be safely practiced54, a sample size of 892 was considered desirable.
While it might be decided to conduct multiple imputation, assuming listwise deletion provides
a conservative estimate of sample size calculation. We rounded the number up to 900 and
assuming a 50% response rate from the respondents, we used a computerised randomisation
program and tagged 1800 potential participants in the electronic medical records.

2.7

Statistical Analysis

Descriptive analysis was used to describe the characteristics of the data set. We described the
mean and median for continuous variables with their respective standard deviation and
interquartile range.

For categorical variables, we described proportions.

Frequencies,

percentages, cross-tabulations, and graphical display were used to present results.
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Bivariate analyses were conducted to examine the associations between the outcomes and
different instruments for measuring the level of multimorbidity without controlling for each
other. Non-parametric tests were used for EQ-5D UI and EQ-5D VAS as they failed the
normality tests56 (Appendix 4-9). CMC was considered to have a normal distribution and
parametric test was used55 (Appendix 4-8).

We used the chi-square tests to examine the association between the level of multimorbidity
(CDCS) with depression (PHQ-9) and anxiety (GAD-7) (Table 4-7). The Kruskal Wallis tests
were used to examine the association between the level of multimorbidity (CDCS) with the
quality of life (EQ-5D UI and EQ-5D VAS) (Table 4-8). Chi-square tests were conducted to
examine the level of multimorbidity (ADC-SR and ADC-EMR) with depression (PHQ-9) and
anxiety (GAD-7) (Table 4-9). The Kruskal Wallis tests were used to examine the association
between the level of multimorbidity (ADC-SR and ADC-EMR) with the quality of life (EQ5D UI and EQ-5D VAS) (Table 4-10). Student t-tests were used to examine the association
between the level of multimorbidity (CMC) with depression (PHQ-9) and anxiety (GAD-7)
(Table 4-11). Spearman correlation was used to examine the relationship between the level of
multimorbidity (CMC) with the quality of life (EQ-5D UI and EQ-5D VAS) (Table 4-11). We
did not adjust for multiple paired comparisons using Bonferroni adjustment as the main
findings were explained by the multivariable regression analyses as described below.

Binary logistic regression was used to test the association between the two outcomes of
depression (PHQ-9) and anxiety (GAD-7) and the four instruments for measuring the level of
multimorbidity (Table 4-12). Linear regression with the log link function was used to test the
association between the two quality of life outcomes (EQ-5D UI and EQ-5D VAS) and four
instruments for measuring the level of multimorbidity after log transformation§§§§§§ of EQ-5D
UI and EQ-5D VAS (Table 4-13). We adjusted all regression analyses for age, sex, and the
other eight independent variables including ethnicity, first language, marital status, education
level, housing type, ownership status of current housing, monthly household income, and body
mass index. We measured multicollinearity for the independent variables by using the variance
inflation factor (VIF) which assessed how much the variance of an estimated regression
coefficient increased if the predictors were correlated with some of the other independent

§§§§§§

We log transformed the variables EQ-5D UI and EQ-5D VAS as both variables and their residuals failed the normality
tests (Appendix 4-9).
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variables57 (Appendix 4-10). We used the lower conventional VIF cut-off of greater than five
as suggestive for detecting multicollinearity57.

Concordance for the additional chronic conditions between self-reported and those recorded in
electronic medical records was evaluated using Cohen’s kappa statistics (κ) (Table 4-14). This
was a methodological section embedded within the cross-sectional study. Cohen’s kappa is a
measure that adjusts for the agreement that is expected by chance58. However, on its own, a
kappa value is not very informative and it is strongly recommended that the positive and
negative agreements be presented together58. Therefore, we also reported the bias index (BI),
prevalence index (PI), and the prevalence-adjusted bias-adjusted kappa (PABAK) as the
magnitude of κ is highly influenced by the prevalence of the condition as well as the bias
between the two data sources59.

Statistical significance was defined as p < 0.05 and confidence intervals were set at 95% for
both bivariate and multivariable analysis. The interpretation for kappa (κ) was based on Landis
and Koch’s classification60.

We carried out a sensitivity analysis on the multivariable regression analyses to assess the
robustness of the results to probable departures from the missing data assumption made in the
main analysis. IBM SPSS version 24 was used for all statistical analysis.

2.8

Handling of missing data

We employed several approaches to look at the extent of missing data, the missing data
mechanism and patterns of missing data61. First, we used SPSS to find the variables with
missing data and also the total number of cases with missing data. We next conducted the
Little’s test62 to check for the missing data mechanism to determine whether they were missing
completely at random (MCAR). If the missing data were not MCAR, we explored the
missingness to make a judgement call on whether they were missing at random (MAR) or
missing not at random (MNAR). Finally, we looked at the patterns of missingness to see
whether they were monotone (i.e., if a participant drops out at one point, his/her data are
missing on subsequent measures) or arbitrary (i.e., random fashion) in nature63. Depending on
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the above findings, our team would consider using the conventional approach like listwise or
pairwise deletion, or the principled method to deal with missing data like multiple imputation64.

If multiple imputation was used, the number of imputations used would be higher than the
percentage of the missing data in the analysis65 (i.e., if 7.9% of data was missing, the number
of imputations used should be eight).

2.9

Subgroup Analysis

We used chi-square tests for comparing proportions to examine the difference between the
demographic characteristics of participants who did not disclose their household income with
those who declared.
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3 Results
Figure 4-1. Flow chart of participant recruitment

Total number of patients with at least
three of the specified chronic
conditions
(n=11,389)

Total number of patients who fulfilled
the age criteria
(n=9,954)

Total number of patients randomly
selected
(n=1,800)

Total number of patients approached for
participation
(n=1,650)
Not meeting inclusion criteria
(n=284)
Total number of patients eligible for
participation
(n=1,366)

Declined to participate (n=238)

Other reasons (n=195)

Withdrew (n=1)

Total number of participants
(n=932)
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3.1

Patient participation

We approached 1,650 potential participants and invited them to participate in this study. There
were 284 of these potential participants who were deemed not meeting inclusion criteria
leaving 1,366 eligible patients. The main reason was due to the language barrier. Of these
1,366 eligible potential participants, there were 238 patients who refused to participate, 195
patients who were not able to participate due to various reasons (mainly due to inability to get
a scheduled appointment for interview), and one patient who withdrew the next day after
completing the interview. The final number of participants recruited was 932 out of 1,366
giving a response rate of 68.2%.

Four hundred and thirty-four potential participants did not join the study due to various reasons.
We collected the de-identified information of the sex and ethnicity characteristics of all
potential participants who declined to take part in the study to detect whether there were
differences in characteristics between them and those who participated in the study.

Table 4-1. Demographic Characteristics of patients who Declined participation and patients
who were Recruited for the Study
Declined (n=434)

Recruited (n=932)

p-value^

Sex
Male

209 (48.2%)

513 (55.0%)

0.02*

Female

225 (51.8%)

419 (45.0%)

Ethnicity
Chinese

347 (80.0%)

769 (82.5%)

Malay

33 (7.6%)

70 (7.5%)

Indian

46 (10.6%)

77 (8.3%)

Others

8 (1.8%)

16 (1.7%)

0.56

We performed a chi-square test to explore whether there were differences between sex and
ethnicity of those who participated and those who did not (Table 4-1). The difference between
the sex composition was statistically significant (p = 0.02). There were significantly more men
than women in the study as more women than men declined to participate.
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3.2

Missing Values

There were six variables with missing data (Figure 4-2), namely monthly household income,
BMI, ADC-SR, CDCS due to various missing data of glycated haemoglobin (HbA1c), lowdensity lipoprotein (LDL-C), and/or blood pressure (BP), housing type, and house ownership
(Table 4-2). In total, there were 306 participants or 32.8% of the data with missing data from
the 932 participants (Figure 4-3).
We conducted the Little’s test to check for the null hypothesis that all the missing values were
missing completely at random (MCAR) using SPSS62. The null hypothesis was rejected*******,
and therefore the missing data were not MCAR. As more than 25% of participants did not
declare their household income, we assumed that missing data of household income might not
be missing at random (MAR). We aggregated all those with missing data for the declaration
of household income into one new category - ‘Income not disclosed’, and treated that as a valid
response category in the analysis.

Figure 4-2. Missing data by variables

*******

Figure 4-3. Missing data by cases

The Little's MCAR test showed a Chi-Square value of 117.630 (14), p < 0.001
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Table 4-2. Predictor Variables with Missing Data
Missing Values
Predictor Variables

N

%

Valid N

Monthly Household Income

238

25.5

694

BMI

38

4.1

894

ADC-SR

29

3.1

903

CDCS

19

2.0

913

Housing Type

2

0.2

930

House Ownership

1

0.1

931

After excluding this variable, we repeated the Little’s test, and the null hypothesis ††††††† was
again rejected despite having 9.12% (n=85) of all cases having a missing value (Figures 4-4 &
4-5). We explored the missingness of the data and concluded that these missing data were
likely to be missing at random (MAR). For example, the missing values for BMI were likely
due to sporadic weighing machine downtime that failed to port over the values to the EMR.
Consequently, the team concluded that listwise deletion (LD) would introduce bias and
multiple imputation (MI) using SPSS would be used for determining the relationship between
the level of multimorbidity and depression, anxiety and quality of life. MI was also used to
determine the factors associated with the three outcomes. We used MI as it is a powerful
statistical tool for handling missing data and have an advantage of including auxiliary
information about the missing data into the final analysis66. With 9.12% missing data, we
performed multiple imputation using ten imputations for all our analyses65. For preserving the
maximum amount of data collected from all the participants, we described the data in Tables
4-4 and 4-5 using pairwise deletion. We also used pairwise deletion for determining the
concordance rate between additional chronic conditions self-reported (ADC-SR) and electronic
medical records (ADC-EMR) (Table 4-14).

†††††††

The Little's MCAR test showed a Chi-Square value of 122.372 (14), p < 0.001
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Figure 4-4. Missing data by variables
(excluding Monthly household income)

Figure 4-5. Missing data by cases
(excluding Monthly household income)

Table 4-3. Predictor Variables (exclusion of Monthly Household Income) with Missing Data
Missing Values
Predictor Variables

N

%

Valid N

BMI

38

4.1

894

ADC-SR

29

3.1

903

CDCS

19

2.0

913

Housing Type

2

0.2

930

House Ownership

1

0.1

931

3.3

Descriptive Data

Table 4-4 summarises the sociodemographic characteristics of 932 recruited participants. The
median age of the participants was 65.0 years (IQR 58.0 – 71.0). There were more male
participants than female participants (55%:45%), and the majority of the participants were of
Chinese ethnicity (82.5%). More than 37% of participants used Mandarin, ¼ of them used
English with close to another ¼ of them using Chinese dialects as their first language. Close
to 80% of the participants were married. Approximately half of them had primary education
and below; the other half had secondary education and above. A large majority of them stayed
in subsidised housing, and more than 80% of them owned their own homes. The largest group
of participants had a household income of less than SGD 2,000. Slightly more than ¼ of the
participants did not disclose their monthly household income.
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Table 4-5 summarises the clinical parameters and characteristics of the study population. The
median body mass index (BMI) was 26.0 kg/m2 (IQR 23.7 – 28.8). Based on the Asian cutoff of BMI at 23 kg/m2, 80.3% of the participants were overweight. The median HbA1c was
7.1% (IQR 6.5 – 7.8) with 57.1% of the participants having sub-optimal diabetes control
according to the cut-off of 7.0%. The median LDL-C level was 2.20 mmol/L (IQR 1.78 – 2.48)
indicating that a large majority of the participants (80.2%) were optimally controlled with a
cut-off of 2.6 mmol/L. Blood pressure using a cut-off of 140/80 mmHg showed that 66.1% of
the participants were optimally controlled. Using the Chronic Disease Control Score (CDCS)
to classify participants into the various levels of multimorbidity based on the four individual
biomedical parameters, 235 or 25.7% of the participants had all three conditions optimally
controlled (CDCS ‘1’). The majority (433 or 47.4%) had at least one out of the three chronic
conditions that was controlled sub-optimally (CDCS ‘2’).
The mean number of ADC-SR by the participants was 0.7 (SD‡‡‡‡‡‡‡ 0.8), and the mean number
identified for ADC-EMR was 1.2 (SD 1.0). The mean number of chronic medication count
(CMC) retrieved from the electronic medical records was 4.5 (SD 2.1).

Table 4-6 summarises the proportion of participants that belonged to each category for the
outcome variables. The prevalence of participants reporting depressive symptoms was 12.0%.
The prevalence of participants reporting anxiety symptoms was 11.8%. The mean EQ-5D UI
score for the participants was 0.890 (SD§§§§§§§ 0.190). The median VAS score was 75.0 (IQR
65.0 - 80.0).

‡‡‡‡‡‡‡

SD – standard deviation. The mean instead of the median was presented for easier comparison between ADC-SR and
ADC-EMR because median was 1.0 for both the variables due to the skewed frequency distribution .
§§§§§§§
SD – standard deviation. The mean and standard deviation was given for EQ-5D UI as the median was 1.000 due to
the ceiling effect of the scale.
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Table 4-4. Sociodemographic Characteristics of Recruited Participants
Parameters and Characteristics
Age
n
Mean ± SD
Median (IQR)
<55 years old
55-64 years old
65-74 years old
≥75 years old
Sex
n
Male
Female
Ethnicity
n
Chinese
Non-Chinese
Malay
Indian
Others
First Language
n
English
Mandarin
Chinese Dialects
Others
Marital Status
n
Married
Single/Separated/Divorced/Widowed
Education Level
n
No Formal Education
Primary
Secondary
Post-Secondary
Housing Type
n
HDB 1/2/3 Room
HDB 4 Room
HDB 5 Room/Executive/HUDC
Private Housing
Ownership Status of Current Housing
n
Owner
Non-Owner
Monthly Household Income
n
<SGD2,000
SGD2,000 – SGD3,999
SGD4,000 – SGD5,999
≥SGD6,000
Income Not Disclosed

Descriptive Statistics

%

932
64.5 ± 8.5
65.0 (58.0 – 71.0)
115
330
360
127

12.3
35.4
38.6
13.6

932
513
419

100.0
55.0
45.0

932
769
163
70
77
16

100.0
82.5
17.5
7.5
8.3
1.7

932
233
348
227
124

100.0
25.0
37.3
24.4
13.3

932
739
193

100.0
79.3
20.7

932
172
294
315
151

100.0
18.5
31.5
33.8
16.2

930
194
390
233
113

100.0
20.9
41.9
25.1
12.1

931
766
165

100.0
82.3
17.7

932
340
160
99
95
238

100.0
36.5
17.2
10.6
10.2
25.5
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Table 4-5. Clinical Parameters and Characteristics of Recruited Participants
Parameters and Characteristics
Body Mass Index (BMI) (kg/m2)
n
Mean ± SD
Median (IQR)
Normal (<23.0 kg/m2)
Overweight (≥23.0 kg/m2)
Glycated Haemoglobin (HbA1c) (%)
n
Mean ± SD
Median (IQR)
Optimal Control (<7.0%)
Sup-Optimal Control (≥7.0%)
Low Density Lipoprotein Cholesterol (LDLc) (mmol/L)
n
Mean ± SD
Median (IQR)
Optimal Control (<2.6mmol/L)
Sup-Optimal Control (≥2.6mmol/L)
Systolic Blood Pressure (SBP) (mmHg)
n
Mean ± SD
Median (IQR)
Optimal Control (<140mmHg)
Sup-Optimal Control (≥140mmHg)
Diastolic Blood Pressure (DBP) (mmHg)
n
Mean ± SD
Median (IQR)
Optimal Control (<80mmHg)
Sup-Optimal Control (≥80mmHg)
Blood Pressure (BP) (mmHg)
n
Optimal Control
Sup-Optimal Control
Chronic Disease Control Score (CDCS)
n
Median (IQR)
1 (All 3 conditions optimally controlled)
2 (1 condition sub-optimally controlled)
3 (2 conditions sub-optimally controlled)
4 (3 conditions sub-optimally controlled)
Additional Disease Count – Self Reported (ADC-SR)
n
Mean ± SD
Median (IQR)
0
1
2+
Additional Disease Count – Electronic Medical
Records (ADC-EMR)
n
Mean ± SD
Median (IQR)
0
1
2+
Chronic Medication Count (CMC)
n
Mean ± SD
Median (IQR)

Descriptive Statistics

%

894
26.5 ± 4.2
26.0 (23.7, 28.8)
176
718

19.7
80.3

930
7.3 ± 1.3
7.1 (6.5, 7.8)
399
531

100.0

915
2.20 ± 0.64
2.20 (1.78, 2.48)
734
181

100.0

931
130 ± 14
130 (120, 138)
726
205

100.0

931
72 ± 9
70 (66, 78)
722
209

100.0

931
615
316

100.0
66.1
33.9

913
2 (1, 3)
235
433
197
48

100.0

932
0.7 ± 0.8
1.0 (0.0, 1.0)
467
356
109

100.0

932
1.2 ± 1.0
1.0 (1.0, 2.0)
230
385
317

100.0

932
4.5 ± 2.1
4.0 (3.0, 6.0)

100.0

42.9
57.1

80.2
19.8

78.0
22.0

77.6
22.4

25.7
47.4
21.6
5.3

50.1
38.2
11.7

24.7
41.3
34.0
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Table 4-6. Outcome Variables Obtained from PHQ-9, GAD-7, EQ-5D Questionnaires of
Recruited Participants
Outcome Variables
PHQ-9
Mean ± SD
Median (IQR)
Minimal (0-4)
Mild to Severe (5-27)
GAD-7
Mean ± SD
Median (IQR)
Minimal (0-4)
Mild to Severe (5-21)
EQ-5D Utility Index (UI)
Mean ± SD
Median (IQR)
EQ-5D Visual Analogue Scale
(VAS)
Mean ± SD
Median (IQR)

3.4

Frequency (n=932)

%

1.6 ± 2.7
1.0 (0.0, 2.0)
820
112

88.0
12.0

1.5 ± 3.0
0.0 (0.0, 2.0)
822
110

88.2
11.8

0.890 ± 0.190
1.000 (0.850, 1.000)

73.6 ± 15.5
75.0 (65.0, 80.0)

Bivariate Analyses

There were no associations found between Chronic disease count score (CDCS) and depressive
symptoms (PHQ-9), and CDCS and anxiety symptoms (GAD-7) (Table 4-7). There were also
no associations found between CDCS and quality of life for both utility index (EQ-5D UI) and
visual analogue scale (EQ-5D VAS) (Table 4-8).

A higher number of self-reported additional disease count (ADC-SR) was associated with
higher depressive symptoms (PHQ-9) (Table 4-9), and with a lower quality of life score for
EQ-5D UI (Table 4-10). ADC-SR was not associated with anxiety symptoms (GAD-7) (Table
4-9) nor EQ-5D VAS (Table 4-10). A higher number of additional disease count from the
electronic medical records (ADC-EMR) was associated with a lower quality of life (EQ-5D
UI) (Table 4-10). There were no associations found between ADC-EMR and depressive
symptoms (PHQ-9), anxiety symptoms (GAD-7) and EQ-5D VAS (Table 4-9 & 4-10).

Chronic medication count (CMC) was not associated with depressive nor anxiety symptoms
(Table 4-11). Although a weak negative correlation was noted between CMC and quality of
life (both EQ-5D UI and EQ-5D VAS), statistical significance was not reached (Table 4-11).

196
Table 4-7. Effect of Chronic Disease Count Score on Depression and Anxiety (n=932)
Outcome
PHQ-9
Minimal
Mild to Severe
% of mild to severe depression
GAD-7
Minimal
Mild to Severe
% of mild to severe anxiety

Chronic Disease Count Score (CDCS)
1
2
3
4
n
n
n
n
209
384
181
46
30
57
21
4
12.6%
12.9%
10.4%
8.0%
212
27
11.3%

390
51
11.6%

175
28
13.8%

p-value*

0.58

45
4
8.2%

0.74

ˢp-value was obtained from chi-square test comparing between CDCS and PHQ-9 or GAD-7. *p<0.05 is considered
statistically significant

Table 4-8. Effect of Chronic Disease Count Score on Quality of Life (n=932)
Outcome
EQ5D-UI
n
Mean Rank
EQ5D-VAS
n
Mean Rank

1

Chronic Disease Count Score (CDCS)
2
3

4

p-value*
0.09

239
452.23

441
479.91

202
442.41

50
514.49

239
448.17

441
474.79

202
465.90

50
483.74

0.61

ˣp-value was obtained from Kruskall-Wallis test comparing between CDCS and ED5D-UI or EQ5D-VAS. *p<0.05 is
considered statistically significant.

Table 4-9. Effect of Additional Disease Count on Depression and Anxiety (n=932)

Outcome
PHQ-9
Minimal

0
n
425

ADC-SR
1
≥2
n
n
312

Level of Multimorbidity Measures
ADC-EMR
0
1
≥2
p-value
n
n
n

84

209

340

271

<0.01*
Mild to Severe
% of mild to
severe depression

42

44

25

21

45

46

9.0%

12.4%

22.9%

9.1%

11.7%

14.5%

415

318

89

194

348

280

36

37

37

15.7%

9.6%

11.7%

p-value

0.16

GAD-7
Minimal
Mild to Severe

52

38

20

% of mild to
severe anxiety

11.1%

10.7%

18.4%

0.07

0.08

ˇp-value was obtained from chi-square test between ADC-SR or ADC-EMR and PHQ-9 or GAD-7, ˆp-value was obtained
from t-test comparing between CMC and PHQ-9 or GAD-7; **p<0.05 is considered statistically significant.
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Table 4-10. Effect of Additional Disease Count on Depression, Anxiety and Quality of Life
(n=932)

EQ5D-UI
n
Mean Rank

0
467
518.91

Level of Multimorbidity Measures
ADC-SR
ADC-EMR
1
≥2
p-value#
0
1
≥2
356
109
230
385
317
<0.01*
434.50
346.58
499.43
485.05
420.08

EQ5D-VAS
n
Mean Rank

467
474.54

356
465.53

Outcome

109
435.18

0.37

230
472.20

385
476.81

p-value#
<0.01*

317
449.85

0.384

# p-value was obtained from Kruskall-Wallis test comparing between ADC-SR or ADC-EMR and EQ5D-UI or EQ5D-VAS,
*p<0.05 is considered statistically significant.

Table 4-11. Effect of Chronic Medication Count on Quality of Life (n=932)
Outcome

n

Chronic Medication Count
Correlation coefficient
Mean
(Rho)

p-value*

PHQ-9
Minimal
Mild to Severe

820
112

4.51
4.69

NA

0.40

GAD-7
Minimal
Mild to Severe

822
110

4.51
4.68

NA

0.37

EQ5D-UI
EQ5D-VAS

NA
NA

NA
NA

-0.054
-0.060

0.10
0.07

*p-value was obtained from t-test comparing between CMC and PHQ-9 or GAD-7, and p-value was obtained from
Spearman’s Correlation test comparing between CMC and EQ5D-UI or EQ5D-VAS. *p<0.05 is considered statistically
significant.

3.5

Multivariable Regression Analysis

We measured multicollinearity for the independent variables by using the variance inflation
factor (VIF) which assessed how much the variance of an estimated regression coefficient
increased if the predictors were correlated with some of the other independent variables57. The
VIFs obtained were around 1.000, and therefore, we retained all the independent variables in
the regression analysis (Appendix 4-10).

3.5.1

Depression and Anxiety

Logistic regression was performed to assess the impact of several factors on the likelihood that
participants would report that they had a problem with depressive symptoms (Table 4-12).
Only two of the independent variables made a unique statistically significant contribution to
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the model: marital status; and ADC-SR.

This indicated that participants who were

single/separated/divorced/widowed had 1.69 times greater odds of reporting a higher score for
depressive symptoms using the PHQ-9 scale compared to those who were married (p=0.048).
Participants who self-reported two or more additional chronic conditions had 3.09 times greater
odds of reporting a higher score for depressive symptoms than those who did not report any
additional chronic conditions (p < 0.01).

Another logistic regression was conducted to assess the impact of the 14 predictor variables on
the likelihood that participants would report that they had a problem with anxiety symptoms
(Table 4-12).

Two of the independent variables made a unique statistically significant

contribution to the model – ADC-SR and ADC-EMR. Participants who self-reported two or
more additional chronic conditions had 2.07 times greater odds of reporting a higher score for
anxiety symptoms than those who did not report any additional chronic conditions (p=0.02).
However, participants who had one additional chronic condition recorded in their electronic
medical records had lower odds of reporting a lower score for anxiety symptoms using the
GAD-7 scale than those who had no additional chronic conditions recorded in their notes
(OR=0.53, p=0.02).
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Table 4-12. The Effect of Sociodemographic and Clinical Predictor Variables on Depression
and Anxiety of Recruited Participants (n=932)
PHQ9
Predictor Variables

Odds
Ratio^

95% CI^

GAD7
p-value^

Odds
Ratio^

95% CI^

p-value^

0.49, 1.79
0.35, 1.43
0.37, 2.23

0.84
0.34
0.84

Age
<55 years old
55-64 years old
65-74 years old
≥75 years old
Sex
Male
Female
Ethnicity
Chinese
Non-Chinese
First Language
English
Mandarin
Chinese Dialects
Others
Marital Status
Married
Single/Separated/Divorced/Widowed
Education Level
No Formal Education
Primary
Secondary
Post-Secondary
Housing Type
HDB 1/2/3 Room
HDB 4 Room
HDB 5 Room/HUDC
Private Housing
Ownership Status of Current
Housing
Owner
Non-Owner
Monthly Household Income

REF
1.62
1.14
1.61

0.73, 3.60
0.50, 2.61
0.61, 4.21

0.24
0.75
0.33

REF
0.93
0.71
0.91

REF
0.90

0.57, 1.40

0.63

REF
1.18

0.75, 1.85

0.47

0.87

REF
0.63

0.23, 1.72

0.37

0.40, 1.36
0.27, 1.16
0.66, 5.44

0.33
0.12
0.24

<SGD2,000
SGD2,000 – SGD3,999
SGD4,000 – SGD5,999
≥SGD6,000
Income not disclosed

REF
0.92

0.33, 2.57

REF
0.84
0.87
1.41

0.45, 1.58
0.43, 1.77
0.48, 4.18

0.59
0.70
0.53

REF
0.74
0.56
1.89

REF
1.69

1.01, 2.85

0.048*

REF
1.66

0.98, 2.82

0.06

0.58, 2.03
0.26, 1.09
0.31, 1.74

0.80
0.08
0.48

REF
1.12
0.72
0.49

0.62, 2.04
0.36, 1.42
0.19, 1.23

0.71
0.34
0.13

REF
1.09
0.53
0.73

REF
0.68
0.70
0.84

0.40, 1.14
0.37, 1.33
0.37, 1.94

0.14
0.28
0.69

REF
0.79
1.39
0.86

0.45, 1.40
0.74, 2.58
0.35, 2.09

0.42
0.30
0.73

REF
1.11

0.64, 1.93

0.71

REF
0.86

0.47, 1.56

0.61

REF
1.07
1.17
1.45
0.63

0.59, 1.95
0.52, 2.60
0.66, 3.17
0.35, 1.12

0.83
0.71
0.35
0.11

REF
1.58
0.97
1.23
0.82

0.88, 2.82
0.44, 2.13
0.56, 2.72
0.45, 1.48

0.12
0.93
0.61
0.51

^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered
statistically significant.
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Table 4-12. The Effect of Sociodemographic and Clinical Predictor Variables on Depression
and Anxiety of Recruited Participants (n=932) (continued)
PHQ9
Predictor Variables
Body Mass Index (BMI)
Chronic Disease Control
Score (CDCS)
1 (All 3 conditions optimally
controlled)
2 (1 condition sub-optimally
controlled)
3 (2 conditions sub-optimally
controlled)
4 (3 conditions sub-optimally
controlled)
Additional Disease Count –
Self Reported (ADC-SR)
0

GAD7

Odds Ratio^

95% CI^

p-value^

0.97

0.92, 1.02

0.26

REF

Odds
Ratio^
1.01

95% CI^

p-value^

0.96, 1.06

0.78

REF

1.15

0.69, 1.91

0.59

1.06

0.62, 1.80

0.83

0.83

0.43, 1.58

0.57

1.06

0.57, 1.97

0.86

0.51

0.15, 1.68

0.27

0.63

0.20, 1.99

0.43

REF

REF

1

1.36

0.84, 2.20

0.21

1.05

0.65, 1.69

0.85

2+

3.09

1.71, 5.58

<0.01*

2.07

1.12, 3.84

0.02*

Additional Disease Count –
Electronic Medical Records
(ADC-EMR)
0

REF

1

1.11

0.62, 1.99

0.72

0.53

0.31, 0.90

0.02*

2+

1.16

0.62, 2.14

0.65

0.61

0.34, 1.07

0.09

REF

Chronic Medication Count
1.04
0.94, 1.16
0.43
1.06
0.95, 1.18
0.33
(CMC)
^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered
statistically significant.

3.5.2

Quality of Life (EQ-5D UI and EQ-5D VAS)

We conducted a linear regression with log link function to explore the impact of using the same
predictor variables with the quality of life (EQ-5D UI) as the dependent variable (Table 4-13).

There were four independent predictors with a statistically significant lower quality of life
score. Participants who were 75 years old and above were more likely to report a lower UI
score compared to those younger than 55 years old (p=0.03). Those who received primary
educational level were more likely to report a lower UI score compared to those who had no
formal education (p=0.01). A higher body mass index was associated with a lower UI score
(p=0.01). Finally, participants who reported one or more additional chronic conditions were
more likely to report a lower UI score when compared with those who did not self-report any
additional chronic conditions (one condition, p < 0.01; and two or more conditions, p < 0.01).
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There were two independent predictors that were associated with a statistically significant
higher quality of life score. Participants who stayed in private housing were more likely to
report a higher UI score as compared to those who stayed in the smallest public housing
(p=0.03). Participants who had all three chronic conditions (hyperlipidaemia, hypertension,
and diabetes) sub-optimally controlled also reported a higher UI score when compared to those
participants who had all three chronic conditions optimally controlled (p=0.03).

We conducted a second linear regression with log link function to explore the impact of using
the same predictor variables with the quality of life (EQ-5D VAS) as the dependent variable
(Table 4-13). There were three independent predictors with a statistically significant lower
quality of life.

Participants who had higher education were more likely to report a lower VAS score compared
to those who had no formal education (p < 0.01 for all three categories). The trend seemed to
suggest that the higher the education, the lower the VAS score. Participants who did not
disclose their income also reported lower VAS score when compared to those who earned less
than SGD 2,000 (p < 0.01). A higher chronic medication count was associated with a lower
VAS score (p=0.02).
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Table 4-13. The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=932)
EQ5D-UI
Predictor Variables

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

Beta
Coefficient^

<55 years old

0.910 (0.177)

0.883 (0.021)

REF

55-64 years old

0.899 (0.169)

0.881 (0.016)

65-74 years old

0.895 (0.194)

≥75 years old
Sex

EQ5D-VAS
95% CI^

p-value^

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

-0.002

-0.045, 0.042

0.94

0.877 (0.015)

-0.007

-0.053, 0.039

0.837 (0.241)

0.825 (0.020)

-0.068

-0.128, -0.008

Male

0.904 (0.192)

0.877 (0.015)

REF

Female
Ethnicity

0.873 (0.190)

0.856 (0.014)

-0.025

Chinese

0.893 (0.194)

0.861 (0.015)

REF

Non-Chinese
First Language

0.877 (0.180)

0.871 (0.022)

0.012

English

0.922 (0.140)

0.877 (0.018)

REF

Mandarin

0.892 (0.206)

0.875 (0.019)

Chinese Dialects

0.872 (0.212)

Others
Marital Status

Beta
Coefficient^

95% CI^

p-value^

72.3 (17.1)

74.2 (1.7)

REF

72.6 (14.8)

74.2 (1.3)

-0.001

0.77

74.1 (15.6)

-0.045, 0.044

0.98

75.2 (1.3)

0.014

-0.033, 0.061

0.57

0.03*

75.9 (15.0)

76.6 (1.8)

0.032

-0.027, 0.090

0.29

72.3 (14.7)

74.4 (1.2)

REF

75.1 (16.3)

75.7 (1.2)

0.018

-0.010, 0.046

0.22

73.2 (15.2)

73.1 (1.2)

REF

75.4 (16.7)

77.1 (2.0)

0.054

-0.008, 0.116

0.09

Age

-0.053, 0.004

0.09

-0.050, 0.073

0.71

71.3 (15.0)

74.7 (1.5)

REF

-0.003

-0.040, 0.035

0.89

73.8 (14.6)

76.4 (1.7)

0.022

-0.017, 0.061

0.27

0.867 (0.021)

-0.011

-0.056, 0.033

0.61

74.5 (15.8)

74.8 91.8)

0.000

-0.045, 0.045

0.99

0.862 (0.191)

0.846 (0.023)

-0.036

-0.103, 0.031

0.29

75.7 (17.4)

74.4 (2.0)

-0.005

-0.071, 0.061

0.89

Married
Single/Separated/Divorced/Widowed
Education Level

0.899 (0.187)
0.857 (0.206)

0.853 (0.017)
0.880 (0.014)

REF
-0.031

-0.067, 0.005

0.10

73.4 (15.2)
74.5 (16.2)

75.3 (1.2)
74.8 (1.4)

REF
-0.008

-0.043, 0.027

0.67

No Formal Education

0.883 (0.172)

0.886 (0.020)

REF

79.8 (17.2)

81.9 (1.7)

REF

Primary

0.855 (0.243)

0.839 (0.016)

-0.055

-0.096, -0.014

0.01*

73.0 (16.1)

74.7 (1.4)

-0.092

-0.130, -0.053

<0.01*

Secondary

0.912 (0.155)

0.871 (0.016)

-0.017

-0.061, 0.027

0.44

72.3 (13.6)

73.4 (1.3)

-0.11

-0.153, -0.068

<0.01*

Post-Secondary

0.922 (0.156)

0.869 (0.019)

-0.019

-0.073, 0.035

0.49

70.3 (13.7)

70.7 (1.6)

-0.147

-0.202, -0.093

<0.01*

HDB 1/2/3 Room

0.864 (0.230)

0.844 (0.017)

REF

73.7 (15.8)

73.7 (1.5)

REF

HDB 4 Room

0.886 (0.183)

0.860 (0.015)

0.019

-0.018, 0.055

0.31

74.1 (14.8)

75.1 (1.3)

0.019

-0.017, 0.054

0.30

HDB 5 Room/HUDC

0.899 (0.193)

0.866 (0.016)

0.026

-0.016, 0.068

0.23

73.4 (16.7)

75.9 (1.4)

0.029

-0.012, 0.070

0.17

Private Housing

0.935 (0.132)

0.895 (0.021)

0.059

0.007, 0.111

0.03*

72.4 (14.6)

75.6 (1.9)

0.026

-0.027, 0.079

0.34

Housing Type

^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 are considered statistically significant
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Table 4-13. The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=932) (continued)
EQ5D-UI
Predictor Variables

EQ5D-VAS

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

Beta
Coefficient^

95% CI^

Owner

0.899 (0.176)

0.866 (0.014)

REF

Non-Owner

0.849 (0.250)

0.866 (0.018)

0.000

<SGD2,000

0.887 (0.198)

0.877 (0.015)

REF

SGD2,000 – SGD3,999

0.903 (0.140)

0.872 (0.019)

-0.005

-0.045, 0.034

SGD4,000 – SGD5,999

0.930 (0.140)

0.876 (0.021)

0.000

≥SGD6,000

0.918 (0.158)

0.859 (0.022)

-0.020

Income not disclosed

0.859 (0.235)

0.847 (0.016)

-0.035

NA

NA

-0.006

1 (All 3 conditions optimally controlled)

0.874 (0.230)

0.846 (0.016)

REF

2 (1 condition sub-optimally controlled)

0.901 (0.181)

0.864 (0.014)

0.022

-0.012, 0.055

3 (2 conditions sub-optimally controlled)

0.878 (0.178)

0.851 (0.017)

0.006

-0.035, 0.047

4 (3 conditions sub-optimally controlled)

0.940 (0.099)

0.905 (0.027)

0.068

Additional Disease Count – Self
Reported (ADC-SR)
0

0.929 (0.145)

0.920 (0.015)

REF

1

0.865 (0.214)

0.871 (0.015)

2+

0.802 (0.251)

Additional Disease Count – Electronic
Medical Records (ADC-EMR)
0

p-value^

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

Beta
Coefficient^

95% CI^

p-value^

73.3 (15.0)

74.6 (1.1)

REF

74.7 (17.4)

75.6 (1.5)

0.013

-0.024, 0.051

0.49

75.8 (15.3)

76.6 (1.3)

REF

0.80

72.1 (15.0)

73.8 (1.6)

-0.036

-0.076, 0.004

0.08

-0.048, 0.047

0.99

74.1 (13.7)

-0.070, 0.030

0.43

72.7 (15.0)

76.9 (1.9)

0.005

-0.044, 0.053

0.86

76.3 (2.0)

-0.003

-0.054, 0.048

0.91

-0.071, 0.001

0.06

-0.010, -0.002

0.01*

71.6 (16.5)

71.8 (1.4)

-0.065

-0.100, -0.030

<0.01*

NA

NA

-0.002

-0.006, 0.001

0.24

72.5 (15.6)

73.2 (1.3)

REF

0.20

73.9 (15.5)

75.4 (1.2)

0.031

-0.003, 0.064

0.07

0.77

73.9 (15.3)

75.8 (1.4)

0.035

-0.005, 0.075

0.08

0.006, 0.130

0.03*

74.9 (16.4)

75.9 (2.3)

0.037

-0.027, 0.101

0.26

73.6 (15.5)

75.8 (1.2)

REF

-0.056

-0.085, -0.026

<0.01*

73.2 (15.4)

75.3 (1.3)

-0.006

-0.036, 0.024

0.72

0.811 (0.020)

-0.127

-0.174, -0.080

<0.01*

71.8 (15.1)

74.1 (1.7)

-0.023

-0.068, 0.023

0.33

0.925 (0.120)

0.878 (0.017)

REF

73.8 (15.5)

75.5 (1.5)

REF

1

0.902 (0.182)

0.874 (0.015)

-0.004

-0.038, 0.029

0.79

74.2 (15.4)

75.6 (1.3)

0.001

-0.032, 0.035

0.93

2+

0.851 (0.235)

0.847 (0.015)

-0.036

-0.074, 0.002

0.07

72.7 (15.5)

74.0 (1.3)

-0.020

-0.058, 0.017

0.29

NA

NA

-0.005

-0.012, 0.001

0.13

NA

NA

-0.008

-0.015, -0.001

0.02*

Ownership Status of Current Housing

-0.039, 0.039

0.99

Monthly Household Income

Body Mass Index (BMI)
Chronic Disease Control Score (CDCS)

Chronic Medication Count (CMC)

^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered statistically significant
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3.6 Concordance of self-reported additional chronic conditions and
those recorded in Electronic Medical Records (EMR)
We explored the agreement between self-reported additional chronic conditions and those
recorded in the electronic medical records by using kappa statistics in SPSS (Table 4-14). We
excluded 29 cases with missing data in this analysis.
We considered κ values of < 0.20 as slight, 0.21 - 0.40 as fair, 0.41 - 0.60 as moderate, 0.61 –
0.80 as substantial, and 0.81 – 1.00 as almost perfect according to the Landis and Koch’s
classification60. Out of fifteen conditions, ten of them showed a statistically significant
difference in the concordance rate between self-reported conditions and those reported in the
EMR. Stroke was the only condition that had substantial agreement with a concordance rate
(κ) of 0.61. Parkinson’s disease, Schizophrenia, and Asthma had a moderate agreement with
a concordance rate (κ) of 0.44, 0.43, and 0.42 respectively. Dementia and Major Depression
had a fair agreement with a concordance rate (κ) of 0.31 and 0.27 respectively. Osteoporosis,
Anxiety, Osteoarthritis, and Chronic Kidney Disease (CKD) had a slight agreement with a
concordance rate (κ) of 0.13, 0.10, 0.06, and 0.01 respectively. Benign prostate hypertrophy,
Rheumatoid Arthritis, and Bipolar Disorder had no agreement and were not statistically
significant. The concordance rate was not calculated for COPD and Psoriasis as no patients
self-reported the former condition and the EMR did not record any participant for the latter
condition.

The positive agreement ranged from 0.04 to 0.65 for the ten conditions that were found to have
a p-value for prevalence-adjusted bias-adjusted kappa (PABAK) < 0.05.

The negative

agreement ranged from 0.58 to 1.00. In general, κ was aligned with the positive and negative
agreement.

However, PABAK was very different ranging from -0.18 to 0.99.

κ was

consistently lower than PABAK with the difference ranging from 0.19 (chronic kidney disease)
to 0.86 (anxiety).
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Table 4-14.Concordance of Additional Disease Count between Self-Reported and Electronic Medical Records of Recruited Participants (n=903)
No
Stroke
ADC-SR

Parkinson’s Disease
ADC-SR

Schizophrenia
ADC-SR

Asthma
ADC-SR

Dementia
ADC-SR

Major Depression
ADC-SR

Osteoporosis
ADC-SR

Anxiety
ADC-SR

%

ADC-EMR
Yes
%

Total

%

No
Yes
Total

769
8
777

85.2
0.9
86.0

62
64
126

6.9
7.1
14.0

831
72
903

92.0
8.0
100.0

No
Yes
Total

896
2
898

99.2
0.2
99.4

3
2
5

0.3
0.2
0.5

899
4
903

99.6
0.4
100.0

No
Yes
Total

892
1
893

98.8
0.1
98.9

7
3
10

0.8
0.3
1.1

899
4
903

99.6
0.4
100.0

No
Yes
Total

847
26
873

93.8
2.9
96.7

14
16
30

1.6
1.8
3.3

861
42
903

95.3
4.7
100.0

No
Yes
Total

892
0
892

98.8
0.0
98.8

9
2
11

1.0
0.2
1.2

901
2
903

99.8
0.2
100.0

No
Yes
Total

867
7
874

96.0
0.8
96.8

23
6
29

2.5
0.7
3.2

890
13
903

98.6
1.4
100.0

No
Yes
Total

864
8
872

95.7
0.9
96.6

28
3
31

3.1
0.3
3.4

892
11
903

98.8
1.2
100.0

No
Yes
Total

885
6
891

98.0
0.7
98.7

11
1
12

1.2
0.1
1.3

896
7
903

Positive
Agreement
0.65

Negative
Agreement
0.96

Kappa

Prevalence
Index
0.78

PABAK

0.61

Bias
Index
0.06

0.84

p-value for
PABAK
<0.01*

0.44

1.00

0.44

0.00

0.99

0.99

<0.01*

0.43

1.00

0.43

0.01

0.98

0.98

<0.01*

0.44

0.98

0.42

0.01

0.92

0.91

<0.01*

0.31

0.99

0.31

0.01

0.99

0.98

<0.01*

0.29

0.98

0.27

0.02

0.95

0.93

<0.01*

0.14

0.98

0.13

0.02

0.95

0.92

<0.01*

0.11

0.99

0.10

0.01

0.98

0.96

<0.01*

99.2
0.8
100.0

kappa< 0 no agreement, 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost perfect agreement. *p<0.05 is considered statistically significant.
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Table 4-14. Concordance of Additional Disease Count between Self-Reported and Electronic Medical Records of Recruited Participants
(n=903)(Continued)
Osteoarthritis
ADC-SR

CKD
ADC-SR

Benign Prostate
Hypertrophy
ADC-SR

Rheumatoid Arthritis
ADC-SR

Bipolar Disorder
ADC-SR

COPD
ADC-SR

Psoriasis
ADC-SR

ADC-EMR
Yes
%

No

%

No
Yes
Total

783
12
795

86.7
1.3
88.0

102
6
108

No
Yes
Total

361
1
362

40.0
0.1
40.1

530
11
541

No
Yes
Total

870
15
885

96.3
1.7
98.0

17
1
18

Total

%

11.3
0.7
12.0

885
18
903

98.0
2.0
100.0

58.7
1.2
59.9

891
12
903

89.7
1.3
100.0

1.9
0.1
2.0

887
16
903

853
46
899

94.5
5.1
99.6

3
1
4

0.3
0.1
0.4

856
47
903

94.8
5.2
100.0

No
Yes
Total

899
2
901

99.6
0.2
99.8

2
0
2

0.2
0.0
0.2

901
2
903

99.8
0.2
100.0

No
Yes
Total

889
0
889

98.4
0.0
98.4

14
0
14

1.6
0.0
1.6

903
0
903

100.0
0.0
100.0

899
4
903

99.6
0.4
100.0

0
0
0

0.0
0.0
0.0

899
4
903

Negative
Agreement
0.93

Kappa

Prevalence
Index
0.86

PABAK

0.06

Bias
Index
0.10

0.75

p-value for
PABAK
0.01*

0.04

0.58

0.01

0.59

0.39

-0.18

0.03*

0.06

0.98

0.04

0.00

0.96

0.93

0.22

0.04

0.97

0.03

0.05

0.94

0.89

0.07

0.00

1.00

-0.002

0.00

1.00

0.99

NA

0.00

0.99

NA

0.02

0.98

0.97

NA

0.00

1.00

NA

0.00

1.00

0.99

NA

98.2
1.8
100.0

No
Yes
Total

No
Yes
Total

Positive
Agreement
0.10

99.6
0.4
100.0

kappa< 0 no agreement, 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost perfect agreement. *p<0.05 is considered statistically significant.
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3.7

Subgroup Analysis

We examined the difference in demographic characteristics between those who did not disclose
their household income with those who did using a chi-square test (Table 4-15). Six of the
eight demographic variables showed statistically significant differences.

Table 4-15. Sociodemographic and Clinical Characteristics of Recruited Participants Who
Declared or Refused to Declare Monthly Household Income

Predictor Variables

Age
<55 years old
55-64 years old
65-74 years old
≥75 years old
Sex
Male
Female
Ethnicity
Chinese
Non-Chinese
First Language
English
Mandarin
Chinese Dialects
Others
Marital Status
Married
Single/Separated/Divorced/Widowed
Education Level
No Formal Education
Primary
Secondary
Post-Secondary
Housing Type
HDB 1/2/3 Room
HDB 4 Room
HDB 5 Room/HUDC
Private Housing
Ownership Status of Current
Housing
Owner
Non-Owner

Declared Household
Income (n=694)

Refused to Declare
Household Income
(n=238)
n
%

p-value^

n

%

98
265
256
75

14.1
38.2
36.9
10.8

17
65
104
52

7.1
27.3
43.7
21.8

411
283

59.2
40.8

102
136

42.9
57.1

<0.01*

548
146

79.0
21.0

221
17

92.9
7.1

<0.01*

193
249
140
112

27.8
35.9
20.2
16.1

40
99
87
12

16.8
41.6
36.6
5.0

558
136

80.4
19.6

181
57

76.1
23.9

107
205
253
129

15.4
29.5
36.5
18.6

65
89
62
22

27.3
37.4
26.1
9.2

146
292
178
77

21.0
42.1
25.6
11.1

48
98
55
36

20.2
41.2
23.1
15.1

602
91

86.7
13.1

164
74

68.9
31.1

^ p-values were obtained from chi-square tests; *p<0.05 is considered statistically significant.

<0.01*

<0.01*

0.15

<0.01*

0.40

<0.01*
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Those who did not disclose their household income were more likely to be older, be women
rather than men, be of Chinese ethnicity, use Mandarin and Chinese dialects as their first
language, have no formal or only primary education, and more likely not to own their current
housing.

3.8

Sensitivity Analysis

We carried out a sensitivity analysis by comparing the different methods of dealing with
missing data on the multivariable regression analysis for the four outcome variables. We
considered the use of listwise deletion because a large enough sample was available, the
listwise deletion method was not prone to Type 1 error, the method was simple, and it provided
‘factual’ standard errors that reflected the actual amount of information obtained from the
study54,67. Furthermore, the regression analysis would have chosen listwise deletion by default
as SPSS software would delete cases with any missing data on the variables of interest for
complete case analysis or listwise deletion67.

Therefore, regression analyses were conducted using listwise deletion. The two tables in
Appendix 4-11 show the full multivariable regression for complete case analysis of 847
participants. Multiple imputation and listwise deletion provided exactly similar analysis results
for three outcome variables PHQ-9, GAD-7, and EQ-5D VAS. However, for EQ-5D UI, there
were four discrepancies. Conflicting results are compared in Tables 4-16 & 4-17 to that found
with multiple imputation (Tables 4-12 & 4-13).

Using the multiple imputation method, age group (p=0.03) and chronic disease control score
(CDCS) (p=0.03) were found to be associated with EQ-5D UI score but the listwise deletion
method did not pick up these two predictor variables (Table 4-16).

The listwise deletion method also picked up two other predictor variables that were negatively
associated with EQ-5D UI. These two variables were sex (p=0.09) and marital status (p=0.10)
which were not picked up by the multiple imputation method (Table 4-17). We noted that the
mean EQ-5D UI score for male and female participants who were excluded from the listwise
deletion method (n=85) was 0.721 and 0.842 respectively. For the same group of participants
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who were excluded from the listwise deletion, the mean EQ-5D UI score for those who were
married and those who were not married were 0.764 and 0.831 respectively (Table 4-17).

Table 4-16. Two variables where Multiple Imputation method showed significant p-value but
not Listwise Deletion method
n = 932
Variables

n = 847

EQ-5D UI
Unadjusted
mean
(Multiple
Imputation)

BetaCoefficient

p-value^

< 55 years old

0.910

REF

REF

≥ 75 years old

0.837

-0.068

0.874

0.940

EQ-5D UI
Unadjusted
mean
(Listwise
Deletion)

BetaCoefficient

p-value^

0.900

REF

REF

0.03*

0.869

-0.039

0.15

REF

REF

0.894

REF

REF

0.068

0.03*

0.939

0.047

0.08

Age

Chronic Disease Control Score
1
(All conditions
optimally controlled)
4
(All conditions not
optimally controlled)

^ p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered
statistically significant.

Table 4-17. Two variables where Listwise Deletion method showed significant p-value but
not Multiple Imputation method
n = 932

n = 847

Variables
EQ-5D UI
Unadjusted
mean
(Multiple
Imputation)

BetaCoefficient

p-value^

Male

0.904

REF

REF

Female

0.873

-0.025

Married

0.899

Not married

0.857

EQ-5D UI
Unadjusted
mean
(Listwise
Deletion)

n = 85
EQ-5D UI
Unadjusted
mean
(Excluded
participants
from
Listwise
Deletion)

BetaCoefficient

p-value^

0.922

REF

REF

0.721

0.09

0.877

-0.036

<0.01*

0.842

REF

REF

0.913

REF

REF

0.764

-0.031

0.10

0.859

-0.042

0.01*

0.831

Sex

Marital Status

^ p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered
statistically significant.
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4

Discussion

There were four objectives to this study. The primary objective was to determine whether a
higher level of multimorbidity was associated with a higher degree of depression and anxiety
symptoms, and a lower quality of life.

We found that all four different instruments for

measuring the level of multimorbidity were variably associated with the three outcomes.
Comparisons of our findings and the possible reasons for the associations are discussed in more
detail in Sections 4.1 to 4.5.

The second objective of the study was to describe the prevalence of depression and anxiety,
and the average score of quality of life in individuals with the commonest triad of
multimorbidity in primary care in Singapore. We found that the prevalence of depression was
12.0%, the prevalence of anxiety was 11.8%, the mean score of EQ-5D utility index score was
0.890, and the mean score of EQ-5D visual analogue scale score was 73.6.

Our third objective was to determine the factors associated with depression, anxiety or poor
quality of life for patients with the commonest triad of multimorbidity in Singapore. We found
that marital status was associated with depression. Age, education level, housing type, and
body mass index were associated with quality of life. Comparisons of our findings and the
possible reasons for the associations are discussed in more detail in Sections 4.1 to 4.3.

The final objective of this study was to determine the concordance rate between self-reported
medical conditions by patients and medical conditions recorded in their electronic medical
records. We found that ten out of the fifteen conditions had a slight to substantial agreement.
We will discuss this further in Section 4.6.

4.1

Depression

The prevalence of mild to severe depression was 12.0% in this study. This was consistent with
rates of 6-22% which were reported in clinical trials of depression screening68. Compared to
the 11.4% prevalence of depression in individuals 55 years and above with coexisting medical
comorbidity using the Geriatric Depressive Scale in the local community69, the prevalence rate
was slightly higher in the primary care setting.

211
The only sociodemographic factor that was found to be associated with depression was marital
status. In our study, we found that the odds ratio of participants who were not married
compared to those who were married was 1.69 (p = 0.048). It has been reported that different
marital statuses were found to be associated with depression but the strength of association was
modified by age and sex70.

As a large majority of participants were married, our study did

not have ample power to further differentiate whether there were differences between those
who were single, separated, divorced, or widowed.

4.2

Anxiety

The prevalence of subthreshold generalised anxiety disorder reported in a systematic review
ranged from 1.3% to 8.3% for primary care patients71 and 2.1% in the local general
population72. Therefore, the prevalence of 11.8% for mild to severe anxiety in this study
indicated that anxiety level was generally higher for the most common pattern of
multimorbidity compared to other studies that included people with and without
multimorbidity. No sociodemographic factors were found to be associated with anxiety.

4.3

Quality of life (Utility Index)

The EQ-5D UI value norms for 20 countries based on country-specific time trade-off values
ranged from 0.855 to 0.95873. The mean score of EQ-5D UI was 0.890 in this study population.
This was lower than the mean score of 0.95 that was reported for the general population in
Singapore52. The EQ-5D UI score was 0.87 for patients with diabetes, and 0.91 for patients
with hypertension indicating that the mean EQ-5D UI score in this study was not dissimilar in
those with chronic conditions.

Those aged 75 years and older reported lower quality of life compared with those younger than
55 years old. The negative correlation between age and quality of life, even after adjustment
for the effect of chronic conditions, was supported by several studies74,75. Hunger et al.76
showed that the age-related decline in the quality of life was only observed from the age of 70
years old onwards which was very similar to this study.
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Those with primary school education reported a poorer quality of life compared to those who
had no formal education. Looking at the adjusted mean EQ-5D UI score, those with secondary
education or above also seemed to have a poorer quality of life score compared to those with
no formal education without statistical significance (Table 4-13). This finding is more
pronounced in the EQ-5D VAS score and will be discussed more in the next section.

Using housing as a measure of socioeconomic status, we found those in private housing
reported better quality of life compared to those who stayed in HDB 1/2/3 room flats. Many
other studies supported this finding of better housing being associated with better quality of
life80-83.

An increased body mass index has been found to be strongly associated with health-related
quality of life77-79. Our study result was consistent with this finding.

4.4

Quality of life (Visual Analogue Scale)

The EQ-5D VAS value norms for 20 countries based on country-specific time trade-off
values ranged from 70.4 to 83.373. The mean score of EQ-5D VAS was 73.6 in this study
population. The VAS score for the patients with diabetes was 69.9 in a 2012 local study84.

Generally, international studies have shown that the amount of schooling was positively
associated with quality of life in the physical, psychological, social and environmental domains
across countries, culture, sex and age85. This differs from what we found in this study. Our
results showed that participants who had any level of education were found to have a lower
quality of life compared to those who had no formal education. The trend seemed to suggest
that the higher the education level, the lower the quality of life.
Powdthavee86 in a study in 2008 found that after controlling for income and employment status,
life satisfaction was on average lower for those with higher levels of education. She cited a
plausible explanation for this was that a comparison effect could be present where a higher
education level raised the expectation of quality of life. It is highly possible that her findings
and explanation for the British citizens may be similar for our population in Singapore too.
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More than 25% of participants did not disclose their household income. This is not uncommon
in surveys and ways to improve the response rates to this sensitive question have been
reported87. We found that participants who did not disclose their income reported lower VAS
score when compared to those who earned less than SGD 2,000 (p < 0.01). We explored the
characteristics for participants who did not disclose their income in Table 4-15. Those who
did not disclose their household income were more likely to be older, be women rather than
men, be of Chinese ethnicity, use Mandarin and Chinese dialects as their first language, have
no formal or only primary education, and were more likely not to own their current housing.
Answers to sensitive question are subject to normal sources of reporting errors but they also
have an added problem whereby respondents basically do not want to tell the truth88. As such,
interpreting the findings from household income may not be accurate and alternative ways of
getting such information should be considered in future studies.

Six independent predictor variables were associated with EQ-5D UI while three independent
predictor variables were associated with EQ-5D VAS. Out of these, education was the only
factor where the EQ-5D UI and EQ-5D VAS data was aligned. The observed differences in
results between EQ-5D UI and EQ-5D VAS have been reported by other studies89. Compared
to the EQ-5D UI where participants were asked to rate their quality of life based on five
dimensions, the EQ-5D VAS asked for the participants’ overall rating of their health. Any
aspects of health-related quality of life that mattered to the participants (i.e., not just the five
dimensions) would influence the way they rate their overall health. Our study confirms that
the visual analogue scale (EQ-5D VAS) measures a broader underlying construct of health
summarising overall health that is closer to the patient’s perspective compared to the utility
index (EQ-5D UI)89.

4.5

Instruments for measuring the level of multimorbidity

We included all four instruments in the same regression model and found that there was no
multicollinearity (Appendix 4-10).

This indicated the multi-dimensional nature of

multimorbidity as all four instruments for measuring the level of multimorbidity were
associated with all the outcome measures (depression, anxiety and quality of life) in some way
or another with differing results.
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4.5.1. Chronic Disease Control Score (CDCS)

No associations were found between the CDCS and depression or anxiety symptoms.
However, CDCS showed an association with quality of life using EQ-5D UI (not EQ-5D VAS).
Interestingly, patients classified as CDCS ‘4’ (all three chronic conditions sub-optimally
controlled) was associated with a better quality of life when compared with those who were
optimally controlled, i.e., CDCS ‘1’. This was contrary to our hypothesis.

There could be several explanations to this observation. Firstly, the trajectory of living with
chronic disease is not linear90. The period directly after newly acquiring a chronic disease may
lead to a decreased quality of life that might diminish or disappear when a patient has adjusted
to the newly acquired illness91. Adaptation and resilience may be at play here where the quality
of life is maintained or in this case, better, in the face of objectively poor health conditions92.
Our study did not look at the duration of the chronic conditions which could have helped to
shed more information on this phenomenon.
Secondly, poor agreement between patients and doctors on their diverging views on patients’
suffering and quality of life is not new93-95. It is plausible that a poorer quality of life resulted
from the treatment burden imposed on patients when they work hard to keep all the three
clinical parameters optimally controlled. Conversely, those patients who chose not to be
restrained by the treatment burden resulting in sub-optimal control of their clinical conditions
experienced a better quality of life before illness burden became overbearing. This explanation
further highlights the chasm that may exist between patients and doctors’ perspectives on
multimorbidity.

4.5.2 Additional disease count – self-reported (ADC-SR) and electronic medical
records (ADC-EMR)
The association of higher disease count and poorer mental health has been well-documented9698

. The inverse relationship between the number of self-reported chronic conditions and quality

of life has also been shown in multiple studies12, 15-17, 19, 99. Our results in this study were
consistent with these findings. The ADC-SR was found to be positively associated with
depressive symptoms, anxiety symptoms, and negatively associated with quality of life using
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the EQ-5D (UI) (not EQ-5D VAS). When more chronic conditions were self-reported, the
more likely the patient had a lower quality of life.

ADC-EMR did not show a similar result. On the contrary, the anxiety score of patients who
had one additional chronic condition compared to those with none was reduced. The direction
of the anxiety score seemed to be similar when more additional chronic conditions were
considered even though there was no statistical significance (Table 4-12). One explanation for
this might be that when physicians documented conditions that mattered to the patients, their
anxiety level dropped. It was plausible that anxiety level went up if patients were concerned
with certain chronic conditions but these conditions were not acknowledged and documented
by their doctors (as in ADC-SR). Our postulation of the above relationship between ADCEMR and anxiety symptoms would need to be further explored in future studies.

4.5.3

Chronic medication count (CMC)

A higher CMC was found to be associated with a poorer quality of life using the EQ-5D VAS
(not EQ-5D UI). This was consistent with findings on the effects of polypharmacy and quality
of life in several studies100,101.

4.6

Concordance

There are several clinical implications for the findings from the concordance study. First of
all, Singapore had consistently ranked as one of the top five countries in the world with the
highest number of end-stage renal disease102. Alarmingly, more than half of the patients
(58.7%) with chronic kidney disease (CKD) recorded in their EMR did not self-report about
the condition (Table 4-14). There could be several reasons for this discrepancy. From the
clinicians’ perspectives, this could imply that either the doctors were downplaying the
significance of early stage CKD and not informing patients, or they were not explaining the
condition well to patients. From the patients’ perspectives, it could be that they had been
informed but did not consider the condition important enough to be reported during the
interview, or they did not understand what was explained to them.

216
Secondly, it has been reported that patients often confused the term ‘rheumatoid arthritis’ with
rheumatism103. The results of this study also seemed to suggest that as ‘rheumatoid arthritis’
had the lowest positive agreement of only 0.04. This was one of the three conditions where
patients self-reported more than that recorded in the EMR. Health literacy and communication
between care providers and patients may be the main issue here.

Thirdly, according to the kappa statistic, the majority of conditions in this study had only slight
to fair agreement between what was self-reported by patients and what was recorded in the
EMR. Adjusting for the low prevalence of the conditions studied, resulted in substantially
higher agreement coefficients as measured by PABAK, except for CKD. However, the very
high PABAK values with low positive agreement e.g., anxiety and osteoarthritis, raise doubt
about its reliability as an agreement statistic. Therefore, PABAK values should still be
interpreted with caution and the evaluation and conclusion for the strength of agreement should
be judged from many aspects104.

Fourthly, all ten conditions that were statistically significant had a high negative agreement of
more than 0.90 except CKD which was only at 0.58. From the results of this study, sole reliance
on the use of medical records may not be warranted. This is especially so in a fee-for-service
environment where patients may obtain multiple sources of care for different health conditions.
Self-reporting of medical conditions allows patients to provide their perception of those
problems that interfere more in their everyday lives and are in line with the concept of the
evidence-based patient information105. Therefore, self-reports may better reflect conditions
more likely to affect patients’ mental health status and quality of life. The discrepancy between
the two sources of medical diagnoses is a concern for epidemiological research106.

On average, patients in this study reported fewer additional chronic conditions during the
interview than what was documented in the EMR (twelve conditions had lower self-reported
‘yes’ compared to EMR). This was contrary to what was reported in a similar study in 2008107.

The possible reasons for the lower self-reports are summarised below. Firstly, it could be due
to a lack of awareness on the part of the patients about the presence of a condition108. Secondly,
patients might consider some health conditions were not important enough to use health
services and failed to report them. Thirdly, because the study was conducted as a face-to-face
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interview, the social desirability effect could be at play especially for mental disorders109.
Fourthly, sporadic diseases from the patients’ perspective may not be reported; studies have
reported that conditions like osteoarticular diseases tend to be reported less frequently by
patients due to its sporadic course110.

4.7

Multiple imputation and Listwise deletion

We explored the reasons for the discrepancy between the results in the multivariable regression
analysis that we found when we used the two methods of dealing with missing data as
demonstrated in the sensitivity analysis.
For the two predictors ‘age’ and ‘CDCS’, type II error was introduced due to the loss of sample
size when listwise deletion was used (Table 4-16). The loss of data led to larger standard errors,
wider confidence intervals, and a loss of power in hypotheses testing67.

We next explored the reasons for the listwise deletion method identifying two predictor
variables as significant – sex and marital status which the multiple imputation did not find. The
mean EQ-5D UI scores were lower for the male participants (0.721) and for participants who
were married (0.764) than the mean EQ-5D UI scores for the males (0.922) and those married
(0.913) for the complete case analysis using the listwise deletion method (Table 4-17). As
such, when these participants were included in the multiple imputation method, the mean EQ5D score was pulled down and did not achieve a significant difference for either the female
participants or those who were not married resulting in a Type I error when using listwise
deletion.

When data were not missing completely at random, listwise deletion may have introduced bias.
This was clearly demonstrated in our case above for selecting the EQ-5D UI as an outcome
even though the two methods provided similar results for the other three outcomes - PHQ-9,
GAD-7 and EQ-5D VAS. Multiple imputation is therefore advocated because it uses
information in the incomplete cases, performs better as more variables are included in the
analysis model, and it is valid when values were missing at random (MAR) where listwise
deletion is biased111.
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4.8

Strengths and Limitations of the study

4.8.1

Strengths

The strengths of the study include the following. First of all, we randomly selected all patients
known in Hougang Polyclinic that had come for follow-up of the most common triad of
multimorbidity instead of convenience sampling. This helps to reduce selection bias by
including patients who made unplanned visits. It is a known fact that patients who attend
physician visits that are unplanned consistently have a poorer state of health112. Second, we
used all the official languages in Singapore to interview our participants so as not to exclude
potential patients from the minority group. Third, we took into account the implications of
missing value and conducted a sensitivity analysis. We further provided a detailed analysis of
the possible reasons for the discrepancies noted between the two different analyses. Fourth,
we provided the positive and negative agreements and preference-adjusted and bias-adjusted
kappa (PABAK) to better understand the agreement between self-reported medical conditions
and those recorded in the EMR. Finally, we provided the report of the study based on the
STROBE guidelines33.

4.8.2

Limitations

Our study also has several limitations other than some that have been mentioned before. First,
this was a cross-sectional study using the point estimate of depression, anxiety, quality of life,
and only the last single clinical parameter during and around the period of the interview.
Causation cannot be determined because of the design of the study. Second, the quality of
morbidity coding in primary care consultations may be variable among diagnoses, e.g., coding
of diabetes tended to be of higher quality than coding of asthma113. Third, the study did not
take into account other missing data mechanisms under which multiple imputation is biased
and listwise deletion is not. These mechanisms do not correspond to missing completely at
random, missing at random or missing not at random categories, but cut across this
classification111. Fourth, despite the random selection of eligible participants, we found that
there were more male to female participants and therefore the study findings may not be
generalisable. Lastly, we did not include lifestyle behaviours that may have impact on the three
outcomes including smoking, physical activity, diet and sleep.
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4.9

Conclusion and future

Out of the four instruments for measuring the level of multimorbidity, only Additional Disease
Count - Self-Reported (ADC-SR) was positively associated with depression and anxiety
symptoms, and negatively associated with quality of life (Utility Index). Patients with all three
chronic conditions that were sub-optimally controlled reported a higher score for quality of life
compared to those who were optimally controlled (Chronic Disease Control Score). A higher
chronic medication count was also associated with a poorer quality of life. Finally, a higher
number of additional chronic conditions using electronic medical records was associated with
a lower score for anxiety symptoms reported by participants. These findings together with the
finding that, for the majority of chronic conditions, there was only slight to fair concordance
between ADC-SR and AC-EMR further highlights the discrepancy of the source of chronic
conditions reported by patients and those reported by the doctors i.e., medical records.

The prevalence of depressive symptoms was 12.0% and the prevalence of anxiety symptoms
was 11.8% for patients with the most common triad of multimorbidity in primary care; both
prevalence rates were higher than the general population in Singapore. The average score of
quality of life using the EQ-5D utility index for patients with multimorbidity in primary care
was 0.890 which was lower that of the general population but comparable to those with chronic
diseases. The average score of quality of life using the EQ-5D visual analogue scale was 73.6
which was higher than 69.9 reported by patients with diabetes in Singapore.

Factors found in our study that were associated with depression, anxiety and quality of life
were largely consistent with those found in the current literature. These included older age of
75 years and above, participants living in small public housing, and those with higher body
mass index being associated with poorer quality of life; and unmarried participants being
associated with higher levels of depressive symptoms. Contrary to most other studies, a higher
education level was associated with a poorer quality of life.
We found that only the condition, stroke showed substantial agreement between patients’ selfreported medical conditions and the electronic medical records (EMR). The majority of
chronic conditions had only slight to fair concordance, and this study further highlights the
incongruency of the source of chronic conditions reported by patients and those reported by
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the doctors, i.e., medical records. In general, patients self-reported fewer conditions than what
was recorded in the EMR. More than half of the patients with chronic kidney disease (58.7%)
recorded in their EMR did not self-report about the condition.
Understanding the patients’ expectations and experiences of multimorbidity would improve
the alignment of goals of clinicians and patients in the documentation of medical conditions
that truly matter to the patients, and may alleviate health care systems’ and clinicians’ obsession
with surrogate clinical parameters. It is essential to include the perspective of patients
themselves who are the real experts in the day-to-day reality of living with multimorbidity
thereby potentially embracing patient-centredness and reducing treatment burden. Better
communication with patients could also improve patient knowledge of their actual conditions.
Future studies should look at the psychological process underlying patient adjustment to
multimorbidity because of its potential to predict clinical, quality of life, and mental health
outcomes.
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Appendix 4-5. A summary list of all the outcome and independent variables

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Variable name
Age
Sex
Ethnicity
First language
Marital status
Education level
Housing type
Ownership status
Monthly household income
Body Mass Index
Chronic Disease Control Score
Additional disease count – self-reported
Additional disease count – electronic medical
records
Chronic medical count
Depression score
Anxiety score
Quality of life – utility index
Quality of life – visual analogue scale

Abbreviation
Age
Sex
Ethnicity
Language
Marital status
Education
Housing
Ownership
Income
BMI
CDCS
ADC-SR
ADC-EMR

Type
Categorical (4)
Dichotomous
Dichotomous
Categorical (4)
Categorical (4)
Categorical (4)
Categorical (4)
Dichotomous
Categorical (5)
Continuous
Categorical (4)
Categorical (3)
Categorical (3)

CMC
PHQ-9
GAD-7
EQ-5D UI
EQ-5D VAS

Count
Dichotomous
Dichotomous
Continuous
Continuous
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Appendix 4-6. Chronic Disease Condition Score (CDCS)
Table 1 – Clinical control of chronic conditions based on Chronic Disease Management
Program Handbook45
Chronic Condition
47

Diabetes

Hyperlipidaemia44
46

Hypertension

Optimally controlled

Sub-optimally controlled

HbA1c < 7.0%

HbA1c ≥ 7.0 %

LDL-c < 2.6mmol/L

LDL-c ≥ 2.6 mmol/L

SBP < 140mmHg and

SBP ≥ 140mmHg or

DBP < 80mmHg

DBP ≥ 80mmHg

Table 2 – Chronic Disease Condition Score (CDCS) definition
Score

Explanation and remarks

1

All three conditions were optimally controlled

2

One of the three conditions was sub-optimally controlled and the other two were optimally controlled

3

Two of the three conditions were sub-optimally controlled and the other one was optimally
controlled
All three conditions were sub-optimally controlled

4
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Appendix 4-7. List of additional disease counts for ADC-SR & ADC-EMR
List of Other Chronic Conditions for determining Additional Disease Count – self-reported and
Additional Disease Count – Electronic Medical Record
1. Stroke
2. Asthma
3. Chronic Obstructive Pulmonary Disease (COPD)
4. Major Depression
5. Schizophrenia
6. Dementia
7. Bipolar Disorder
8. Anxiety
9. Parkinson’s Disease
10. Chronic Kidney Disease
11. Benign Prostate Hypertrophy
12. Osteoarthritis
13. Rheumatoid Arthritis
14. Osteoporosis
15. Psoriasis
16. Others, please specify: _____________
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Appendix 4-8. Normality tests for independent variables - BMI, CMC, ADC-SR & EMR
BMI (Body Mass Index)

Kolmogorov-Smirnov test
Variable
BMI

Shapiro-Wilk test

Statistic

df

Sig.

Statistic

df

Sig.

.063

866

.000

.970

866

.000

From visual inspection, the variable BMI was considered not to be normally distributed as the frequency
distribution showed right skewness, and the Q-Q plot did not form a straight diagonal line55. Moreover, both the
Lilliefors corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests were statistically significant (p < 0.05).
Therefore, the variable BMI was not normally distributed.

CMC (Chronic Medication Count)

Kolmogorov-Smirnov test
Variable
CMC

Shapiro-Wilk test

Statistic

df

Sig.

Statistic

df

Sig.

.105

866

.000

.977

866

.000

The variable CMC was considered to be normally distributed as the frequency distribution and the Q-Q plot
satisfied the visual methods for assessing normality despite having significant test results for both the Lilliefors
corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests55.
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Appendix 4-8. Normality tests for independent variables - BMI, CMC, ADC-SR & EMR
(Continued)
ADC-SR
(Additional Disease Count – Self-Reported)

ADC-EMR
(Additional Disease Count – Electronic Medical Record)

The distribution frequency of ADC-SR and ADC-EMR were both positive skewed with clustering at ‘0’.
Therefore, the two variables were changed to categorical variables with three categories of ‘0’, ‘1’, ‘2 and
more’.

237
Appendix 4-9. Normality tests for dependent variables – EQ-5D UI & EQ-5D VAS
EQ-5D Utility Index

Kolmogorov-Smirnov test
Variable
EQ-5D UI

Shapiro-Wilk test

Statistic

df

Sig.

Statistic

df

Sig.

.314

932

.000

.615

932

.000

From visual inspection, the variable EQ-5D UI was considered not to be normally distributed as the frequency
distribution showed left skewness with clustering at ‘1.000’, and the Q-Q plot did not form a straight diagonal
line55. Moreover, both the Lilliefors corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests were statistically
significant (p < 0.05). Therefore, the variable EQ-5D UI was not normally distributed.

EQ-5D Visual Analogue Scale

Kolmogorov-Smirnov test
Variable
EQ-5D VAS

Statistic

df

Sig.

Shapiro-Wilk test
Statistic

df

Sig.

.122
932
.000
.957
932
.000
From visual inspection, the variable EQ-5D VAS was considered not to be normally distributed as the frequency
distribution showed left skewness, and the Q-Q plot did not form a straight diagonal line55. Moreover, both the
Lilliefors corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests were statistically significant (p < 0.05).
Therefore, the variable EQ-5D VAS was not normally distributed.
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Appendix 4-9. Normality tests for dependent variables – EQ-5D UI & EQ-5D VAS
(Continued)
EQ-5D UI Residual

From visual inspection, the EQ-5D UI residuals showed left skewness in the frequency distribution, and the P-P
plot did not form a straight diagonal line55. Therefore, the residuals of EQ-5D UI was not normally distributed.

EQ-5D VAS Residual

From visual inspection, the EQ-5D VAS residuals showed left skewness in the frequency distribution, and the
P-P plot did not form a straight diagonal line55. Therefore, the residuals of EQ-5D VAS was not normally
distributed.
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Appendix 4-10. Multicollinearity Tests

Variance Inflation Factor
Variables

VIF

First Language

Constant

Marital Status

1.141

Education Level

1.205

Housing Type

1.212

Ownership Status of Current Housing

1.192

Monthly Household Income

1.078

Variables

VIF

CDCS

Constant

ADC-SR

1.062

SDC-EMR

1.071

CMC

1.136
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Appendix 4-11. Multivariable Regression Analysis using listwise deletion (n=847)
Table 1A: The Effect of Sociodemographic and Clinical Predictor Variables on Depression and Anxiety of
Recruited Participants (n=847)
PHQ9
Predictor Variables

Odds
Ratio^

GAD7
95% CI^

p-value^

1.29

0.57,2.94

0.55

1.08

0.46,2.51

0.86

1.47

0.53,4.07

0.46

0.59,1.53

0.84

0.33,3.12

0.98

0.90

0.46,1.79

0.77

1.17

0.55,2.50

0.69

1.92

0.60,6.13

0.27

1.19,3.55

0.01*

1.05

0.56,1.98

0.87

0.74

0.36,1.52

0.41

0.59

0.22,1.54

0.28

0.76

0.43,1.32

0.33

0.71

0.36,1.41

0.67

0.27,1.67

Odds
Ratio^

95% CI^

p-value^

0.87

0.44,1.73

0.70

0.68

0.33,1.42

0.30

1.02

0.40,2.63

0.96

0.78,1.99

0.37

0.26,2.03

0.54

0.68

0.36,1.27

0.22

0.56

0.26,1.21

0.14

1.70

0.58,4.99

0.34

0.95,2.90

0.08

1.26

0.65,2.47

0.50

0.63

0.29,1.35

0.23

0.88

0.35,2.17

0.77

0.78

0.43,1.42

0.41

0.33

1.40

0.73,2.69

0.31

0.39

0.79

0.32,1.98

0.61

0.42,1.52

0.50

Age
<55 years old
55-64 years old
65-74 years old
≥75 years old
Sex
Male
Female
Ethnicity
Chinese
Non-Chinese
First Language
English
Mandarin
Chinese Dialects
Others
Marital Status
Married
Single/Separated/Divorced/Widowed
Education Level
No Formal Education
Primary
Secondary
Post-Secondary
Housing Type
HDB 1/2/3 Room
HDB 4 Room
HDB 5 Room/HUDC
Private Housing
Ownership Status of Current
Housing
Owner
Non-Owner
Monthly Household Income

REF

<SGD2,000
SGD2,000 – SGD3,999
SGD4,000 – SGD5,999
≥SGD6,000
Income not disclosed

REF

REF

REF
0.95

REF

REF
1.02

REF

REF

REF

REF

1.66
REF

REF

REF

REF
0.88

0.73
REF

REF
2.05

1.24

REF
0.48,1.61

0.67

0.80

1.11

0.59,2.10

0.74

1.56

0.85,2.86

0.16

1.01

0.42,2.41

0.98

0.90

0.40,2.06

0.81

1.73

0.78,3.82

0.18

1.28

0.57,2.86

0.55

0.55

0.30,1.02

0.06

0.78

0.43,1.45

0.44

REF

^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered
statistically significant.
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Table 1A: The Effect of Sociodemographic and Clinical Predictor Variables on Depression and Anxiety of
Recruited Participants (n=847) (continued)
PHQ9
Predictor Variables

GAD7

Odds Ratio^

95% CI^

p-value^

Odds
Ratio^

95% CI^

p-value^

Body Mass Index (BMI)

0.96

0.90,1.01

0.13

1.00

00.94,1.05

0.87

Chronic Disease Control
Score (CDCS)
1

REF

2

1.33

0.77,2.30

0.31

1.12

0.64,1.96

0.69

3

0.91

0.46,1.78

0.78

1.10

0.58,2.09

0.78

4

0.48

0.13,1.73

0.26

0.69

0.22,2.20

0.53

Additional Disease Count –
Self Reported (ADC-SR)
0

REF

1

1.35

0.82,2.23

0.24

0.98

0.59,1.61

0.93

2+

2.86

1.53,5.34

0.001*

2.08

1.10,3.91

0.024*

Additional Disease Count –
Electronic Medical Records
(ADC-EMR)
0

REF

1

0.99

0.54,1.83

0.99

0.55

0.32,0.96

0.034*

2+

1.02

0.53,1.95

0.95

0.62

0.34,1.12

0.11

REF

REF

REF

1.06
0.95,1.19
0.31
1.06
0.95,1.19
0.30
Chronic Medication Count
(CMC)
^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered
statistically significant.
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Table 1B: The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=847)
EQ5D-UI
Predictor Variables

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

Beta
Coefficient^

<55 years old

0.900 (0.186)

0.870 (0.018)

REF

55-64 years old

0.907 (0.156)

0.877 (0.013)

65-74 years old

0.908 (0.151)

≥75 years old
Sex

0.869 (0.173)

Male

0.922 (0.142)

0.880 (0.013)

REF

Female
Ethnicity

0.877 (0.178)

0.849 (0.012)

-0.036

Chinese

0.908 (0154)

0.863 (0.013)

REF

Non-Chinese
First Language

0.868 (0.186)

0.866 (0.019)

0.003

English

0.927 (0.138)

0.876 (0.016)

REF

Mandarin

0.909 (0.156)

0.880 (0.017)

Chinese Dialects

0.893 (0.162)

Others
Marital Status

0.850 (0.197)

Married
Single/Separated/Divorced/Widowed
Education Level

EQ5D-VAS
95% CI^

p-value^

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

0.007

-0.031,0.046

0.71

0.876 (0.013)

0.007

-0.033,0.047

0.837 (0.018)

-0.039

-0.090,0.013

-0.061,-0.012

0.004*

-0.050,0.057

0.91

0.005

-0.027,0.037

0.77

0.872 (0.018)

-0.004

-0.043,0.034

0.830 (0.020)

-0.053

-0.112,0.006

0.913 (0.150)
0.859 (0.191)

0.883 (0.012)
0.846 (0.014)

REF
-0.042

No Formal Education

0.892 (0.152)

0.878 (0.017)

REF

Primary

0.876 (0.187)

0.845 (0.014)

Secondary

0.922 (0.133)

Post-Secondary
Housing Type

0.919 (0.160)

HDB 1/2/3 Room

0.889 (0.176)

0.851 (0.015)

REF

HDB 4 Room

0.891 (0.161)

0.854 (0.013)

HDB 5 Room/HUDC

0.910 (0.159)

Private Housing

0.940 (0.127)

Beta
Coefficient^

95% CI^

p-value^

71.3 (17.1)

73.1 (1.8)

REF

72.6 (14.7)

73.8 (1.3)

0.010

-0.037,0.058

0.67

0.74

74.3 (15.4)

0.15

75.5 (14.2)

74.7 (1.3)

0.023

-0.026,0.072

0.37

75.3 (1.8)

0.030

-0.032,0.091

0.34

72.0 (14.4)

73.3 (1.3)

REF

75.3 (16.1)

75.2 (1.3)

0.025

-0.004,0.054

0.09

73.5 (15.0)

72.8 (1.3)

REF

73.7 (16.4)

75.6 (2.0)

0.038

-0.028,0.103

0.26

71.3 (15.1)

74.3 (1.6)

REF

74.1 (14.5)

75.7 (1.7)

0.019

-0.021,0.059

0.35

0.82

74.6 (15.5)

0.08

73.9 (17.1)

73.9 (1.8)

-0.004

-0.051,0.042

0.85

73.0 (2.0)

-0.017

-0.087,0.054

0.65

-0.073,-0.011

0.009*

73.3 (15.1)
74.1 (16.0)

74.8 (1.2)
73.7 (1.4)

REF
-0.015

-0.051,0.022

0.43

-0.039

-0.074,-0.004

0.03*

80.5 (16.3)

81.7 (1.8)

REF

72.6 (16.0)

73.5 (1.5)

-0.106

-0.146,-0.067

<0.0001*

0.874 (0.014)

-0.005

-0.042,0.033

0.861 (0.016)

-0.019

-0.066,0.027

0.80

71.9 (13.4)

72.1 (1.3)

-0.124

-0.168,-0.081

<0.0001*

0.41

70.6 (13.9)

70.1 (1.6)

-0.153

-0.209,-0.097

<0.0001*

0.004

-0.027,0.035

0.81

73.2 (15.2)

72.7 (1.5)

REF

73.8 (14.8)

74.0 (1.3)

0.018

0.863 (0.014)

0.014

-0.022,0.050

-0.019,0.055

0.33

0.45

73.7 (16.5)

75.3 (1.4)

0.035

-0.008,0.078

0.11

0.891 (0.018)

0.046

0.002,0.091

0.04*

72.6 (14.5)

75.0 (1.9)

0.031

-0.024,0.085

0.27

Age

^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 are considered statistically significant
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Table 1B: The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=847) (continued)
EQ5D-UI
Predictor Variables

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

Beta
Coefficient^

Owner

0.910 (0.148)

0.865 (0.012)

REF

Non-Owner

0.866 (0.206)

0.864 (0.015)

-0.001

<SGD2,000

0.900 (0.168)

0.877 (0.013)

REF

SGD2,000 – SGD3,999

0.903 (0.135)

0.862 (0.016)

SGD4,000 – SGD5,999

0.936 (0.135)

≥SGD6,000

0.913 (0.162)

Income not disclosed

EQ5D-VAS
95% CI^

p-value^

Unadjusted
Mean (SD)

Adjusted
Mean (SE)

Beta
Coefficient^

73.3 (14.7)

73.9 (1.2)

REF

74.6 (17.4)

74.6 (1.5)

0.010

95% CI^

p-value^

-0.029,0.049

0.62

Ownership Status of Current Housing

-0.034,0.033

0.97

75.4 (15.1)

75.6 (1.3)

REF

-0.017

-0.051,0.017

0.33

71.7 (14.8)

72.7 (1.6)

-0.039

-0.081,0.002

0.06

0.878 (0.018)

0.002

-0.038,0.043

0.92

74.5 (13.5)

76.5 (1.9)

0.012

-0.037,0.061

0.63

0.849 (0.019)

-0.032

-0.075,0.011

0.14

72.8 (14.9)

75.3 (2.0)

-0.004

-0.056,0.048

0.88

0.884 (0.173)

0.857 (0.014)

-0.023

-0.053,0.007

0.14

72.0 (16.3)

71.1 (1.4)

-0.061

-0.097,-0.025

0.001*

NA

NA

-0.003

-0.006,0.000

0.023*

NA

NA

-0.002

-0.006,0.001

0.20

1 (All 3 conditions optimally controlled)

0.894 (0.171)

0.854 (0.014)

REF

72.7 (15.1)

72.6 (1.4)

REF

2 (1 condition sub-optimally controlled)

0.914 (0.149)

0.866 (0.012)

0.014

-0.004,0.064

0.09

3 (2 conditions sub-optimally controlled)

0.875 (0.179)

0.843 (0.014)

4 (3 conditions sub-optimally controlled)

0.939 (0.101)

0.895 (0.023)

Additional Disease Count – Self
Reported (ADC-SR)
0

0.934 (0.136)

0.914 (0.013)

REF

1

0.885 (0.164)

0.871 (0.013)

2+

0.817 (0.201)

0.811 (0.017)

Additional Disease Count – Electronic
Medical Records (ADC-EMR)
0

0.924 (0.122)

0.869 (0.015)

REF

1

0.911 (0.162)

0.869 (0.013)

2+

0.875 (0.179)
NA

Monthly Household Income

Body Mass Index (BMI)
Chronic Disease Control Score (CDCS)

Chronic Medication Count (CMC)

-0.014,0.042

0.33

73.8 (15.4)

74.5 (1.2)

0.030

-0.014

-0.048,0.02

0.43

74.0 (15.0)

75.6 (1.4)

0.040

0.000,0.081

0.05

0.047

-0.006,0.100

0.08

73.4 (15.8)

74.1 (2.4)

0.021

-0.045,0.086

0.54

73.8 (15.4)

74.7 (1.2)

REF

-0.048

-0.073,-0.023

<0.0001*

73.4 (15.3)

74.2 (1.3)

-0.007

-0.037,0.023

0.64

-0.119

-0.159,-0.079

<0.0001*

72.8 (14.6)

73.8 (1.7)

-0.012

-0.057,0.032

0.59

73.4 (15.5)

74.4 (1.5)

REF

0.000

-0.029,0.029

0.99

74.1 (15.1)

74.8 (1.3)

0.006

-0.029,0.041

0.75

0.854 (0.013)

-0.017

-0.050,0.015

0.29

72.9 (15.3)

73.5 (1.3)

-0.012

-0.051,0.026

0.53

NA

-0.004

-0.009,0.002

0.24

NA

NA

-0.008

-0.015,-0.001

0.024*

^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered statistically significant
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1 Introduction
The major gaps in multimorbidity research concern the immaturity of the different
measurements of multimorbidity: prevalence, levels of morbidity burden, and outcomes.
Therefore, this thesis aimed to narrow these gaps by providing a uniform definition for
multimorbidity in order to define the prevalence of multimorbidity in the primary care
population in Singapore, identifying a list of instruments to measure the levels of
multimorbidity and exploring some patient-reported outcomes and their association with
different levels of multimorbidity.

Three studies were conducted to achieve the above aims. Chapter Two reported the first study
on the prevalence and patterns of multimorbidity: the title is ‘The Prevalence and the common
patterns of multimorbidity in Singapore: An Epidemiological Study based on Administrative
Data’ (PESAD); Chapter Three reported the systematic review and the title is ‘A Systematic
review on the Instruments used for measuring the level of multimorbidity’ (SIM); Chapter Four
reported the study of the outcomes of multimorbidity and the title is ‘Multimorbidity and its
association with depression, anxiety and quality of life’ (MDAQ).

The thesis has met these aims. In Chapter Two (PESAD) on prevalence and patterns of
multimorbidity, the study compared the standardised prevalence rates of multimorbidity based
on two different multimorbidity lists (CDMP and Fortin lists) with two different cut-points,
and identified the Fortin list with ‘three or more’ chronic conditions as a better definition of
multimorbidity in the primary care population. The systematic review, Chapter Three (SIM),
found 33 different instruments reported since January 2010 to August 2018 that were used to
measure the levels of multimorbidity for specific outcomes in the primary care and general
population. Finally, Chapter Four (MDAQ), a study of outcomes of multimorbidity, found that
the outcomes depressive symptoms, anxiety symptoms, and quality of life of patients with
multimorbidity were associated with different levels of multimorbidity.

Section 2 of this concluding chapter will elaborate further on these results and synthesise what
was learnt from the findings reported in Chapters Two, Three and Four. Section 3 discusses
the importance of considering age, sex and ethnicity when studying multimorbidity. Based on
all the findings reported in Chapters Two, Three and Four, some new insights are shared in

246
Sections 4, 5 and 6 where the future directions in the conceptualisation of multimorbidity,
future directions in multimorbidity research, and future directions in clinical practice will be
discussed.

2 The measurement of multimorbidity
2.1

Defining multimorbidity

The fundamental reason for a wide variety of prevalence rates among multimorbidity studies
is the contentious issues related to the definition of multimorbidity. On top of using reporting
guidelines like RECORD1 for Chapter Two (PESAD) on the prevalence and patterns of
multimorbidity and STROBE2 for Chapter Four (MDAQ) for the cross-sectional study on the
outcomes of multimorbidity, five components of the definition of multimorbidity were also
identified and included in both chapters. These five components were:
a) the types of conditions selected to form the multimorbidity list;
b) the total number of conditions considered in the multimorbidity list;
c) the data sources of the chronic conditions;
d) the cut-points used to define multimorbidity; and
e) the reference population.

When data were extracted for the included articles for the systematic review in Chapter Three
(SIM), the provision of these five components were purposefully searched from each article.
Only 34.3% of the included studies provided at least a brief statement of what a chronic
condition was. The total number of conditions considered in the multimorbidity list ranged
from seven to 147 diseases in this review but only slightly more than half of them, i.e., 56.7%
of the studies, provided a full list of the conditions. Finally, only 34.3% of the studies stated
clearly the cut-points they used to define multimorbidity. In total, only 20.9% of the studies
included all three components, i.e., the definition of chronic condition, list of conditions and
cut-points used to define multimorbidity. The data sources of the chronic conditions and the
reference population were the only two components that were stated in all the included studies.

In Chapter Two (PESAD), different definitions of multimorbidity for determining the
prevalence of multimorbidity in the Singapore primary care population were explored and it
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was found that Fortin’s list with a cut-off of ‘three or more’ conditions was clinically more
meaningful. However, using ‘three or more’ conditions as a cut-off was not commonly used
in multimorbidity studies. For the included studies in the systematic review in Chapter Three
(SIM) where the cut-points was mentioned, only two studies used the cut-off of ‘three or more’
conditions3-5. The MDAQ study reported in Chapter Four used a cut-off of three specific
chronic conditions as the inclusion criteria.

2.2

Measuring multimorbidity

Lefevre et al.6 listed four common methods of measuring multimorbidity as described in
Chapter One. They are: by simple counts of chronic diseases from a list of individual
conditions (i.e., disease count), by grouping chronic diseases into dyads or triads (i.e., dyad and
triad patterns), by identifying homogeneous groups of people with common disease and
characteristics (i.e., non-random association patterns), and by using an index of variable
complexity (i.e., weighted indices). However, this classification does not clearly explain the
different purposes of measuring multimorbidity7.

It is important to establish the purpose of measuring multimorbidity and to note that the
same instrument can serve different purposes8. According to de Vet et al.8, the three main
purposes of measurement in medicine are for diagnosis, evaluation of intervention and
prediction of outcome. Discriminant measurement is for diagnosis, evaluation measurement
is for evaluation after an intervention, and predictive measurement is to predict a specific
outcome. The studies conducted in this thesis have improved on the terminology of
measuring multimorbidity based on Lefevre et al.’s6 classification. Therefore, it is proposed
that explicitly described measurements of multimorbidity should be upfront in all
multimorbidity studies and should include the purpose, i.e., discriminant, evaluative or
predictive, using de Vet et al.’s8 framework. As the studies in this thesis did not involve
intervention studies, the types of measurement of multimorbidity described in this thesis
were mainly discriminant and predictive measurements. These two types of measurements
are described below.
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2.2.1

Discriminant measurement

Measuring the prevalence of multimorbidity is a discriminant measurement and using disease
count is a common practice as used in Chapter Two (PESAD). For understanding the patterns
of multimorbidity, ‘dyads and triads’ of combinations and random associations of chronic
conditions are frequently used, and these are also discriminant measurements. ‘Dyads and
triads’ was used in Chapter Two (PESAD) and distinct differences in patterns of
multimorbidity between the different ethnic/sex groups were found.

Multimorbidity is common. Comparing the outcomes between patients with multimorbidity
and no multimorbidity has already been well-established as described in Chapter One (Section
4.1 to 4.3 p5-6). However, in this thesis, measuring different levels of multimorbidity in
Chapters Three (SIM) and Four (MDAQ) were also done. The frequent instruments used for
measuring the level of multimorbidity include disease count, weighted indices of varying
complexity, case-mix, and drug counts as reported in the systematic review. Chronic disease
control score, additional disease count-self-reported, additional disease count-electronic
medical records, and chronic medication count were used in Chapter Four (MDAQ). In de Vet
et al.’s8 framework, these instruments are also discriminant measurements as they distinguish
among the different levels of multimorbidity.

Out of the four different instruments used in Chapter Four (MDAQ) that comprises of chronic
disease control score (CDCS), additional disease count-self-reported (ADC-SR), additional
disease count-electronic medical records (ADC-EMR), and chronic medication count (CMC),
only CDCS was not found in the list of instruments identified in the systematic review in
Chapter Three (SIM).

2.2.2

Predictive measurement

Chapters Three (SIM) and Four (MDAQ) also looked at the specific outcomes that were
predicted******** by the different levels of multimorbidity. In this case, the different levels of
multimorbidity were used as predictive measurements for specific outcomes like depressive

The term ‘predicted’ is used here to mean ‘associated with’ as the MDAQ study is a cross-sectional study
whereby causal relationships cannot be ascertained.
********
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symptoms, anxiety symptoms and quality of life in Chapter Four. However, when focusing on
the independent variables, the differentiation of multimorbidity into different levels is a
discriminant measurement as mentioned in Section 2.2.1 above.
Four different instruments in Chapter Four (MDAQ) were used to predict the outcomes of
patients with multimorbidity in primary care using an observational interviewer-administered
questionnaire. The study found that poorer disease control was associated with a better quality
of life which was contrary to the hypothesis. It was postulated that when patients worked hard
to keep all the three clinical parameters for each of the chronic diseases optimally controlled,
the resultant treatment burden imposed on them led to a poorer quality of life. Conversely,
those patients who chose not to be restrained by the treatment burden resulting in sub-optimal
control of their clinical conditions experienced a better quality of life before illness burden
became overbearing. This finding was interpreted based on the conceptual framework of
minimally disruptive medicine that is described further in Section 4 later.

In summary, the work done in this thesis has improved the description and terminology of
measurements of multimorbidity based on Lefevre et al.’s6 classification. Authors should make
it clear to readers whether investigators are discriminating between patients with
multimorbidity or no multimorbidity, or among patients with different levels of
multimorbidity.

The same instrument, i.e., disease count, can be used as a prediction

instrument for specific outcomes, or an evaluation instrument if there were an intervention. De
Vet et al.8 suggested to speak of discriminative, predictive or evaluative applications than of
instruments because the same instrument can be used for different purposes.

2.3

Disease count by self-report or electronic medical records

In Chapter Three (SIM), out of the 33 instruments identified in the systematic review for
measuring the level of multimorbidity, 21 of them were obtained from administrative or
medical records, 12 of them were self-reported by participants of the studies, and two of the
studies obtained data from both medical records and self-reports of participants. Despite the
different sources of data on chronic conditions in these studies, the outcomes associated with
the different levels of multimorbidity were all aligned.
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However, in the study of outcomes of multimorbidity in Chapter Four (MDAQ), additional
disease count-self reported (ADC-SR) and additional disease count-electronic medical record
(ADC-EMR) were associated in different directions for the patient-reported outcome of anxiety
symptoms. A higher number of ADC-SR was associated with a higher level of anxiety, but a
higher number of ADC-EMR was associated with a lower level of anxiety. (Chapter Four
Table 4-12 p199).

Additionally, there was, at the most only, moderate agreement between the two data sources
for 15 chronic conditions. The one exception was for the condition ‘stroke’ where there was
substantial agreement.

The patient-reported outcomes (depressive symptoms, anxiety

symptoms, and quality of life) associated with ADC-SR were aligned with the findings of the
systematic review in Chapter Three (SIM) but not ADC-EMR. The implications of this
disparity are discussed further in Section 4.

3 Age, sex and ethnicity
This section looks at the significance of considering age, sex and ethnicity when studying
multimorbidity especially in a multi-ethnic society of Singapore that comprises the three main
ethnic groups of Chinese, Malay and Indian.

3.1

Age

Age was related to the standardised prevalence rates of multimorbidity in Chapter Two
(PESAD) in much the same way as in the literature9-16 with a rise in the prevalence rates with
advancing age. Similarly, in Chapter Four (MDAQ), it was found that being in the oldest age
group was associated with a lower quality of life (EQ-5D utility index) compared to those less
than 55 years old, which was consistent with previous literature17,18.

3.2

Sex

Although the evidence of an association between multimorbidity and sex has not been
consistent across studies19, investigators who conducted multimorbidity studies in primary
care found no sex differences in the prevalence of multimorbidity20-24. Similarly, in Chapter
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Two (PESAD), no sex differences in the standardised prevalence rates of multimorbidity was
found. Sex was also not found to be associated with depressive symptoms, anxiety symptoms,
or quality of life in the MDAQ study (Chapter Four).

3.3

Ethnicity

The literature on race or ethnic group in relation to multimorbidity is sparse as shown by the
systematic review in Chapter Three (SIM) finding that only two25,26 of 22 studies using
prognostic models included race. Therefore, the addition this thesis makes to the literature is
somewhat original and potentially important. In the descriptive study on the prevalence and
patterns of multimorbidity in Chapter Two (PESAD), the standardised prevalence rates were
not found to be clinically different among the three major ethnic groups of Singapore (Chinese,
Malay, and Indian) for those age from 0 to 99. However, different distinct patterns of dyads
and triads of multimorbidity were noted between the different ethnic/sex groups for those ages
45 years old and above. The latter finding indicates how potentially important it will be for
future studies in multi-ethnic communities to identify any clinically important differences in
the patterns of dyads and triads, to prepare clinicians to provide appropriate care, hopefully
using relevant guidelines developed for the unique communities of patients. Ethnicity was not
found to be associated with depressive symptoms, anxiety symptoms, or quality of life in
Chapter Four (MDAQ).

4 Future directions in the conceptualisation of multimorbidity
Chapter One introduced two concepts/frameworks of relevance to multimorbidity: the PatientCentred Clinical Method (PCCM); and Minimally Disruptive Medicine (MDM). The thesis
findings resonate well with PCCM because the variable that was the most strongly associated
with patient-reported outcomes was the patient self-reported count of chronic conditions. In
other words, the patient’s perspective, i.e., the measure of patients’ self-reported conditions,
was the most valid in terms of its relationship with outcomes. Once again, as has been found
before in the literature, patient perceptions are the key to patient outcomes27.

Minimally disruptive medicine (MDM) emphasises the importance of balancing the capacity
of patients with the workload experienced by patients with multimorbidity. The workload of
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such patients is imposed both by the treatment rendered by the health care providers (treatment
burden) and the demands of life which are outside the control of health care providers28. The
concept of MDM was used to explain the unexpected finding in the MDAQ study reported in
Chapter Four where patients with multimorbidity that have poorer disease control were
associated with a better quality of life. Buffel du Vaure et al.29 reported that the potential
workload for patients with multimorbidity in applying different clinical practice guidelines was
too arduous and not practical for patients and inevitably induced poor adherence, wasted
resources and poorer outcomes29. Similarly, the capacity of coping with multimorbidity was
overwhelmed by the treatment burden imposed such that poorer surrogate outcomes (i.e.,
control of individual chronic conditions) were observed in patients who chose not to adhere to
the clinical advice and therefore reported better quality of life.

While both concepts PCCM and MDM have been used to interpret the findings in Chapter Four
(MDAQ), the prevalence study in Chapter Two (PESAD) highlighted the importance of
individual chronic conditions that when combined, constituted the phenomenon of
multimorbidity.

The literature supports considering multimorbidity as an entity of

interdependent parts which the PCCM advocates in its language about understanding the whole
person. Cassel talks of this interdependence30 and Koestler31 described the ‘wholes’ that
simultaneously are ‘parts’ of other ‘wholes’ as ‘holons’. Single conditions are the ‘parts’ of
multimorbidity (‘whole’), and the same multimorbidity is also a ‘part’ or ‘holon’ of the overall
health (‘whole’).

The new insights obtained from looking at how multimorbidity is formed from single
conditions suggested that multiple conditions within an individual, are not necessarily caused
by independent mechanisms32. A common underlying physiological disease process(es) may
be at play. These underlying process(es) affect the whole individual across the molecular,
personal and social domains of life and physiologically lead to a new state of objective and
subjective adaptation. Recognising that multimorbidity reflects an underlying disturbance in a
network of interlinked neuroendocrine, immunological and cellular processes allows clinicians
and scientists to view an individual with multimorbidity as both a ‘whole’ and a ‘part’ of the
bigger scheme of life.
Future directions should consider the notion of ‘interdependence with an underlying unifying
mechanism’ together with PCCM and MDM in the conceptualisation of multimorbidity.
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5 Future directions in multimorbidity research
The results of this thesis have led to the recognition of two important directions for
multimorbidity research: involvement of patients in multimorbidity research; and the creation
of the most appropriate data sources for the measurement of multimorbidity.

Involving the individuals with multimorbidity in priority setting and preferences in a resourcescarce climate in healthcare is both rational and ethical. The finding in this thesis, that patient
self-reported measure of multimorbidity was the most highly associated with outcomes,
supports this thrust. Besides, research into patients’ perspectives on how multimorbidity
affects their health, well-being, and clinical care is pertinent lest one falls into the McNamara
fallacy†††††††† of focusing on certain metrics of measuring multimorbidity and neglecting the
less easily quantifiable attributes of health care such as self-management behaviour and
treatment burden33. The shift to involve patients in multimorbidity research will encompass
abandoning a linear, reductionist view of the world to an integrated understanding of the
complexity of multimorbidity and its management moving from ‘what is the matter?’ to ‘what
matters?’34 to the patient.
The lack of a ‘gold standard’ data source in obtaining accurate medical conditions is a hurdle
in multimorbidity research. There have been advocates in the scientific community to adopt
real-world data (RDW) such as electronic medical records and administrative data for the
evaluation of epidemiology and burden of disease, treatment patterns, adherence, persistence,
and health outcomes of different treatments35. However, there are also concerns about their
use36,37, with similar apprehensions being echoed from findings in this thesis. Fundamentally,
the problem lies in the messy evolvement of our medical records that have grown cumbersome
for serving too many purposes38. A re-conceptualisation and further research work on how we
document chronic conditions for patient care and clinical research is urgently needed. Until
issues related to the re-conceptualisation of our current documentation of chronic conditions

††††††††

“The first step of McNamara’s fallacy is to measure whatever can easily be measured. This is OK as far as it goes.
The second step is to disregard that which can’t be easily measured or to give it an arbitrary quantitative value.
This is artificial and misleading. The third step is to presume that what can’t be measured easily really isn’t
important. This is blindness. The fourth step is to say that what can’t be easily measured really doesn’t exist. This
is suicide.” (O'Mahony S. Medicine and the McNamara fallacy. J R Coll Physicians Edinb 2017;47(3):281-87.)
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are addressed such that the documentation truly captures patients concerns, chronic conditions
self-reported by patients would be the preferred data source for multimorbidity research for
now.

Finally, researchers studying multimorbidity should aim to make their work reproducible by
reporting their work transparently to allow direct and conceptual replication. All the work done
for multimorbidity to improve the body of knowledge on the subject should be incremental and
useful to the world literature. In preparing this thesis, it was found that most researchers were
not as transparent as they should be, making it difficult to achieve the above aim. This is an
area of improvement in multimorbidity research that should not be trivialised.

6 Future directions in clinical practice
System-level rationing is the norm in the current model of care where ageing and
multimorbidity threatens the sustainability of many health care systems40. The findings in this
thesis point to paying closer attention to the patients’ perceptions of their morbidity as these
are the measures that were related to the outcomes of interest and therefore the best solution
for sustainability at the patient, clinician, and system level.
Care is better when it recognises what patients’ defined problems are rather than focusing only
on what the diagnoses are41. Health care providers should aim to provide minimally disruptive
medicine by not focusing solely on improving clinical parameters as recommended by
individual clinical practice guidelines42. The overall aim is to provide patient-centred care as
described by Stewart et al.43, the ‘willingness to become involved in the full range of difficulties
individuals bring to their doctors, and not just their biomedical problems’. However, medical
education in the last few decades has concentrated on the latter and promoted reductionism,
specialisation, mechanistic models of disease, and faith in a definitive cure44. The way we
deliver caregiving will have to be revamped in both undergraduate, postgraduate training and
daily practice especially in our management of individuals with multimorbidity.

Although there were no clinically significant differences in the prevalence rates of
multimorbidity between the different sexes and among the different ethnic groups, but
importantly distinct patterns of multimorbidity were identified in the different ethnic and sex
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groups in our population.

Kastner et al.’s systematic review on effective interventions for

managing multimorbidity in older adults also found the occurrence of commonly occurring
diseases dyads like diabetes and cardiovascular diseases, and urged researchers to investigate
the potential impact of interventions on these clusters of chronic conditions45. As such, primary
care physicians should partake in the development of guidelines for the most common
combinations of chronic conditions that are personalised to each subgroup. Ideally, the payoff
time framework‡‡‡‡‡‡‡‡ should be included in the guidelines and preferably in electronic form
individualised to each patient46.

7 Conclusion
The research work undertaken in this thesis has added to the body of knowledge on the
definition of multimorbidity and suggested the most appropriate data source for multimorbidity
research pertaining to patient-reported outcomes in a multi-ethnic country. The thesis has also
helped to improve on the terminology used in measuring multimorbidity and provided an
updated list of instruments for measuring the level of multimorbidity in community-dwelling
adults with multimorbidity bearing in mind that the same instrument may have several
applications.

Developing strategies to manage individuals with multimorbidity on what truly matters to them
will need further work. These will include the identification of the unifying underlying
mechanism(s) in the development of multimorbidity, involvement of patients in multimorbidity
research, and development of multimorbidity clinical practice guidelines targeting specific
sex/ethnic groups for health care providers.

‡‡‡‡‡‡‡‡

The earliest time when cumulative incremental beneﬁts attributable to a clinical guideline exceed cumulative
incremental harms attributable to that guideline.
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